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Abstract 
 
The aim of treatment in STEMI is to improve outcomes for patients in terms of mortality 
and quality of life. Mortality rates have improved with increased use of PPCI as first-line 
therapy however in-hospital mortality remains 5-8%. There are multiple therapies that may 
be beneficial for some patients, as adjuncts to PPCI. There is limited evidence for the use of 
these therapies and deciding which patients should receive them is challenging.  
If operators could identify patients during the acute MI who may be at high risk of adverse 
outcomes, they may decide to administer adjunctive therapies or increase the length of 
critical care admissions, which could improve outcomes. Invasive methods, such as IMR, 
can identify patients with poor reperfusion following PPCI. However, clinical and 
angiographic variables that are easily recorded during PPCI could be used to risk assess 
patients, avoiding the need for extra invasive tests.  
Clinical and angiographic variables that are readily available during PPCI were examined for 
associations with a composite outcome of 28-day mortality or subsequent severe 
impairment of left ventricular function (ejection fraction ≤35%). These variables included 
age, gender, culprit location, TIMI flow grade, myocardial blush grade, thrombus burden 
and corrected TIMI frame count. Variables with an association with the outcome were 
included in a multivariate logistic regression analysis to develop a predictive model – the 
Liverpool MI Risk Model.  
Independent variables included in the Liverpool MI Risk Model were age, culprit vessel 
location and myocardial blush grade. The model accurately predicts the outcome of death 
within 28 days or subsequent severe impairment of left ventricular function (c statistic 0.79; 
95% CI 0.75 to 0.83). External validation of the model using an independent cohort of 
patients showed good discrimination (c statistic 0.837; 95% CI 0.723 to 0.951) although the 
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model overestimated the risk of outcome events in the new cohort. The model was 
accurate in predicting adverse events in the validation cohort after simple recalibration. 
The Liverpool MI Risk Model is a practical tool that uses information available during PPCI 
to accurately predict the occurrence of an adverse outcome. Using this model could help 
operators to make decisions regarding adjunctive therapies and duration of stay in critical 
care areas. External validation of the risk model overestimated the occurrence of an 
outcome in the validation cohort, prior to recalibration, likely due to differences in 
measurement methods, eligibility criteria and risk profiles between the two cohorts. A 
study including unselected STEMI patients using the same measurement methods as the 
derivation cohort should be used to validate the Liverpool MI Risk Model.  
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Thesis Outline 
Primary percutaneous coronary intervention is the optimum treatment for acute 
reperfusion in STEMI. However, adverse events are still common despite timely reperfusion 
therapy. To improve outcomes in STEMI, operators need to identify patients who may 
benefit from adjunctive treatments, more intensive monitoring, and longer hospital stays as 
well as those who can be safely managed with a less aggressive approach. It may be 
possible to infer the subsequent clinical risk from information that is available at the time of 
index reperfusion.  
In Chapter 1, I discuss the nature and magnitude of adverse events in STEMI and consider 
the potential methods by which an outcome may be improved. There are multiple 
therapies available as adjuncts to PPCI, however, the ideal patient population with potential 
for greatest gain at acceptable risk has not been well characterised. It is likely that the 
patients with most to gain from adjunctive therapies are those who experience poor 
microvascular reperfusion and may develop more substantial infarction damage as a result. 
Flow in the main coronary arteries does not always indicate good reperfusion at the level of 
the heart muscle tissue. 50% of patients with epicardial blood flow following PPCI 
demonstrate poor myocardial reperfusion on subsequent CMR and, therefore, patients 
with poor microvascular reperfusion following PPCI are less likely to be identified during the 
acute event. I examine methods of identifying poor myocardial reperfusion and how they 
can be applied during the acute MI. Several methods of identifying poor myocardial 
reperfusion have been developed, such as the index of myocardial resistance (IMR). 
However, this is an invasive test and adds time and cost to the procedure. It is possible that 
knowledge of these methods may help operators to identify patients with poor myocardial 
reperfusion during PPCI, and therefore aid decisions regarding adjunctive therapies and 
appropriate post-procedure surveillance.  
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HEAT-PPCI was a randomised trial of antithrombotic therapy in STEMI. The clinical and 
outcome data plus the angiograms from the trial were available for use in this thesis. In 
Chapter 2, I describe the methods used to assess the angiographic variables identified in 
Chapter 1, and the design of the database used for collecting relevant data on the variables.  
The HEAT-PPCI database includes outcome data up to 28-days following STEMI. In Chapter 
3, I explore the possibility of extending follow-up to 12 months for use in the Liverpool MI 
derivation study and evaluate the accuracy of Hospital Episode Statistics in identifying 
clinical outcomes by comparison with outcomes identified by medical notes review and 
independent physician adjudication.  
The HEAT-PPCI database includes data on patient mortality up to 28 days following the 
index event. In Chapter 4, I evaluate mortality data up to 12 months following the index 
event and compare the mortality rate between the two treatment groups (randomised to 
either heparin or bivalirudin). In addition, I examine the causes of death of participants 
using data derived the death certificates of the patients.  
Observational studies are often criticised because of the potential for unmeasured 
confounding affecting results. Operators’ choice of access site is a potential confounder in 
the HEAT-PPCI trial. In Chapter 5, I examine the associations between the final access site 
used for the procedure, the default operator preference for access site and clinical 
outcomes. I also look at differences between operators when performing procedures via 
femoral access.  
If the angiographic variables described in Chapter 2 are to be used by any operator 
performing PPCI, it is important to establish the agreement between repeat measurements 
to give an estimate of the reliability and reproducibility. In Chapter 6, I evaluate my ability 
to match my own assessments of each angiographic variable on repeat testing and compare 
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my assessments to those of a second observer, quantifying the intra- and inter-observer 
agreement.  
In Chapter 7, I examine several clinical and angiographic variables that previous studies 
have shown to be associated with clinical outcomes in STEMI. I test each variable for 
associations with mortality and LV function with the aim of developing a risk prediction 
model. The initial purpose for developed this model was to identify high-risk patients 
during PPCI to aid operators’ decisions regarding adjunctive treatments. However, given the 
lack of evidence for the use of adjunctive therapies in PPCI, this model may more usefully 
be used to categorise the low-risk patients, identifying those in whom a prolonged critical 
care stay may not be necessary and therefore, improving allocation of hospital resources.  
All risk prediction scores should be externally validated. In Chapter 8, I test the predictive 
model on an independent cohort of STEMI patients. In Chapter 9, I explore the associations 
between the variables that are included in the model developed in Chapter 7 and infarct 
size quantified using cardiac magnetic resonance imaging.  
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 Contemporary management of acute myocardial 
infarction 
 
 Background 
Coronary artery disease is the leading cause of death worldwide, causing 9.43 million 
deaths in 2016.1,2. Acute myocardial infarction (AMI) is a term used to describe the 
occurrence of symptoms and signs consistent with myocardial ischaemia with consequent 
evidence of myocardial injury.3 AMI is divided into cases with or without persistent ST 
elevation on electrocardiogram (ECG).4 ST-segment elevation indicates complete 
obstruction of an epicardial artery, whereas non-ST elevation myocardial infarction 
(NSTEMI) represents partial or transient obstruction of a coronary artery. Both result in a 
degree of ischaemic damage, demonstrated by a rise in cardiac enzymes. The management 
and outcomes of patients with ST-elevation myocardial infarction (STEMI) is the main topic 
of this thesis.  
AMI is most frequently caused by the rupture or erosion of a coronary atherosclerotic 
plaque, resulting in thrombus formation and obstruction of the coronary artery.5 This 
causes an acute reduction of coronary blood flow and insufficient oxygen supply to the 
myocardium. This then results in myocardial necrosis due to prolonged ischaemia.  
The primary aim of treatment in STEMI is to restore blood flow to the myocardium as 
quickly as possible. Ischaemic time is defined as the time from symptom onset to initiation 
of treatment for STEMI and directly correlates with the extent of myocardial necrosis. 
Patient survival improves with shorter ischaemic time.6,7 Options for reperfusion therapy in 
STEMI include percutaneous coronary intervention (PCI) (termed primary percutaneous 
coronary intervention (PPCI) when performed in the context of STEMI), or thrombolysis.  
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Patients presenting within 12 hours of symptom onset and with persistent ST-segment 
elevation should undergo pharmacological or mechanical reperfusion as early as possible.8 
In trials of prompt and high-quality PPCI versus thrombolysis, superior outcomes are shown 
with PPCI.9 To reduce ischaemic times and system delays, PPCI services have become 
increasingly stream-lined: when a STEMI diagnosis is made in the pre-hospital setting 
patients will bypass the emergency department and be brought directly to the 
catheterisation laboratory. This practice is associated with a 20-minute saving in the 
ischaemic time.3 Alternative treatment strategies such as pharmacological reperfusion 
using thrombolysis should be considered if this can be delivered within 120 mins of first 
medical contact and PPCI cannot be performed within 120 minutes of when thrombolysis 
would otherwise be administered.3 
STEMIs comprise 39% of UK hospital admissions for AMI.10 Mortality is approximately 12% 
in the 6 months following the event11 but increases in patients with pre-existing conditions, 
such as heart failure and renal disease.12 PPCI is the best treatment if it can be performed 
by an experienced centre and within a reasonable time-frame.4 However, there is still a 
significant rate of adverse events following treatment. In-hospital mortality is around 5-
8%13 and a recent study showed that 3.5% of patients have a recurrent MI following PPCI in 
the 30 days following the procedure.14 These statistics suggest there is scope to decrease 
mortality and complication rates in this group by improving their management.  
 
 Measuring and predicting outcomes in STEMI 
The aim of treatment in STEMI is to improve outcomes for patients in terms of length and 
quality of life.15 Examining outcomes in short- and long-term follow-up helps to establish 
the possible benefits of a new management strategy or treatment. Most cardiovascular 
trials will measure the rates of all-cause and cardiovascular mortality in follow-up.15,16 In 
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addition, rates of important clinical events that are likely to increase mortality are often 
measured, such as stroke and myocardial infarction.17 Other outcomes used with varying 
frequency include patient-reported outcomes, quality-of-life questionnaires, rates of 
hospitalisation and residual left ventricular (LV) function or infarct size.15,16  
In clinical practice, patients at higher risk for poor long-term outcomes following STEMI can 
be identified using diagnostic tests: the magnitude of cardiac enzyme release and less 
favorable LV function are both used to help risk stratify patients and guide their 
management. Cardiac enzymes such as Troponin I and T and creatinine kinase-MB (CK-MB) 
are sensitive biomarkers for myocardial injury.18 They are used in the diagnosis of AMI. The 
universal definition of acute myocardial injury states that the troponin value must be above 
the 99th percentile of the upper reference limit for the normal range of the assay used.19 
Troponin levels peak between 12-24 hours following the acute event. CK-MB is a cardiac-
specific isoenzyme of creatinine kinase. It is highly sensitive and specific for cardiac tissue 
damage and begins to rise 4-6 hours after the onset of an acute MI.20 It returns to baseline 
after 36-48 hours (troponin takes up to 2 weeks) and can therefore be used to accurately 
detect reinfarction. An increased CK-MB or troponin value reflects a greater size of infarct 
in patients following AMI.21 It has also been shown to decrease with early reperfusion 
therapy in animal models, so can be useful in assessing the success of reperfusion 
therapy.22 In STEMI, cardiac enzymes may not be available at the time of PPCI, but can be 
used after the acute event for risk stratification. The degree of enzyme release is predictive 
of the extent of myocardial injury and the size of the infarct.23 Infarct size is a predictor of 
long-term mortality and heart failure in STEMI survivors.3 Enzyme release can therefore be 
used, in combination with other clinical information, to predict mortality in patients with 
AMI.11,24 Peak CK-MB values have been shown to predict in-hospital mortality with greater 
accuracy than peak troponin.18 
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International guidelines recommend assessment of the LV function and ejection fraction 
(EF) in all patients with STEMI prior to discharge.3 LV dysfunction is a key prognostic factor 
in STEMI and is routinely measured using echocardiography.19 Other imaging modalities 
such as cardiac magnetic resonance imaging (CMR) can be used if echocardiographic 
images obtained are poor quality. A measure of LV function reflects the extent of muscle 
damage following the acute event and is associated with infarct size and mortality.25  
Patients with a pre-discharge LV ejection fraction of <41% should be re-assessed 6-12 
weeks following revascularisation to evaluate the need for further therapies such as an 
implantable cardioverter defibrillator.3 
 
 Measuring the success of PCI 
The success of the PCI procedure is described by observing a return of normal flow in the 
culprit coronary artery. The predominant method currently used to characterise flow is the 
TIMI flow grade. This is a qualitative, visual, angiographic assessment divided into 4 grades 
depending on the observed speed of flow of radiographic contrast in the culprit artery 
(Table 1.1). The TIMI flow can be assessed in real time by the operator from the 
angiographic images produced during the procedure. It was first described by the TIMI trial 
group (in angiograms performed for trial purposes) to assess the efficacy of thrombolytic 
therapy in acute myocardial infarction.26 Although TIMI flow was originally designed for use 
in thrombolysis trials, it has been used extensively in subsequent research to assess 
epicardial revascularisation after AMI. It is recommended practice to record the TIMI flow 
after all PCI procedures.27 A TIMI flow grade of 2 or less indicates suboptimal flow through 
the vessel and poor myocardial perfusion, likely resulting in worse LV function and 
increased mortality.28,29 A TIMI flow of 2 or less may occur despite successfully opening the 
culprit artery. This concept is known as “no-reflow” and is associated with less favourable 
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outcomes.30 TIMI grade 3 is associated with lower rates of death at 30 days and improved 
LV function.31,32 TIMI flow grade less than or equal to 2 is associated with worse symptoms 
of heart failure and a higher rate of in-hospital mortality.33 
 
Table 1.1: Definitions of perfusion in the TIMI trial 
 
 
 Why are outcomes sometimes poor, despite “successful” PPCI? 
Restoration of normal flow (TIMI flow grade 3) through the epicardial artery does not 
guarantee tissue reperfusion. Adequate patency and function of the microvasculature is 
Grade 0 (no perfusion): There is no antegrade flow beyond the point of occlusion. 
Grade 1 (penetration without perfusion): The contrast material passes beyond the area 
of obstruction but "hangs up" and fails to opacify the entire coronary bed distal to the 
obstruction for the duration of the cineangiographic filming sequence. 
Grade 2 (partial perfusion): The contrast material passes across the obstruction and 
opacifies the coronary bed distal to the obstruction. However, the rate of entry of 
contrast material into the vessel distal to the obstruction or its rate of clearance from 
the distal bed (or both) are perceptibly slower than its entry into or clearance from 
comparable areas not perfused by the previously occluded vessel opposite coronary 
artery or the coronary bed proximal to the obstruction. 
Grade 3 (complete perfusion): Antegrade flow into the bed distal to the obstruction 
occurs as promptly as antegrade flow into the bed proximal to the obstruction, and 
clearance of contrast material from the involved bed as rapid as clearance from an 
uninvolved bed in the same vessel or the opposite artery. 
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also required to ensure blood is then distributed to the capillary bed. A reduction of blood 
flow in the microvasculature of the heart is termed poor myocardial perfusion and can be 
identified on CMR as coronary microvascular obstruction (CMVO).  
CMVO was described by a recent review using 4 interacting pathophysiological 
mechanisms:34  1: ischaemic-related injury which occurs when sustained ischaemia causes 
necrosis of myocytes and capillaries. 2: reperfusion injury then occurs when reperfusion is 
achieved but ischaemic duration was >3 hours. This is thought to occur because reperfusion 
potentiates ischaemic injury by stimulating the production of free radicals, causing cell 
swelling and cell disruption. The combination of these two mechanisms can cause 
myocardial oedema and haemorrhage as well as a generalized vascular inflammatory 
response. 3: distal embolisation of thrombi causing blockage of arterioles perpetuating an 
inflammatory response. 4: individual susceptibility of patients to developing CMVO caused 
by genetic factors. CMR is the best method for characterising the extent of myocardial 
damage in detail. Following the MI, areas of haemorrhage and oedema within the 
myocardium can be seen on CMR, confirming the presence of CMVO.  
 
In a large proportion of STEMI patients, PPCI alone does not restore normal myocardial 
perfusion. A recent meta-analysis showed that over 50% of patients treated with PPCI have 
reduced microcirculatory blood flow on CMR following the acute event.35 These patients 
have a higher risk of death, and survivors tend to have worse LV function.36-39 Studies show 
that both infarct size and CMVO measured on CMR following PCI were good predictors of 
unfavourable LV remodelling and decreased LV function.36,38,39 Reopening the obstructed 
artery restores blood flow in the visible epicardial vessels but may not restore normal blood 
flow in the microvasculature. 
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 Adjunctive therapies in STEMI 
There are multiple adjunctive therapies that can be used during PPCI or in the immediate 
post-procedural phase. In the next section, I discuss several adjunctive therapies that may 
improve myocardial reperfusion in the acute phase of MI, resulting in a decreased infarct 
size and improved long-term outcomes for patients. The list is not exhaustive but describes 
some of the treatments that could be considered by operators for use during or 
immediately after PPCI. Decisions to use adjunctive therapies must be carefully considered 
as each may have additional risks to the patient, as well as extra costs. Therapies may be 
expensive to purchase, require additional time from staff and increase demand for hospital 
resources, including longer stays in higher dependency areas. There is uncertainty about 
the most appropriate application for these adjunctive treatments.  
 Glycoprotein 2b3a inhibitors 
Platelet activation and aggregation is central to the pathophysiology of ACS. The most 
recent guidance advises that all patients with STEMI should be treated with oral antiplatelet 
agents prior to PCI and intravenous anticoagulation during the procedure.4 Glycoprotein 
2b3a inhibitors (GPIs) are drugs that block the key receptor involved in the final common 
pathway of platelet aggregation. Administration of GPIs, therefore, results in rapid and 
potent inhibition of platelets aggregation. The European Society of Cardiology (ESC) 
guidelines reserve these agents for selective use in patients with STEMI, however they may 
play a role in patients with suboptimal reperfusion by preventing platelet aggregation and 
subsequent distal embolization of thrombi in myocardial capillaries.4 GPIs, such as tirofiban 
and abciximab, are often used by operators as an adjunct to improve myocardial perfusion 
if there is evidence of poor coronary blood flow after the culprit vessel has been reopened 
or in cases with large thrombus burden. ESC guidance considers use of GPIs as “bailout” 
therapy to be considered when there is angiographic evidence of large thrombus, slow or 
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no-reflow following mechanical revascularisation. This is despite the absence of 
randomised trials in this area.4 Recent National Institute for Health and Care Excellence 
(NICE) guidance advises the considered use of GPIs as an adjunct to PCI in patients with 
multi-vessel disease or diabetes.40 Disadvantages to the use of GPIs include the cost of the 
drug and the extra time required by nursing staff to administer an intravenous medication. 
NICE estimates that when GPIs are used as an adjunct to PCI in high risk patients the base-
case cost per quality-adjusted life year (QALY) is £25,811.40 Side effects and adverse 
reactions must be considered such as thrombocytopenia and major bleeding which are 
listed as common side effects with a rate of at least 1%.41  
 Thrombolytics 
Administration of fibrinolytic agents to achieve coronary reperfusion as the primary 
treatment in STEMI is only recommended in the event of a time delay in primary PCI. More 
recent research suggests there may be a role for fibrinolytic therapy given to patients 
directly into the coronary artery during PCI. Microthrombi within the myocardial capillaries 
have a mixed composition of both platelets and fibrin.42 This suggests that a combination of 
anti-platelets agents and thrombolytics may improve myocardial perfusion. One study has 
demonstrated an improvement in myocardial reperfusion when streptokinase was given at 
the end of PCI.43 However, a recent randomised trial comparing low-dose intracoronary 
alteplase versus placebo showed no difference in the extent of microvascular obstruction.44 
As with GPIs, thrombolytic use is associated with bleeding. Intracerebral and 
gastrointestinal bleeds are listed as common side effects with a rate of at least 1%. The cost 
of the medication must be considered with alteplase priced at £144 per 10mg.45 
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 Vasodilators 
Some guidance recommends use of intracoronary vasodilators to treat PCI-related no-
reflow during PPCI.27 Randomised controlled trials looking at intravenous adenosine in 
patients with acute myocardial infarction showed a reduction in infarct size measured on 
single-photon emission computed tomography (SPECT) in those receiving adenosine.46,47 
Studies looking at intracoronary adenosine in this setting showed a decreased incidence of 
no-reflow phenomenon.48 One study showed benefit in giving intracoronary verapamil in 
improving coronary flow as measured by TIMI frame count.49,50 Similar benefits have been 
shown in the administration of sodium nitroprusside in improving TIMI flow after 
mechanical revascularisation.51 However, one study showed no benefit from this treatment 
so further research is needed in this area.52 Furthermore, interpretation of the positive 
findings is complicated by the fact that both adenosine and sodium nitroprusside (via the 
generation of nitric oxide) inhibit platelet aggregation and inflammatory adhesion molecule 
function.51,53,54 Risks with these drugs include their potential to cause hypotension, heart 
block and ventricular tachycardia. These need to be considered alongside the cost of the 
medication and the additional staff time required for each patient to receive an additional 
infusion.48 Infusion time was up to 3 hours in some studies.  
 Intra-aortic balloon pump (IABP) 
Intra-aortic balloon pumps (IABP) are invasive devices that are placed percutaneously via 
the femoral or axillary artery and advance to the descending thoracic aorta. They work by 
inflating a helium balloon in diastole, creating augmentation of diastolic pressure after 
aortic valve closure.  The balloon deflates in systole, reducing afterload. This may increase 
coronary and systemic flow and can potentially improve myocardial recovery after STEMI. 
Intra-aortic balloon pumps have been advocated for use in patients with STEMI complicated 
by cardiogenic shock due to mechanical complications.3 Recent trials looking at STEMI 
37 
 
patients treated with or without an intra-aortic balloon pump found no benefit in terms of 
30-day survival or left ventricular function in patients without cardiogenic shock.55,56 There 
could be an additional role for these devices in stable STEMI patients with suboptimal 
myocardial reperfusion following PCI however there is little evidence to support use in this 
setting.  There are significant risks associated with this invasive procedure, with 
complication rates between 20-30%.57 Costs of the device itself and the costs of extra staff 
time required for insertion and monitoring must be considered.    
 Deferred stenting 
Deferred stenting is where primary stenting during PCI is not immediately performed in 
suspected STEMI. Instead the culprit artery is reperfused using either a guidewire, 
aspiration thrombectomy or a balloon catheter. The stent can then be implanted during a 
second procedure 1-3 days later, after antithrombotic treatment has been administered. 
This approach allows time for thorough assessment of the patient as well as optimisation of 
stent placement. During the acute phase, vessel diameter can be underestimated due to 
reduced flow-mediated dilatation and increase of factors that promote vascular spasm. The 
longitudinal extent of the underlying atheroma is more evident after removal of adherent 
thrombus, so the appropriate size of stent can be more accurately estimated. By allowing 
increased time for reduction in coronary thrombus burden prior to stenting, this strategy 
likely minimises distal emboli, reducing infarct size. However deferred stenting involves a 
second procedure with risks to the patient and costs in terms of staff time and prolonged 
hospital stay.  The DEFER-STEMI trial showed that performing immediate balloon dilatation 
of the culprit vessel but delaying stent implantation in selected higher risk patients 
improved the myocardial salvage index and reduced no-reflow.58 Subsequent trials 
investigating delayed stenting in patients without stratifying them into categories of risk 
showed no benefit in the patients randomised to deferred stenting.59,60 This suggests a 
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possible role for deferred stenting in patients with multiple risk factors or who have 
indicators suggesting suboptimal myocardial reperfusion after PCI. There were concerns 
related to acute coronary reocclusion in these patients which occurred in 2-4% of cases.  
 Thrombus aspiration 
Thrombus aspiration is sometimes performed in patients undergoing PCI for STEMI. The 
aim of thrombectomy in this setting is to restore patency of the culprit vessel and to 
prevent distal embolisation of thrombotic material and plaque debris into the 
microvasculature of the heart. Studies show that manual aspiration of thrombus is not 
indicated routinely during PCI for STEMI.61,62  It may be beneficial as an adjunctive therapy 
to patients who are at risk of suboptimal reperfusion.63 
 Pressure-controlled intermittent coronary sinus occlusion  
Pressure-controlled intermittent coronary sinus occlusion (PICSO) aims to improve 
myocardial reperfusion after PPCI. A balloon-tipped catheter is introduced into the 
coronary sinus to intermittently increase the pressure in the cardiac venous outflow tract. 
This technique has been hypothesized to enhance washout from the microcirculation and 
redistribute venous blood to the infarcted myocardium. This may reduce the extent of 
myocardial necrosis.64 A recent trial showed that the technique is safe in the STEMI 
setting.65 Observational trials aimed at evaluating the efficacy of PICSO as an adjunct to 
PPCI are currently ongoing.66   
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 Identifying patients with poor myocardial reperfusion in the acute 
phase 
No-reflow is not immediately apparent on angiographic review in all patients who are 
subsequently shown to have CMVO on CMR. Around 50% of patients with TIMI 3 flow after 
PCI may have reduced myocardial perfusion that is undetected in the acute phase.34 These 
patients are, therefore, not considered for additional therapies or closer surveillance that 
could improve their outcome. Although CMR can accurately identify CMVO, it cannot be 
performed in-lab. It can only be used after the acute phase of STEMI once the patient has 
already missed the opportunity to benefit from adjunctive therapies that must be 
administered in-lab. 
In our aim to improve outcomes in STEMI, we need to make informed decisions regarding 
the use of adjunctive therapies. To deliver therapies during the acute phase of STEMI, the 
risk of adverse outcomes must be estimated in the catheter lab. The current method of 
assessing myocardial perfusion, TIMI flow grade, does not identify a high proportion of 
patients who go on to develop CMVO and is therefore not likely to identify all high-risk 
patients. CMR or other imaging is useful but cannot easily be performed in-lab. There are 
several other methods that have been developed, aimed at identifying poor myocardial 
reperfusion in the acute phase of STEMI.  
 
 Invasive methods 
 Index of myocardial resistance (IMR) 
At invasive angiography, it is possible to measure indices of coronary flow that may reflect 
tissue perfusion.67  The index of microvascular resistance (IMR) gives a quantitative 
measurement of microvascular resistance down each epicardial vessel.68 IMR is a coronary 
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guidewire-based measurement and provides information regarding microvascular function. 
IMR is calculated by multiplying the distal coronary pressure by the mean transit time of a 
saline bolus.67 The mean transit time is calculated by measuring the temperature change of 
the saline bolus between two transistors on the guidewire. A thermistor located 3cm from 
the distal end of the coronary guidewire simultaneously measures pressure and 
temperature. Measurement of mean distal coronary pressures is performed at coronary 
hyperaemia induced by intravenous adenosine. An IMR <20 is considered normal, and an 
IMR >30 is elevated and indicates microvascular dysfunction. IMR has been shown to be an 
independent predictor of LV function at 3 months post-infarct. It is also a predictor of 
mortality in 3 year follow up.69 A recent trial looked at the ability of IMR to predict CMVO 
on subsequent CMR.70 IMR was measured at the end of PCI and CMR was performed 
several days later. This study found that IMR was a good predictor of CMVO, LV function 
and death. A trial performed in Oxford developed a scoring system that used clinical and 
angiographic variables to predict IMR cut-offs.71 This trial used age, thrombus burden and 
pre-stenting IMR value to predict the post-stenting IMR value. This study showed that 
clinical and angiographic factors may add value in predicting poor myocardial perfusion.  
IMR measurement requires an extra invasive diagnostic procedure and administration of IV 
vasodilators to achieve maximal hyperaemia.72 This adds time and cost to each case. 
Operators are unlikely agree to perform IMR measurements in every patient with STEMI. 
This highlights the need for the development of non-invasive, inexpensive methods of 
characterising myocardial perfusion that can accurately predict outcomes.73 
 
 Clinical methods  
When considering clinical characteristics that could predict outcomes following STEMI, I 
have examined factors that are likely to be known or estimable in all patients during the 
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acute phase. I have not included factors such as previous medical history or co-morbid 
conditions in this review because these may not be known during the time of primary 
reperfusion therapy, particularly in very unwell patients. 
 Age 
Age is an important risk factor for mortality. As the age of a patient increases, their risk of 
death increases, and they have an increased risk of cardiovascular mortality following 
STEMI. The GRACE study showed that age is an independent predictor of risk in patients 
following AMI.11  The well-known GRACE score predicts in-hospital and 6-month mortality 
in patients following AMI and includes age as a factor in the score. The TIMI risk score 
predicts death at 20-days following STEMI and also includes age in the score.24 Other 
studies have shown that age is a good predictor of in-hospital and 30-day mortality.74,75 Age 
can usually be estimated at diagnosis of STEMI even in patients who are very unwell or 
unable to communicate with medical staff during the acute event.  
 Gender 
Although men tend to have larger infarcts, women experience poorer outcomes following 
STEMI, including a higher mortality rate.76-78 The reasons for this are uncertain but studies 
have shown that differences often exist in baseline characteristics such as age and 
comorbidities as well as in presentation.79 This mortality difference has decreased between 
the genders in the last 20 years, thought to be due to increased rates of reperfusion.80 
Mortality differences between men and women may simply be a result of confounders, 
such as comorbidities and presentation. This baseline information is not always available in 
the acute phase so gender could be a useful as a surrogate for other risk factors and could 
be used to predict adverse outcomes.   
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 Killip classification 
Signs of heart failure can be assessed and classified into the Killip classification system 
(Table 1.2).81 Because the symptoms and signs of heart failure often occur as a result of 
poor left ventricular function, Killip classification is useful in identifying patients who are 
likely to have poor LV function and higher risk of death. Several studies have reported heart 
failure as a predictor of mortality.82,83 The GRACE study demonstrated the association 
between heart failure and increased in-hospital and 6-month mortality in ACS patients and 
included Killip class in the GRACE risk score.84 
Class I No signs of congestion 
Class II S3 and basal rales on auscultation 
Class III Acute pulmonary oedema 
Class IV Cardiogenic shock 
Table 1.2: Killip classification of heart failure 
   
 Ischaemic time 
As discussed earlier in the chapter, ischaemic time is likely to predict poor outcomes in 
STEMI. This is because longer ischaemic times result in increased cardiac myocyte damage 
from prolonged ischaemia. Therefore, increasing ischaemic time is a useful predictor of 
poor outcomes in STEMI. A recent study showed that transmural necrosis, severe CMVO 
and poor LV function were directly related to increased ischaemic time.85 One study 
showed a 37% increase in risk of transmural necrosis and a 21% increase in risk of severe 
CMVO with every 30 minute delay in reperfusion therapy.86 Ischaemic time is recorded by 
43 
 
medical staff during the acute phase of STEMI. In most cases, accurate values of ischaemic 
time rely on the patient’s recollection of the symptom-onset. If symptoms change or evolve 
over several hours, it may be difficult for the patient to determine the exact onset.  
 ECG changes before and after reperfusion treatment  
The presence of pathological Q waves on ECG prior to PCI is found in 20% patients with 
STEMI. A recent study showed that STEMI patients with Q waves on ECG prior to PCI have a 
worse prognosis and a larger infarct size as well as increased CMVO on CMR post-infarct.87 
ST-resolution (STR) on post-PCI ECG is an indicator of the patency of the artery and the 
success of revascularisation. Early STR is a good prognostic marker in acute myocardial 
infarction88 with some studies showing that increasing degrees of ST resolution following 
PCI are associated with reduced mortality rates and increased LV ejection fraction.88-93 
These studies often assessed the STR at multiple time points following the procedure, 
because STR may evolve for several hours following revascularisation. This makes STR an 
unhelpful parameter in the acute phase as it cannot be assessed with certainty during the 
PCI procedure. 12 lead ECG monitoring would be required to assess STR in-lab which is 
rarely standard practice.  
 
 Angiographic methods 
There are several non-invasive measures of coronary flow and myocardial perfusion that 
can be evaluated by examining the primary PCI angiogram. Many of these methods have 
been validated in a research setting but are not routinely used in clinical practice. They 
have a distinct advantage over invasive methods because they use the angiographic images 
already obtained during PPCI. No extra equipment or medication is required and there is no 
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increased risk to the patient. The extra time needed to calculate the measures is minimal 
and they could be immediately implemented in clinical practice. 
 Thrombus burden  
The TIMI thrombus grade gives a measure of the size of the thrombus in the culprit artery 
in terms of the length of the thrombus compared to the epicardial vessel diameter (Table 
1.3).94  
 
Table 1.3: Definition of TIMI thrombus burden grades 
 
 It can be calculated from visual assessment of the angiographic images. There are few 
studies examining the prognostic value of thrombus burden in STEMI patients. One 
retrospective study found a higher thrombus grade to be an independent risk factor for 
major adverse cardiovascular events (MACE), including mortality.95 Distal embolisation of 
thrombus is one of the pathophysiological mechanisms in CMVO. Studies have shown that 
Grade 0: no cineangiographic characteristics of thrombus are present 
Grade 1: possible thrombus is present, with such angiography characteristics as reduced 
contrast density, haziness, irregular lesion contour, or a smooth convex “meniscus” at 
the site of total occlusion suggestive but not diagnostic of thrombus 
Grade 2: there is definite thrombus, with greatest dimensions ≤0.5 of the vessel 
diameter 
Grade 3: there is definite thrombus but with greatest linear dimension >0.5 but <2 
vessel diameters 
Grade 4: there is definite thrombus, with the largest dimension >2 vessel diameters 
Grade 5: there is total occlusion 
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high thrombus burden in STEMI patients is associated with impaired post-procedure 
myocardial perfusion, higher rates of no-reflow and distal embolisation.96,97 Therefore, 
measuring the thrombus burden may help to predict the degree of myocardial injury from 
this mechanism and therefore the subsequent infarct size, LV function and mortality.98 
 TIMI Frame count 
The TIMI frame count (TFC) is another angiographic method used to give a quantitative 
measure that reflects the velocity of coronary blood flow. It was developed as an extension 
of the TIMI flow grade classification system. 99 If operators used TFC to assess angiographic 
flow in the coronary artery following PPCI this could help to eliminate the observer bias 
that may occur when estimating the TIMI flow grade.  TIMI frame count uses the number of 
cineframes, acquired at a rate of 30 frames per second, needed for contrast to reach 
standardized landmarks to objectively reflect coronary blood flow velocity.99 When 
adjusted for vessel length it becomes corrected TFC (cTFC). Because cTFC is a continuous 
variable, it is likely to detect borderline cases of poor myocardial perfusion where coronary 
flow may be deemed “normal” using TIMI flow grade. The original method describing cTFC 
advises increasing the count by a fixed number of frames if nitrates are used during the 
angiogram. TIMI frame count has been shown to have excellent reproducibility and rates of 
inter- and intra- observer agreement.99 The ability of cTFC to predict adverse outcomes is 
uncertain. Some studies have shown that cTFC is a predictor of in-hospital mortality after 
thrombolysis, higher frame counts being associated with improved LV ejection fraction and 
LV wall motion,100,101 but another showed that cTFC has no correlation to adverse 
outcomes, although in this study only two-thirds of available cinefilms were suitable for 
analysis of cTFC.102,103    
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 Myocardial Blush Grade (MBG) 
Myocardial blush grade (MBG) is a qualitative visual assessment of the amount of contrast 
filling areas of the microvasculature supplied by an epicardial artery.104 This grading system 
was originally developed by van’t Hof at al. and categorises the degree of myocardial blush 
into 4 grades, as illustrated in Table 1.4. 
 
Table 1.4: Definitions of myocardial blush grade 
 
MBG looks at blood flow into the microvasculature of the myocardium, which may be a 
useful additional measurement and may be independent of TIMI flow or TFC in cases of 
CMVO. Following PPCI, TIMI flow may be graded as normal, but a low blush grade may 
identify cases where microvascular dysfunction is limiting the passage of dye into the 
microcirculation. MBG can be calculated in-lab during PCI. In the first study describing MBG 
interobserver and intraobserver agreement was 90% and 97% respectively.104 Decreased 
MBG correlates with an increased number of myocardial segments with transmural 
necrosis on CMR. In addition, the phenomenon of staining, classed as MBG 0, is associated 
with severe and persistent microvascular damage.105 MBG of 0 or 1 was associated with an 
increased degree of unfavourable left ventricular remodelling and more frequent 
symptoms of heart failure.106 MBG of 2 or 3 is associated with smaller infarct size, less 
Grade 0: no myocardial blush 
Grade 1: minimal myocardial blush 
Grade 2:  myocardial blush exists to a lesser extent and with less clearance than would 
be expected in a non-infarct related artery 
Grade 3: normal myocardial blush 
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CMVO, improved LV ejection fraction and significantly lower mortality.107,108,109 MBG 3 is a 
strong predictor of freedom from MACE at 5-year follow-up.110  
 TIMI Myocardial Perfusion Grade 
The TIMI myocardial perfusion grade (TMPG) is calculated using a similar method to 
MBG.111 TMPG assesses the filling and clearance of contrast from the myocardial 
vasculature rather than the density of myocardial blush as in MBG, and categorises this into 
4 grades (Table 1.5). 
 
Grade 0: No myocardial blush  
Grade 1: Minimal blush and very slow clearing (e.g. present at beginning of next cine) 
Grade 2: Good blush with slow clearing of myocardial contrast (present at end of cine 
but gone at beginning of next) 
Grade 3: Good blush and normal clearing (ie. gone by end of cine) 
Table 1.5: Definitions of TIMI myocardial perfusion grades 
 
 This is estimated from the ground-glass appearance of the contrast as it penetrates the 
microvasculature and then fades as it drains through the venous system. TMPG is an 
independent predictor of mortality.111,112 TMPG is more complex to calculate than MBG. 
There is less evidence that it relates to LV function or adverse outcomes. The original 
method advises that each angiographic run used to assess TMPG must be at least three 
cardiac cycles long. This may be impractical in an acute setting and exposes the patient to 
increased radiation.  
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 Culprit vessel 
The location of the culprit lesion is often suspected from the ECG findings and subsequently 
confirmed on angiography. The culprit vessel is therefore a clinical and an angiographic 
variable. A recent study evaluating 10 PPCI trials showed that a LAD culprit is associated 
with a larger infarct and a higher risk of death following STEMI.113 The location of the culprit 
lesion is associated with infarct size because a larger culprit vessel, or a culprit vessel 
supplying the anterior myocardium, will result in a larger infarct.114  
 
 Summary 
The aims of treatment in STEMI are to improve survival rates and quality of life for patients. 
STEMI is associated with significant mortality and morbidity even if timely treatment with 
primary PCI is performed. The current method of determining PCI success, the TIMI flow 
grade, does not identify many patients with microvascular obstruction. It may be possible 
to identify more of these patients using clinical information and angiographic variables 
during PPCI. This would allow appropriate administration of adjunctive therapies which 
could improve myocardial perfusion, decreasing eventual infarct size and resulting in 
improved survival rates. However, evidence for the use of adjunctive therapies is weak. 
Therefore, using selected variables to identify low-risk patients may be of value and assist 
operators in making decisions regarding length of critical care stays and early discharge.   
  
The development of a systematic and thorough approach to angiogram interpretation is 
likely to add information regarding the success of PPCI. The addition of well-validated 
angiographic grading systems could minimise the use of more invasive tests such as IMR. 
Core laboratories have developed guidance for systematic angiogram interpretation, but 
this is not applied frequently in clinical practice. These methods should be tested to ensure 
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their reproducibility, particularly using angiograms performed in emergencies that are likely 
to be of lower quality than those obtained during elective procedures.  
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 Selection and development of methods for 
angiographic analysis 
 
 Introduction 
HEAT-PPCI was a single-centre, randomised controlled trial comparing unfractionated 
heparin versus bivalirudin in the treatment of patients with suspected STEMI, for planned 
management with PPCI (registered at clinicaltrials.gov NCT01519518).115 The HEAT-PPCI 
database provided complete and extensive data on a large and unselected population of 
patients with suspected STEMI, undergoing PCI. The angiographic images obtained during 
the HEAT-PPCI trial, as well as the complete study database, were available for use in this 
thesis. This included the baseline characteristics of patients, the nature of the clinical 
presentation, details of the angiographic findings and any reperfusion intervention. The 
database also included estimates of infarct size from enzyme release, LV function from 
echocardiographic data, and surveillance for adverse events over the subsequent 28 days 
from the index event.  
 
The aims, methods, analysis and results of each study that uses data from the HEAT-PPCI 
trial are described in detail in subsequent chapters. In the following chapter, I discuss the 
detail of the HEAT-PPCI trial, and the general methods used to collect clinical and 
angiographic data from the HEAT-PPCI angiograms.  
 How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary 
Intervention: The HEAT-PPCI randomised controlled trial 
Patients were randomised (1:1) at presentation to the Liverpool Heart and Chest Hospital 
and before entry into the catheterisation laboratory. Heparin was given as a bolus dose of 
70U/kg bodyweight before the procedure with additional doses administered according to 
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activated clotting times measured during the procedure. Bivalirudin was given as a bolus of 
0.75mg/kg followed by an infusion of 1.75mg/kg per hour for the duration of the 
procedure. Abciximab was allowed for selected use in both groups due to massive 
thrombus, no-reflow or a thrombotic complication. Participants were tracked during their 
index admission for clinical events, by careful review of the case notes, and followed-up for 
28 days following randomisation. In addition, Hospital Episode Statistics (HES) data were 
obtained for participants at 28 days.  
 
The primary efficacy outcome of the HEAT-PPCI trial was the proportion of patients who 
had at least one MACE at 28 days. MACE included all-cause mortality, cerebrovascular 
accident (CVA), reinfarction or additional unplanned target lesion revascularisation (uTLR). 
The primary safety outcome was the proportion of patients who had a major bleed by 28 
days, classified as type 3-5 according to the Bleeding Academic Research Consortium 
(BARC).115 All outcomes were adjudicated by a physician panel, blinded to the treatment 
allocation.  
 
Recruitment took place from 7 February 2012 to 20 November 2013 and 1812 participants 
were included in the HEAT-PPCI final analysis. The results of the HEAT-PPCI trial showed 
that at least one MACE occurred in 79/905=8.7% patients in the bivalirudin group vs 
52/907=5.7% in the heparin group (relative risk 1.52, 95% CI 1.09 to 2.13, p=0.01). This 
difference was mainly due to an increased number of reinfarction events in the bivalirudin 
group (relative risk 3.01 95% CI 1.36 to 6.66). There was no significant difference in all-
cause mortality or cerebrovascular accident between the two groups.  
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 Rationale for selection of grading systems 
Angiographic grading systems were selected for use if they fulfilled the following criteria: 
• Non-invasive - in that they did not require the application of additional equipment 
or software processing beyond the basic angiographic image acquisition and 
playback 
• Previous research had shown an association with LV function and mortality 
• They could be calculated, with relative ease, from the angiogram during the acute 
phase of MI reperfusion treatment  
Some systems were excluded despite having the potential to predict poor outcomes. For 
example, TMPG was not included because it is very similar to MBG. Both measure the 
movement of contrast within the myocardium by grading the visible contrast density on the 
angiogram. However, MBG was preferred because it has been used in more studies and has 
a greater weight of evidence suggesting it can predict infarct size. In addition, TMPG 
requires the duration of the angiographic run to last at least 3 cardiac cycles to ensure 
complete washout of contrast is visualised, making practical application of TMPG more 
challenging, as well as increasing radiation exposure.  
 
 The angiographic core laboratory 
I studied the literature that described the original methods used to apply each angiographic 
grading system and tested them on all angiograms from the HEAT-PPCI trial. The aim of this 
was to assess the practicality of deriving the grading scales from the existing angiograms 
and examine for technical issues in angiogram quality and acquisition that might 
compromise some estimation exercises.  During this phase, I noted a significant proportion 
of angiograms where application of one or more of the grading scales was challenging due 
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to the quality of the angiogram. For example, grading MBG was difficult if there was 
inadequate image centring and run duration, whereas cTFC could not be confidently 
assessed in images where inadequate panning resulted in minimal views of the distal 
vessel.  Prepared by this fastidious review of the angiographic records of more than 1400 
patients, each comprised of multiple angiographic image runs, I was sufficiently acquainted 
with the core methods and problems associated with quantitative angiographic review.  
To gain an understanding of how to apply the grading systems with more consistent quality 
I visited the Angiographic Core Lab at the Beth Israel Deaconess Medical Centre (BIDMC), 
Boston, MA. Angiographic core labs are the “gold standard” for angiographic analysis. It is 
common practice for research studies of coronary intervention to request angiographic 
core labs to analyse angiograms in clinical trials to ensure accuracy and consistency of 
interpretation and to limit bias. 
The BIDMC core lab was run by the PERFUSE study group who developed the original 
methodology for TIMI flow, cTFC, TIMI thrombus burden and TMPG. I spent 5 days in 
Boston learning the methods of angiographic assessment used at the BIDMC core lab. I was 
able to refine the techniques as defined in the literature for application to a wider range of 
coronary anatomy and angiogram quality.   
 
 Accessing and reviewing the angiograms from the HEAT-PPCI trial  
 A “typical” PPCI procedure 
The details of a PPCI procedure will vary depending on the underlying anatomy and 
pathology of the individual and any complications that arise during the procedure. The 
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following section describes a “typical” PPCI procedure and the process of acquisition of 
PPCI angiograms. 
  
A patient with suspected STEMI is brought into the catheterisation laboratory (lab). The 
arterial access site, usually the right radial artery, is cleaned and infiltrated with local 
anaesthetic.  The operator accessed the arterial system by introducing a sheath into the 
radial artery. Once the sheath is securely placed, the operator introduces a catheter into 
the sheath and manoeuvres the catheter through the arterial system to the ostia of the 
coronaries, under x-ray guidance. Contrast is injected along the length of the catheter to fill 
the target vessel and allow visualisation of the coronary arteries. Once the coronary 
arteries are visualised, the obstructed culprit artery is identified and treated. Treatment 
varied depending on the severity and location of the lesion but usually involved passing a 
wire along the obstructed artery and using other devices (usually balloons or hollow 
thrombus aspiration catheters) to restore blood flow. Stents might then be placed into the 
culprit segment to attempt to restore normal luminal geometry, to support areas of injury 
or dissection in the vessel lining, and aid successful reperfusion. 
 Obtaining angiograms 
Each lab is fitted with an x-ray emitter and image intensifier which are attached to rotating 
arms and can be moved around the patient to view the coronary arteries at different 
angles. If a biplane lab is used, then two x-ray emitters and two image intensifiers are 
available and produce video images (cineruns) in two different planes for a given injection 
of contrast. The x-ray images are viewed on screens visible to the operator in the lab.  
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The operator views the coronaries on the screens and controls the acquisition of cineruns 
for storage and retrospective review. Selected cineruns that are saved for later review are 
obtained at a higher frame rate to increase the quality of the image. 
 Review of the angiograms 
The angiograms from the HEAT-PPCI trial were reviewed using the viewing software Philips 
Xcelera version 3.2. Each cinerun was stored in chronologically order and could be 
retrospectively viewed and analysed in sequence.  
 Quality of the angiograms 
The images stored within Xcelera are compressed to allow multiple images to be stored on 
the hospital network. This is associated with some reduction in image quality when 
compared to the angiograms viewed in the lab during the procedure. In addition, the 
overall image quality can be affected by body habitus and positioning of the patient. Clear 
visualisation of the coronary artery anatomy is required for confident assessment of the 
grading systems.  
 
 Database creation 
The aim was to create a database that allowed easy but structured data collection of the 
selected angiographic grading systems. A detailed description of the database design and 
creation is included in Appendix 1. 
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 Methodology for assessing each angiographic grading system 
 TIMI flow grade 
The TIMI flow grades were recorded as values between 0 and 3 (Chapter 1, Table 1.1).26  
 TIMI thrombus grade 
TIMI thrombus grade was measured using the grading system originally developed by the 
TIMI study group (Chapter 1, Table 1.3).94 To measure thrombus burden, I used the cinerun 
that displayed the first time-point at which dye flows distal to the occlusion. This view 
ensured the thrombus was fully visualised because the flow of contrast was able to outline 
the full mass before the thrombus was likely to be dislodged from the vessel wall. 
Displacement of the thrombus normally occurs after initial wire insertion or balloon 
dilatation of the culprit vessel. If initial wiring or ballooning did not allow blood flow distal 
to the thrombus, and the vessel remained totally occluded, then the thrombus burden was 
graded 5: total occlusion. If thrombus aspiration was performed, the thrombus burden was 
graded in the cinerun before thrombus aspiration. The thrombus burden was graded using 
a measuring tool within the angiogram viewing software (Figure 2.1).  The size of the 
thrombus was measured relative to the vessel diameter, allowing calculation of the ratio of 
thrombus length to vessel diameter and an assessment of thrombus burden (Figure 2.2). A 
change in the angiographic projection angle can make a linear mass appear shorted. This 
can be a source of error. For consistency, measurements of thrombus were made from the 
view where the thrombus appeared to have the longest length. 
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Figure 2.1: The measuring tool within the angiogram viewing software, Xcelera, used to 
measure the length of thrombus burden in the culprit artery 
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Figure 2.2: Using the measuring tool in Xcelera to compare the length of thrombus with 
the diameter of the culprit vessel to grade the thrombus burden 
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Figure 2.3: A: Frame -1, before dye injection B: Frame 0, dye has reached both sides of the 
vessel but there is no evidence of antegrade flow. C: Frame 1, there is clear demarcation 
of the vessel walls and evidence of antegrade flow. This is the initial frame. 
 
 Corrected TIMI Frame Count (cTFC) 
Corrected TIMI frame count (cTFC) was calculated using the method described in the TIMI 4 
trial.99 The cTFC estimates the speed of contrast moving down the coronary artery by 
counting the number of cineframes required for contrast to reach standardised distal 
coronary landmarks. 
 Selecting the initial frame for cTFC 
The first frame used to calculate cTFC was the frame in which dye first fully enters the 
culprit artery after injection of contrast. This was defined when three criteria were met 
(Figure 2.3): 
• A column of nearly full or fully concentrated dye must extend across the entire 
width of the origin of the artery.  
• Dye must touch both borders of the origin of the artery. 
• There must be antegrade motion to the dye  
If the location of the vessel walls was not clear, then the frame where the width of dye 
across the vessel is at a maximum was used.  
 
 
 
   
 
 
A B C 
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If the LAD was subselectively engaged and the circumflex was being assessed, the first 
frame was counted from when the dye first touches both borders of the Cx. 
 Selecting the final frame for cTFC 
The last frame was counted when dye first entered the distal landmark branch. Full 
opacification of the branch was not required; the initial opacification of the branch was 
counted as the final frame.  
 
The distal landmark branches used for analysis: 
• LAD: the distal bifurcation (i.e. the “pitchfork” or “whale’s tail”) (Figure 2.4 – image 
reproduced with permission – see Appendix 2). 
• Circumflex: distal bifurcation of the segment with the longest total distance. If the 
circumflex was the culprit artery, then the longest distance that includes the culprit 
lesion was used (Figure 2.4). 
• Right coronary artery: the first branch arising from the posterior lateral extension 
of the RCA after the origin of the posterior descending artery 
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Figure 2.4: Anatomical landmarks used for TIMI frame counting in LAD and Cx vessels 
 
For the final frame, the branch used must be present for more than one consecutive frame. 
This ensures that it is not a branch from another vessel (overlapping the region of interest) 
or artefact. To identify the final frame in all vessels except the RCA (and branches arising 
from the RCA), I used the branch that appears most distally along the vessel or on the 
vessel closest to the apex in the LAD. If a proximal branch fills after the most distal branch, 
then we used the proximal branch. This is because I was trying to measure the speed of 
blood flow and extent of myocardial perfusion, therefore the last vessel to fill should be the 
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final frame as this will give an approximation of the time taken to fill the smaller vessels and 
microvasculature.  
 Optimum angiographic views for assessing cTFC 
When choosing the correct angiographic image to use for assessing the cTFC, circumflex 
vessels were best assessed in the right or left anterior oblique views with caudal angulation 
whereas the LAD was best assessed with cranial or lateral angulation. The RCA was best 
assessed in the left anterior oblique projection with steep cranial angulation.  
 Correcting for vessel length when assessing cTFC in the LAD.  
The frame count does not differ significantly between the RCA and circumflex. However, 
the frame count in the LAD was significantly increased because the LAD is longer in length 
than the RCA or circumflex. Therefore, the frame count measured for the LAD was divided 
by 1.7 to calculate the final cTFC.   
 cTFC in wraparound LADs 
A proportion of LAD arteries wrapped around the apex of the heart. When measuring the 
TFC in such vessels the aim was to measure the final frame at the frame contrast enters the 
branch that occurs closest to the apex. This vessel is best chosen by drawing a straight line 
from the ostium of the LAD to the apex and choosing the vessel closest to the line (Figure 
2.5). 
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Figure 2.5: Selecting the branch closest to the apex for establishing the final frame for 
cTFC assessment of the LAD 
 
 Estimating cTFC when the full length of a vessel is not visualised 
Some angiograms did not visualise the full length of the culprit vessel. In these cases, the 
vessel length was estimated based on looking at the length of the vessel in other runs and 
the cTFC was measured based on the visible fraction of the vessel on the angiogram. The 
cTFC was then estimated for total length of the vessel giving the “estimated cTFC.”   
 
 Intermediate and diagonal culprit arteries 
CTFC in intermediate and diagonal arteries was measured using the same method as in the 
circumflex artery: I counted the number of frames until contrast reached the most distal 
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bifurcation. If the culprit was the diagonal artery, the initial frame was counted from the 
ostium of the LAD.  
 Posterior left ventricular artery culprit 
If the culprit lesion was the posterior left ventricular (PLV) artery, I recorded the final frame 
as the frame where the first branch of the PLV after the culprit lesion first appeared. 
The original method of measuring cTFC in the RCA specifies counting cTFC to the first 
branch after the origin of the PDA. If the culprit is the PDA or interventricular branch, then 
the branch immediately distal to the culprit branch was used. 
 Frame speed 
The cTFC is designed for angiograms acquired at 30 frames per second. Some angiograms 
during PPCI were acquired at 15 frames per second. To ensure the correct value for TFC was 
recorded, the number of frames counted was corrected for the frame rate, using 30 frames 
per second as the standard. 
 cTFC in an occluded culprit 
If the culprit vessel was occluded, then the cTFC could not be calculated and the 
corresponding database field was left blank.  
 Use of nitrates 
In HEAT-PPCI, the use of nitrates was not recorded, therefore cTFC was not corrected for 
nitrate use, as suggested in the original method.  
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 Myocardial Blush Grade (MBG) 
The MBG was calculated by examining the flow of contrast into the myocardium perfused 
by the culprit artery (either right or left), using the method developed by van’t Hof et al.104 
Figure 2.6 illustrates an example of normal myocardial blush in the RCA.  
 
Figure 2.6: Normal grade 3 myocardial blush is demonstrated in the RCA. The region of 
myocardial blush is ringed in red in the right-hand image 
 
Myocardial blush was graded as normal (grade 3) if the density of contrast appearing in the 
myocardium perfused by the culprit was equal to the density observed in the non-culprit 
side. If the density was less in the culprit side than the non-culprit side, MBG was graded as 
1 or 2, according to the definitions in Chapter 1, Table 1.4. If no contrast appeared in the 
culprit side, MBG was graded 0. The run with the best projection was chosen to assess the 
myocardial region of the infarct-related coronary artery. Angiographic runs had to be 
sustained for long enough to allow some filling of the venous system. Backflow of contrast 
into the aorta should be present to be sure of adequate contrast filling into the epicardial 
coronary artery. If these criteria were not met, the MBG could not be calculated and the 
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corresponding database field was left blank. If myocardial blush is present before the 
injection of contrast, also known as “staining”, this was noted in the study database.  
The method developed by van’t Hof et al. to assess the MBG involved all patients receiving 
the same dose of intracoronary nitroglycerin. In HEAT-PPCI there was no standardization of 
administration of IC nitroglycerin which may have affected the MBG grade.  
 
 Limitations 
In the initial testing phase, I attempted to measure the grading systems as they were 
described in the literature. I found the original methods lacked detail to allow analysis of all 
angiograms in the HEAT-PPCI trial. I addressed these issues at the core lab and adopted 
their specific and proven methods of angiographic assessment.  However, because the core 
labs do not publish their own methods of angiogram analysis there is likely to be variability 
between core labs as well as between research teams using these grading systems. A 
comprehensive method of assessing the grading systems should be published by the core 
labs to ensure the grades are comparable when used in different studies.  
The accuracy of measurements is likely to differ across angiograms of varying quality. Our 
data was collected retrospectively, and the angiograms used were not obtained for the 
purpose of assessing the selected grading systems. In some cases, I was unable to assess a 
grading system because of poor angiographic quality. PPCI angiograms tend to be of poorer 
quality than those used in stable disease and this may impact the reproducibility of our 
methods between observers in the PPCI setting. I address the interobserver variability of 
the angiographic grading systems in Chapter 6.  
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 An examination of the use of Hospital Episode 
Statistics to identify outcomes in clinical trials  
  
 Introduction 
The HEAT-PPCI trial tracked and recorded clinical outcomes for each patient up to 28 days 
following the acute STEMI event. This data could be used to explore possible associations 
between selected clinical and angiographic variables and outcomes. However, establishing 
outcomes for longer follow-up periods can perhaps better elucidate potential differences in 
efficacy between treatments as well as identify late complications.  
Traditional methods of follow-up are often expensive and time-consuming, involving direct 
contact with each study participant over a prolonged period. The use of novel methods of 
trial follow-up, such as electronic databases, may reduce the cost, be more convenient for 
research staff and patients, and avoid loss to follow-up. I aimed to extend the follow-up for 
participants in HEAT-PPCI to 12 months following randomisation using Hospital Episode 
Statistics (HES) data. HES is a centralised database containing information for all patient 
care delivered in England in NHS facilities. HES is compiled from the coding data received 
from NHS trusts. Each episode of care is identified from the patients’ hospital notes and 
recorded as a series of diagnostic and procedural codes. The diagnostic codes are taken 
from ICD-10 (International Classification of Diseases 10th Revision). Each code in HES is 
associated with a tariff that determines how much the hospital is paid per admission. 
Before I could plan a study using HES data to identify outcomes, I needed to establish the 
accuracy of HES in identifying clinical events when compared to traditional methods of 
follow-up.   
The objective of this study was to compare the ability of HES data to identify the occurrence 
of trial-specific events declared by adjudication after examination of individual medical 
records. A second objective was to use the data from the HEAT-PPCI trial to compare ability 
68 
 
of the individual direct contact and HES methods to determine the incidence of confirmed 
readmission.  
 
 Methods 
 Patients and study design 
The HEAT-PPCI trial is described in detail in Chapter 2. The primary objective of follow-up in 
HEAT-PPCI was to establish vital status and the occurrence of any pre-specified outcome 
measures. This involved the identification of all overnight admissions during the follow-up 
period and was achieved by direct patient contact (DC) at 4-6 weeks following 
randomisation. In addition, HES reports were examined for each patient to supplement the 
information obtained by DC. Suspected readmission events identified by HES were then 
confirmed by review of the medical notes.     
 Method of assessing the accuracy of DC and HES in identifying readmissions 
Patients who had both a HES report and were tracked by direct contact were included in 
the analysis. The number of readmissions determined by the individual DC and HES 
methods were then compared to the total number of readmissions suggested by the two 
methods and then confirmed by review of the medical notes. When evaluating DC, if a 
readmission was not identified by DC but was identified by HES and subsequently 
confirmed by medical notes review, this was recorded as a false negative result. When 
evaluating the HES data, if a readmission was identified in the HES data but not confirmed 
by medical notes review, this was recorded as a false positive result. If a readmission was 
not identified by HES but was identified by DC and subsequently confirmed by medical 
notes review, this was recorded as a false negative result. From these data I could then 
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calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) of each method.  
 Method of assessing the diagnostic accuracy of HES data 
The primary efficacy outcome of the HEAT-PPCI trial was the proportion of patients who 
had at least one MACE event at 28 days, as defined in chapter 2. The primary safety 
outcome was the proportion of patients who had at least one major bleed by 28 days, 
classified as BARC type 3-5. Key clinical information from each patient was reviewed by a 
blinded physician adjudication panel. This panel would then establish if outcome events 
had occurred in terms of the specific event definitions declared in the trial protocol.  
The HES data obtained for the 28 days following randomisation were examined to identify 
ICD-10 codes that indicated the occurrence of any primary efficacy or safety outcome pre-
specified in the HEAT-PPCI trial. All patients who were randomised, and for whom HES data 
was obtained, were included in this analysis. To identify key clinical events, the relevant 
ICD-10 codes were used to search the HES database (Tables 3.1 and 3.2). The events 
identified in the HES data were compared with those declared by physician adjudication. If 
a diagnosis was identified in HES that was not identified by physician adjudication, this was 
recorded as a false positive result. If a diagnosis was not identified in HES but was identified 
by physician adjudication, this was recorded as a false negative result.  
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ICD-10 codes used to identify     
recurrent myocardial 
infarctions 
Decoded diagnosis 
I210 ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF ANTERIOR WALL 
I211 ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF INFERIOR WALL 
I212 ACUTE TRANSMURAL MYOCARDIAL INFARCTION OF OTHER SITES 
I213 ACUTE TRANSMURAL MYOCARDIAL INFARCTION, UNSPECIFIED 
I214 ACUTE SUBENDOCARDIAL MYOCARDIAL INFARCTION 
I219 ACUTE MYOCARDIAL INFARCTION, UNSPECIFIED 
I220 SUBSEQUENT MYOCARDIAL INFARCTION OF ANTERIOR WALL 
I221 SUBSEQUENT MYOCARDIAL INFARCTION OF INFERIOR WALL 
I228 SUBSEQUENT MYOCARDIAL INFARCTION OF OTHER SITES 
I229 SUBSEQUENT MYOCARDIAL INFARCTION OF UNSPECIFIED SITE 
  
ICD-10 codes used to identify 
strokes Decoded diagnosis 
I606 SUBARACHNOID HAEMORRHAGE FROM OTHER INTRACRANIAL ARTERIES 
I609 SUBARACHNOID HAEMORRHAGE, UNSPECIFIED 
I611 INTRACEREBRAL HAEMORRHAGE IN HEMISPHERE, CORTICAL 
I618 OTHER INTRACEREBRAL HAEMORRHAGE 
I629 INTRACRANIAL HAEMORRHAGE (NONTRAUMATIC), UNSPECIFIED 
I630 CEREBRAL INFARCTION DUE TO THROMBOSIS OF PRECEREBRAL ARTERIES 
I633 CEREBRAL INFARCTION DUE TO THROMBOSIS OF CEREBRAL ARTERIES 
I634 CEREBRAL INFARCTION DUE TO EMBOLISM OF CEREBRAL ARTERIES 
I638 OTHER CEREBRAL INFARCTION 
I639 CEREBRAL INFARCTION, UNSPECIFIED 
I64X STROKE, NOT SPECIFIED AS HAEMORRHAGE OR INFARCTION 
Table 3.1: ICD-10 codes used to search the HES database and identify outcome events 
for stroke and recurrent myocardial infarction 
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ICD-10 codes used to identify 
bleeds Decoded diagnosis 
D500 IRON DEFICIENCY ANAEMIA SECONDARY TO BLOOD LOSS (CHRONIC) 
H313 CHOROIDAL HAEMORRHAGE OR RUPTURE 
H356 RETINAL HAEMORRHAGE 
H431 VITREOUS HAEMORRHAGE 
J942 HAEMOTHORAX 
K226 GASTRO-OESOPHAGEAL LACERATION-HAEMORRHAGE SYNDROME 
K25 GASTRIC ULCER 
K26 DUODENAL ULCER 
K27 PEPTIC ULCER 
K28 GASTROJEJUNAL ULCER 
K625 HAEMORRHAGE OF ANUS AND RECTUM 
K920 HAEMATEMESIS 
K921 MALAENA 
K922 GASTROINTESTINAL HAEMORRHAGE, UNSPECIFIED 
I60 SUBARACHNOID HAEMORRHAGE 
I61 INTRACEREBRAL HAEMORRHAGE 
I62 OTHER NON-TRAUMATIC INTRACRANIAL HAEMORRHAGE 
N421 CONGESTION AND HAEMORRHAGE OF PROSTATE 
R04 HAEMORRHAGE FROM RESPIRATORY PASSAGES 
R58 HAEMORRHAGE, NOT ELSEWHERE CLASSIFIED 
S064 EPIDURAL HAEMORRHAGE 
S066 TRAUMATIC SUBDURAL HAEMORRHAGE 
S065 TRAUMATIC SUBARACHNOID HAEMORRHAGE 
T792 TRAUMATIC SECONDARY AND RECURRENT HAEMORRHAGE 
T810 HAEMORRHAGE AND HAEMATOMA COMPLICATING A PROCEDURE 
T812 ACCIDENTAL PUNCTURE AND LACERATION DURING A PROCEDURE 
Table 3.2: ICD-10 codes used to search the HES database and identify outcome events for 
bleeding events 
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 Results 
 Identifying readmissions 
The HEAT-PPCI trial included 1812 patients. Following randomisation, 73 patients died in 
hospital before they were discharged from the index event and 39 participants remained 
inpatients at 28 days. Of the remaining 1700 with the potential to be re-admitted during 
the 28-day follow-up period, 1644/1700 = 96.7% were successfully followed up by both DC 
and HES (Figure 3.1). The method of direct contact used was recorded for all participants 
(Table 3.3). 
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1700 follow-up by direct contact and HES is attempted 
1644 successfully followed up by both methods  
56 do not have BOTH HES and direct 
contact: 
3 lost to direct contact  
52 lost to HES 
1 lost to both direct contact and HES  
 
1812 included in HEAT-PPCI analysis 
112 do not require follow-up: 
73 died during index period 
39 remained inpatients at 28 days 
 
1424 have no readmission identified by 
either method 
 
HES OR direct contact identifies 234 readmissions  
167 readmissions are confirmed by review of medical notes 
67 readmissions are refuted by 
review of medical notes 
139 patients confirmed to have 
a single readmission  
14 patients confirmed to 
have 2 readmissions 
Figure 3.1: Flow diagram outlining the follow up obtained by direct contact and HES 
methodology for identifying readmissions 
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Method of direct contact used Number of patients 
Mail 1153 (70.1%) 
Telephone 334 (20.3%) 
Other direct patient contact (email, text message) 47 (2.9%) 
GP or other primary care provider 48 (2.9%) 
Outpatient clinic 44 (2.7%) 
Inpatient 18 (1.1%) 
Total  1644 
Table 3.3: Methods of direct contact used to complete follow-up in HEAT-PPCI 
 
The full results of the analysis of readmissions are presented in Table 3.4. HES identified 
153/166 of confirmed readmissions (sensitivity: 153/166 = 92.2%; 95% CI 87.1% to 95.4%). 
HES missed 13 confirmed readmissions. All readmissions identified by HES were confirmed 
readmissions (specificity: 1492/1492 = 100%; 95% CI 99.7 to 100). During the follow-up 
period, 14 patients experienced 2 confirmed readmissions and 28/28 = 100% of these were 
identified in HES.  
 
DC identified 144/166 confirmed readmissions (Sensitivity: 144/166 = 86.7%; 95% CI 80.7 to 
91.1) and missed 22 confirmed readmissions. DC identified 66 suspected readmissions that 
were not found to be confirmed readmissions (Specificity: 95.6%; 95% CI 94.4 to 96.5). DC 
identified 16/28 readmissions in patients found to have 2 confirmed readmissions.  
 
 
 Outcome from physician adjudication Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) 
 Readmission No readmission     
HES detects readmission 153 0     
HES does not detect readmission 13 1492 92.2 (87.1 to 95.4) 100 (99.7 to 100) 100 (97.6 to 100) 99.1 (98.5 to 99.5) 
 Readmission No readmission     
DC detects readmission 144 66     
DC does not detect readmission 22 1426 86.7 (80.7 to 91.1) 95.6 (94.4 to 96.5) 68.6 (62.0 to 74.5) 98.5 (97.7 to 98.9) 
Table 3.4: The readmissions confirmed by adjudication in the HEAT-PPCI trial are compared to the HES method and the direct contact method of 
identifying readmissions.    
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 Identifying clinical events 
Evaluable HES data was obtained for 1754 patients. Figure 3.2 describes the reasons why 
these data were not obtained for other trial subjects. The full results for this analysis are 
presented in Table 3.5.  
During the index admission, HES correctly identified 1/29 = 3.4% (95% CI 0.6 to 17.2) of the 
recurrent MIs, 16/22 = 72.7% (95% CI 51.8 to 86.8) CVAs and 143/222 = 64.6% (95% CI 57.9 
to 70.4) bleeding events. HES identified 15 recurrent MIs, 1 CVA and 175 bleeding events 
that were not confirmed by adjudication.  
Following discharge, HES identified 2/3 = 66.7% (95% CI 20.8 to 93.9) of recurrent MIs, 4/5 
= 80.0% (95% CI 37.6 to 96.3) CVAs and 15/31 = 48.4% (95% CI 31.9 to 65.2) bleeding 
events. HES incorrectly identified 46 recurrent MIs, 8 CVAs and 7 bleeding events that were 
not confirmed on adjudication. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 patients have 
recurrent MIs 
identified in HES  
333 patients have 
bleeding events 
identified in HES  
 
24 patients have 
CVAs identified in 
HES  
 
85 patients died, 
identified in NHS 
mortality database 
1754 had HES data available for analysis 
1812 included in HEAT-PPCI analysis 
58 patients had no evaluable HES data: 
13 had no NHS number 
43 were not found in HES database 
2 had incorrect NHS numbers 
Figure 3.2: Flow diagram outlining the number of patients who were identified by HES as having a clinical 
event in the 28 days following randomisation 
 
 
Table 3.5: The diagnostic accuracy of the HES data in identifying patients with outcome events during the index admission and in any readmission in the 
follow-up period is compared to the standard provided by the adjudicated events. By assuming the adjudicated events are accurate, the sensitivity and 
specificity of each method can be calculated 
   
 
No. of patients with event during the index admission (prior to discharge) 
Outcome from Physician Adjudication Sensitivity (CI) Specificity (CI) PPV (CI) NPV (CI) 
 Recurrent MI No recurrent MI     
HES detects recurrent MI 1 15     
HES does not detect recurrent MI 28 1710 3.4 (0.6 to 17.2) 99.1 (98.6 to 99.5) 6.2 (1.1 to 28.3) 98.3 (97.7 to 98.9) 
 CVA  No CVA      
HES detects CVA 16 1     
HES does not detect CVA  6 1731 72.7 (51.8 to 86.8) 99.9 (99.7 to 99.9) 94.1 (73.0 to 98.9) 99.7 (99.2 to 99.8) 
  Bleed  No bleed      
HES detects bleeding  143 175     
HES does not detect bleeding  79 1357 64.6 (57.9 to 70.4) 88.6 (86.7 to 90.0) 44.9 (39.6 to 50.5) 94.4 (93.2 to 95.6) 
 
No. of patients with events after discharge 
      
 Recurrent MI No recurrent MI     
HES detects recurrent MI  2 46     
HES does not detect recurrent MI  1 1705 66.7 (20.8 to 93.9) 97.4 (96.5 to 98.0) 4.2 (1.2 to 13.9) 99.9 (99.7 to 100) 
  CVA No CVA      
HES detects CVA 4 8     
HES does not detect CVA  1    1741 80.0 (37.6 to 96.4) 99.5 (99.1 to 99.8) 33.3 (13.8 to 60.9) 99.9 (99.7 to 100) 
 
HES detects bleeding  
HES does not detect bleeding  
Bleed 
15 
16 
No bleeding  
7 
1716 48.4 (32.0 to 65.2) 99.6 (99.2 to 99.8) 68.2 (47.3 to 83.6) 99.1 (98.5 to 99.4) 
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 Discussion 
 Main findings of this study  
HES and DC are both effective methods of ascertaining readmission in a clinical trial. The 
results show that the most comprehensive information was obtained when both methods 
were used together. Compared to DC, HES demonstrated a trend towards better sensitivity 
and specificity. An analysis of HES coding does not result in rates for specific events that 
match those from adjudication, with limitations in both sensitivity and specificity.   
 What is already known on this topic 
A recent study showed that the use of HES data in research has increased from 1 
publication in 1996 to a total of 520 publications by 2014.116 This trend may be due to 
advantages in using HES over more traditional methods of data collection. For instance, HES 
captures all events, diagnoses and procedures as perceived by the health service. It records 
what ‘the system says has occurred’ during a hospital admission. This information may 
better reflect the true societal impact, both clinical and fiscal, of the outcomes of trial 
patients. A study looking at the accuracy of using HES data to calculate inpatient costs 
found that data from HES was accurate when compared to data collected from medical 
notes review.117 The mean difference in costs between the two methods was £899 with HES 
calculating 8% lower costs than medical records. HES data could, therefore, be useful in 
trials aiming to analyse the economic impact of treatments. Traditional trial follow-up pre-
specifies the definitions of a clinical event using thresholds for confirming a diagnosis. This 
selective approach may not accurately reflect the patient experience or cost to the health 
service. A study looking at the non-fatal/non-MACE adverse events in a trial compared PCI 
to coronary artery bypass grafting (CABG) in patients with 2 or 3-vessel coronary artery 
disease.118 The results showed that CABG was associated with a greater number of non-
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MACE events despite the original trial publication favouring CABG because of a lower 
number of MACE adverse events.119 MACE are commonly used as the primary outcome 
measures in trials of cardiovascular interventions. Since HES identifies any hospital 
admission, these data could be used in trials wishing to examine the broader physical and 
psychological impact of admission.  
The accuracy of HES data may vary over time between institutions and is dependent on the 
quality of the clinical coding performed by each NHS trust. In 2013-14 an audit was 
performed of the clinical coding at 50 acute trusts assessing the accuracy of the ICD-10 
codes allocated to each admission. The average error rate, defined as a change to the codes 
that would result in a change in the payment received by each trust, was 7%.120 The lowest 
percentage error for a given trust was 1.1% and the highest 45.8%, demonstrating 
considerable variability in the accuracy of clinical coding across trusts. A systematic review 
performed in 2013 looked at studies of the accuracy of HES data when compared to clinical 
registries and case notes.121 Although there is no consensus for an acceptable threshold of 
diagnostic accuracy, the median accuracy of the HES diagnostic codes was 80.3% when 
compared to notes review or clinical registry data.122 This review also found that there has 
been an improvement in the diagnostic accuracy of HES data over time. A recent study by 
Wright-Hughes et al., assessing the accuracy of HES data in a trial investigating self-harm in 
adolescents, found that HES identified more than double the number of hospital 
attendances that were recorded by researchers.123 In addition, HES identified 62% of self-
harm diagnoses compared to diagnoses reported by researchers. This study concluded that 
HES data is useful in identifying hospital admissions but less accurate in identifying trial-
specific clinical diagnoses.  
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 What this study adds 
In our study, 153/153 = 100% of the readmissions identified by HES were confirmed by 
medical notes review. In comparison, 66/210 = 31.4% of readmissions were identified 
incorrectly by DC. Using HES data removes the need to directly contact any trial patient and 
is likely to reduce the workload of a trial and, subsequently, the overall cost. When a 
patient reports a clinical event or readmission, this is thoroughly investigated by the 
research team, who must review the medical notes to confirm or refute the claim. If HES 
data is used, the reduction in workload may allow trial centres to divert resources from 
follow-up to trial recruitment activity. 
This study showed that accuracy of HES in identifying clinical events is limited, in terms of 
the specific diagnostic thresholds that are the norm in clinical trials. The highly specific trial 
definitions of clinical outcomes in the HEAT-PPCI trial were not developed to be 
comparable to the ICD-10 codes used in HES. Therefore, the frequency of clinical events 
identified in HES is likely to differ when compared to physician adjudicated events. For 
instance, we were unable to stratify bleeding events into degrees of severity because this is 
not specified in any ICD-10 code. Therefore, regardless of severity, all bleeds were flagged 
as events. This demonstrates the limitations related to the number and complexity of 
diagnoses included in the ICD-10. For researchers planning to use HES in a clinical trial, one 
solution would be to tailor clinical outcomes to specific ICD-10 diagnoses. This would 
ensure that the pre-specified outcome measure can be identified in the HES database.  
I was unable to perform analyses for the outcomes of unplanned target lesion 
revascularisation because I could not apply the usual range of trial qualifiers to the 
outcome of additional revascularisation. For example, the ICD-10 codes do not distinguish 
between planned and unplanned revascularisation. A possible solution would be to ensure 
future treatment intentions are recorded on the clinical record form of each patient 
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following the index event. This information could then be used with the HES database to 
establish if further intervention was planned or unplanned.  
HES data only reports admissions that occur in hospitals in England. 2 of the 14 false 
negative readmission events in HES occurred outside this area. This limits the usefulness of 
HES data in tracking patients who move outside of England, or those who are admitted to 
hospitals when abroad. One solution would be to limit study inclusion to those with NHS 
numbers who are resident in England. However, this limits the recruitment and ability to 
generalise the results of the study and does not solve the issue of patients who are 
admitted to hospitals abroad or who live on the border of England and another UK home 
nation or the Republic of Ireland. There is an equivalent of HES data for Wales and 
Scotland, which also use ICD-10 codes and should be used in addition to the English HES 
database. 
The use of the NHS number as an identifier is useful in trials with lengthy follow-up because 
the NHS number remains the same even if a patient moves or changes their name or phone 
number. However, patients without an NHS number will be missed. In this study, 58/1812 = 
3.2% of patients did not return any data in the HES database. There were 13/58 = 22.4% 
patients who did not have an NHS number and an error was found in the NHS number of 
2/58 = 3.4% so the HES database could not identify these patients. This error could be 
reduced by using a simple check digit code to ensure all NHS numbers are correct at the 
time of original recruitment. Using more meticulous methods of checking and rechecking 
the NHS number by the study team would also reduce errors.   
 Limitations of this study 
This study reported very small numbers of clinical events prompting readmission following 
the index event. For example, only 5 strokes occurred after the index admission. It is 
therefore impossible to draw conclusions from such numbers. This study assessed 
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identification of recurrent MI, CVAs and bleeding events. Our assessment of the diagnostic 
accuracy of HES data is therefore limited to a small number of ICD-10 codes. This limits the 
generalisability of the results to studies looking at similar outcome measures. More studies 
should be performed to assess the accuracy of HES data across a wider range of diagnostic 
codes. 
Data from medical notes and physician adjudication were used to confirm the occurrence 
of a readmission or clinical event. I, therefore, had to assume that the medical notes are 
accurate and complete. Any errors or omissions in the medical notes would have affected 
the results. 
The adjudication seeks to ensure events are declared to match trial definitions. These may 
be different from “normal” clinical definitions and from the definitions used to code 
diagnoses in HES. Therefore, when using the same clinical information, there may be 
differences in the numbers of outcomes reported by each, creating perceived errors in the 
HES data.  
Suspected readmissions identified by DC and HES were subsequently confirmed or refuted 
by medical notes review. For confirmation to occur, the suspected readmission had to be 
initially identified by either DC or HES. Therefore, any readmissions missed by both DC and 
HES would not have been identified in the HEAT-PPCI trial follow-up. To ensure all 
readmission events were identified, without using DC or HES, the medical notes of every 
patient in the HEAT-PPCI trial would have to be reviewed which was beyond the resources 
of this study.  
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 Conclusion 
A combination of HES and direct contact provides a comprehensive method of follow-up 
superior to either method alone. Using HES may reduce the resource burden and cost of 
follow-up in clinical studies. HES cannot accurately identify outcome measure events to 
match specific trial definitions tested by independent adjudication. However, the numbers 
of clinical events in this analysis are too small to draw definite conclusions about the 
accuracy of HES data when used for this purpose. A HES-based approach may also provide 
information about the general patient experience and total healthcare costs of a trial. Using 
HES may support patient recruitment and the completeness of follow-up by reducing the 
workload for both investigators and patients.  
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 12-month follow-up from the HEAT-PPCI trial 
 
 Introduction 
In Chapter 3, I examined the accuracy of HES data when used to identify non- fatal clinical 
events in an RCT. There are limitations in both the specificity and sensitivity of this method 
when compared to events identified and confirmed by review of medical notes. For these 
types of events, I concluded that using HES to extend follow-up to 12 months would not 
provide accurate information. In this Chapter, I aimed to identify the mortality rate at 12 
months for patients in HEAT-PPCI and categorise cardiovascular and non-cardiovascular 
causes of death. The rationale for this was: 1) to complete the pre-specified follow-up for 
the HEAT-PPCI trial by recording the 12-month mortality 2) to use the mortality data as a 
clinical outcome in the derivation study for the Liverpool MI Risk Model.  
 
 Background 
There is continuing debate about the relative safety and efficacy of unfractionated heparin 
and bivalirudin when used as the peri-procedural systemic anticoagulant at the time of PPCI 
for the acute reperfusion of myocardial infarction. Several clinical trials and meta-analyses 
have addressed this issue.124-132 There is general agreement that the use of bivalirudin is 
associated with an increased rate of subsequent stent thrombosis but may induce less 
bleeding when compared to higher dose heparin regimes or the combined use of heparin 
and glycoprotein IIbIIIa receptor antagonist (GPI) agents.124-126,130 Trials report conflicting 
results regarding potential advantages of either agent in terms of short- or medium-term 
mortality, although it is difficult to compare results because of differential use of GPIs 
between the treatment groups.  
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 Methods 
In HEAT-PPCI, patients were randomised to heparin (bolus 70U/kg) or bivalirudin (bolus 
0.75mg/kg followed by an infusion 1.75mg/kg/h for the duration of the procedure). The 
design and 28-day results of the HEAT-PPCI trial have been published and discussed in 
earlier chapters.115 The protocol for HEAT-PPCI specified an extended follow-up period for 
analysis of mortality at 12 months. This study reports the results of the pre-specified 
analysis and a post-hoc analysis for cardiovascular and non-cardiovascular cause of death.  
Patients who had died between 28 days and 12 months following randomisation were 
identified using data from Demographics Batch Service, a national database controlled by 
NHS Digital. The cause of death for those who died during this period was then ascertained 
by obtaining death certificates from the national or local registry offices. The cause of death 
was classified as cardiovascular or non-cardiovascular by an adjudication panel, blinded to 
treatment allocation. The panel used to review the events was different from the panel 
used to adjudicate events at 28 days. Cardiovascular causes of death included: myocardial 
infarction, cardiac failure, arrhythmia, cerebrovascular accident, bleeding events, 
pulmonary embolism and dissection. All deaths that developed as a direct result of events 
originating from the index event were considered cardiovascular. Only deaths due to a 
clear, documented, non-cardiovascular cause (e.g. cancer, road-traffic accident) were 
classified as non-cardiovascular. Patients with an unknown or uncertain cause of death 
were counted as cardiovascular deaths for comparative analyses. Sudden death in the 
absence of a clear alternative diagnosis were declared as “unknown cause” and therefore 
classified as a cardiovascular death.    
To investigate possible associations between 12-month mortality and events that occurred 
during the index admission, I examined the association between patients who had 
sustained at least one MACE at 28 days and subsequent mortality. I also compared the 
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procedural characteristics and hospital admission duration of the two randomised 
treatment groups. 
 
 Statistical analysis 
All analyses were performed according to intention to treat. Data are presented as (n/d = 
p%) for categorical variables and as means (standard deviations) or medians (interquartile 
ranges) for continuous variables after testing for normality. I compared categorical data 
with the chi-squared test (or Fisher’s exact test when the absolute number of observed 
events in any group was five or less). I compared continuous data with the t test (or the 
Wilcoxon test in the case of non-normal data). I used time-to-event curves to show the 
mortality data (patients were censored at the time of last follow-up). The protocol pre-
specified comparison with the Cox proportional hazards model, unadjusted for other 
covariates, to calculate hazard ratios (HRs) and 95% confidence intervals. A p value of < 
0.05 (2 sided) was considered statistically significant.  SPSS version 24 (SPSS Inc., Chicago, 
IL, USA) was used for analyses.  
 
 Results 
Between 7th February 2012 to 20th November 2013, 1829 patients were enrolled into the 
HEAT-PPCI trial. It was not possible to obtain consent in 13 cases, and in 4 cases 
participants refused to give, or withdrew consent (Figure 4.1). Therefore, 1812 patients 
were included in the initial analysis. Vital status at 12 months was obtained in 1805/1812, 
representing 99.6% of consented participants. Overall mortality at 12 months was 
160/1805 = 8.9%. It was not possible to obtain death certificates for 3 subjects and in a 
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single additional case it was not possible to determine the cause of death from the 
information presented. For the purpose of this analysis, these cases were assumed to be 
cardiovascular deaths. 
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3 patients lost 
to follow-up 
4 patients lost to 
follow-up 
907 included in the trial and 
subject to mortality check  
905 included in the trial and 
subject to mortality check 
838 alive at 
12 months   
902 identified in 
mortality check 
903 identified in 
mortality check 
65 died within 
12 months   
807 alive at 
12 months   
95 died within 
12 months   
914 assigned to 
receive heparin  
915 assigned to 
receive bivalirudin   
10 patients have no 
consent available 
   7 unable to get 
consent 
   3 refused consent 
7 patients have no 
consent available 
   6 unable to get 
consent 
   1 withdrew consent 
1829 patients randomised into the trial 
Figure 4.1: Flow diagram showing mortality rates at 12 months for participants in HEAT-PPCI 
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Table 4.1 illustrates the difference in all-cause, cardiovascular and non-cardiovascular 
mortality at 12 months between the two treatment groups, excluding patients lost to 
follow-up at 12 months. The rate of all-cause mortality at 12 months was significantly 
higher in the bivalirudin group compared to the heparin group (95/902=10.5% versus 
65/903=7.2%, RR 1.46; 95% CI 1.08 to 1.98; p=0.013). The rate of cardiovascular mortality 
at 12 months was also higher, but the difference did not reach conventional levels of 
statistical significance (71/902 = 7.9% versus 53/903=5.9%; RR 1.34; 95% CI 0.95 to 1.88; 
p=0.092).  The rate of non-cardiovascular mortality at 12 months was significantly higher in 
the bivalirudin group (24/902=2.7% versus 12/903=1.3%; RR 2.00; 95% CI 1.02 to 3.93; 
p=0.043).  
  
 
 
 
Table 4.1: All-cause and cardiovascular mortality rates at 12 months: the absolute risk and relative risk are displayed, excluding patients lost to follow-up 
at 12 months 
Mortality at 12 months Bivalirudin (n=902) Heparin (n=903) Absolute risk difference (95% CI) Relative risk (95% CI) p value 
All-cause 95 (10.5%) 65 (7.2%) 3.33 (0.72 to 5.99) 1.46 (1.08 to 1.98) 0.013 
Cardiovascular 71 (7.9%) 53 (5.9%) 2.00 (-0.33 to 4.38) 1.34 (0.95 to 1.88) 0.092 
Non-cardiovascular 24 (2.7%) 12 (1.3%) 1.33 (0.04 to 2.73) 2.00 (1.02 to 3.93) 0.043 
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Figures 4.2 and 4.3 show the event curves and hazard ratios for all-cause mortality and 
cardiovascular mortality for both treatment groups. The hazard for patients was highest 
during or immediately after the acute event, with 18/160=11.3% of all deaths over 12 
months occurring on the day of randomisation (with an equal distribution between the 
treatment groups). 
 
 
 
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: All-cause mortality over 12 months 
 
 
Figure 4.3: Cardiovascular and non-cardiovascular mortality over 12 months. 
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I wanted to investigate the association between occurrence of non-fatal MACE or major 
bleeding by 28 days and subsequent mortality. In total, 75 patients died during this 11-
month period (49/75 = 65.3% in the bivalirudin group and 26/75 = 34.7% in the heparin 
group). Table 4.2 shows the number of these patients whose fatal event had been preceded 
by an adverse event in the index phase, both in terms of the number of all events observed 
and as a hierarchical analysis for individual patients. The absolute number of events and 
patients experiencing at least one event is very low and hence there is little evidence of an 
association between MACE or major bleeding at 28 days and subsequent mortality. 
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All-cause mortality from 28 days to 12 months 
 Bivalirudin n=49 Heparin n=26 
 Hierarchical All events Hierarchical All events 
 
Non-fatal MACE at 28 days 
    
CVA 3 (6.1%) 3 (6.1%) 1 (3.8%) 1 (3.8%) 
MI 1 (2.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 
uTLR 0 (0.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 
Total events 
 4 (8.2%) 
 
5 (10.2%) 
 
1 (3.8%) 
 
1 (3.8%) 
 
Bleeding outcomes 
    
Major bleeds 1 (2.0%) 1 (2.0%) 2 (7.7%) 2 (7.7%) 
Non-fatal MACE or major bleed 4 (8.2%) 6 (12.2%) 2(7.7%)   3 (11.5%) 
Table 4.2: Comparing rates of non-fatal MACE and bleeding in patients who died between 
28 days and 12 months 
 
As a surrogate for complexity of the clinical course during index management, I compared 
the rates of use of intra-aortic balloon pumps, inotropes, temporary pacing wires, and 
endo-tracheal intubation. There were no significant differences between the two 
randomised groups. When comparing the length of overall hospital admission or the time 
spent in high-dependency areas such as the intensive care unit (ITU) and the coronary care 
unit (CCU), there was no significant difference between the two groups (Table 4.3). 
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Bivalirudin  Heparin   
  (n=905)  (n=907) p value 
 
Intra-aortic balloon pump use* 33/843 (3.9%) 26/843 (3.1%) 0.35 
Temporary pacing wire insertion* 16/825 (1.9%) 15/845 (1.8%) 0.80 
Inotropic support* 34/841 (4.0%) 31/845 (3.7%) 0.69 
Intubation and ventilation* 11/842 (1.3%) 17/844 (2.0%) 0.26 
Number of days in hospital: Total 3 (2.5 to 4) 3 (2.5 to 4) 0.25 
         ITU† 0 (0 to 0) 0 (0 to 0) 0.73 
         CCU‡ 
         Ward 
1 (0.5 to 1) 
2 (1.5 to 3) 
1 (0.5 to 1) 
2 (1.5 to 3) 
0.25 
    0.41 
    
*denominators used for these variables are lower than the total number of patients in the 
trial due to missing data.  
Table 4.3: Additional interventions and admission lengths for the bivalirudin and 
heparin treatment groups. 
  
 Discussion 
 Main findings 
In this single-centre, randomised trial, bivalirudin was compared to heparin in patients 
undergoing primary PCI. The rate of all-cause mortality at 12 months was significantly 
higher in the bivalirudin group. These results differ from other trials comparing heparin and 
bivalirudin in PPCI.128,131,133,134 
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 What is known 
The HORIZONS-AMI randomised trial compared bivalirudin monotherapy versus heparin 
plus a GPI.131,134 The 3-year follow-up showed a lower rate of all-cause and cardiovascular 
mortality in the bivalirudin group (all-cause mortality: 5.9% vs. 7.7%; HR 0.75; 95% CI 0.58 
to 0.97; p=0.03, cardiovascular mortality: 2.9% vs 5.1%; HR 0.56; 95% CI 0.40-0.80; 
p=0.001).134 This trial reported lower rates of major bleeding in the bivalirudin group (6.9% 
vs 10.5%; HR 0.64; 95% CI 0.51-0.80; p=0.0001). Bleeding is an accepted risk factor for 
subsequent mortality so any increased bleeding rates may have an impact on mortality.135 
The MATRIX trial, a large multi-centre RCT comparing bivalirudin monotherapy versus 
heparin plus discretional GPIs in STEMI and high-risk NSTEMI, also showed lower bleeding 
rates and lower mortality in the bivalirudin group.132 (Bleeding events: 2.2% vs 3.3%; RR 
0.68; 95% CI 0.51 to 0.91, all-cause mortality: 3.6% vs 4.6%; RR 0.79; 95% CI 0.63 to 0.99, 
cardiovascular mortality: 2.2% vs 3.0%; RR 0.74; 95% CI 0.55 to 0.99. P values were not 
reported.) Both HORIZONS-AMI and MATRIX involved differential use of GPIs between the 
treatment groups created at randomisation. This may have influenced outcomes, including 
bleeding and subsequent mortality, and makes it difficult to compare the independent 
effects of the antithrombotic agents under evaluation.  
The BRIGHT randomised trial compared bivalirudin monotherapy with heparin 
monotherapy and with heparin plus GPIs in a three-arm design. This showed that 30-day 
bleeding rates was lowest in the bivalirudin arm and highest in the heparin plus GPI arm 
(4.1% vs 7.5% vs 12.3% p=<0.001) but there was no significant difference in mortality rates 
between the 3 arms at 1-year follow-up. Similarly, the EUROMAX randomised trial, 
comparing bivalirudin with heparin, with routine or optional use of GPI in the heparin arm, 
showed a lower rate of major bleeding at 30 days in the bivalirudin group (2.6% vs 6.0%; RR 
0.43; 95% CI 0.28 to 0.66; p=<0.001). This may be related to the differential use of GPIs 
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between the groups (7% GPI use in bivalirudin cases vs 69.1% in heparin cases) but there 
was no significant difference in all-cause or cardiovascular mortality at 1 year (all cause: 
2.7% in each group; RR 1.02; 95% CI 0.72 to 1.45; p=0.92, cardiovascular: 4.0% vs 4.3%; RR 
0.93; 95% CI 0.63 to 1.39; p=0.74).133  
The VALIDATE-SWEDEHEART trial is the largest and most recent trial evaluating bivalirudin 
versus heparin in PCI.127 This multi-centre randomised registry-based study compared 
bivalirudin monotherapy with heparin monotherapy, excluding any patient treated with GPI 
in either group. The results of 180-day follow-up showed no difference in rates of major 
bleeding, all-cause mortality or cardiovascular mortality (major bleeding: 8.6% in each 
group; HR 1.00; 95% CI 0.84 to 1.19; p=0.98, all-cause mortality: 2.9% vs 2.8%; HR 1.05; 95% 
CI 0.78 to 1.41; p=0.76, cardiovascular mortality: 2.4% vs 2.3%; HR 1.04; 95% CI 0.75 to 
1.45; p=0.80). However only 47% of eligible patients were enrolled in the trial and those not 
enrolled tended to be higher risk than those selected for inclusion. The NAPLES III trial 
randomised patients undergoing PCI to bivalirudin monotherapy or heparin monotherapy 
and compared rates of in-hospital major bleeding, showing no significant difference 
between the two groups (OR 0.78; 95%CI 0.35 to 1.72; p=0.54).136 Several meta-analyses 
have been performed comparing heparin and bivalirudin in PCI.124-126,129 The most recent, by 
Nührenberg et al., evaluates 12 RCTs comparing bivalirudin and heparin including 
VALIDATE-SWEDEHEART.129 This analysis showed that there was no difference in mortality 
between the groups and the bleeding rates were similar with balanced use of GPI (OR 0.88; 
95% CI 0.67 to 1.16; p = 0.35; p for heterogeneity < 0.01). 
 What this study adds 
HEAT-PPCI remains the only trial of antithrombotic therapy in PPCI to achieve near 100% 
recruitment of all eligible patients. Exclusion criteria was minimal and all adult patients with 
suspected STEMI who had not previously been enrolled in the trial were included.  The 
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study was more representative of typical practice and mortality rates were comparable to 
those reported by US and UK registries.13,137 HEAT-PPCI compared bivalirudin with heparin 
with use of GPI as bailout only in both groups, resulting in 13% use in the bivalirudin group 
and 15% in the heparin group. The relative safety and efficacy of bivalirudin and heparin 
can only be reliably tested if the use of GPIs is similar in both groups.  
This study appears to show increased all-cause mortality associated with the use of 
bivalirudin. If treatment with bivalirudin results in less favourable initial reperfusion during 
PPCI, or an increased rate of subsequent adverse events - like stent thrombosis - then we 
might expect that the increased mortality rate in the bivalirudin group would be 
attributable to cardiovascular causes.  Cardiovascular mortality was higher with bivalirudin, 
but this difference did not reach conventional levels of statistical significance. 
I looked at markers of infarct size such as LV function on echocardiography and CK-MB 
levels examined after the acute event. These were reported in the original publication and 
showed no significant differences between the treatment groups. In addition, there were 
no significant differences when we examined clinical markers of case complexity or adverse 
clinical course, including additional interventions performed or the length and nature of the 
hospital admission.  There was no obvious association between non-fatal MACE and major 
bleeding at 28 days and subsequent mortality. 
It is important to note that about 23% of all deaths were attributed to a non-cardiovascular 
cause. I observed a significant difference in non-cardiovascular mortality between the 
randomised groups and this is difficult to explain in terms of pharmacology or clinical 
plausibility. It is possible that this may represent the play of chance.  
In Figure 4.3, the graph shows that the number of cardiovascular deaths increases, 
demonstrated by a steep curve, levelling off around day 30. This suggest that deaths 
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occurring in the 30 days after randomisation are most likely to experience a cardiovascular 
death, likely to be related to the index event. Therefore, 30-day mortality may be a more 
informative outcome than 12-month mortality because the deaths are more likely to occur 
due to the acute MI.  
 
 Limitations 
The main limitations of HEAT-PPCI trial have been previously described.115 There are some 
limitations of this study which should be mentioned. The trial was not powered for 12-
month mortality. Therefore, there is poor precision in estimates of hazard ratio for 12-
month mortality. Deaths that occurred between 28 days and 12 months following 
randomisation were determined as cardiovascular or not based on information from the 
death certificate alone.  Medical notes were not available for these patients which may 
have affected the accuracy of the classification.  
 
 Conclusion 
In patients undergoing PPCI for suspected STEMI, the rate of mortality at 12 months was 
significantly higher in patients treated with bivalirudin compared to heparin. There was a 
statistically significant difference in non-cardiovascular mortality between the treatment 
groups which is difficult to explain, raising the possibility that the difference in mortality 
may have occurred by chance.  
30-day mortality may be a useful outcome for the Liverpool MI Risk Model because this 
outcome is likely to include a higher proportion of deaths that result from the acute event 
when compared to 12-month mortality.  
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 Radial versus femoral vascular access in ST-
elevation myocardial infarction: the potential for 
confounding 
 
 Introduction 
In developing the Liverpool MI Risk Model, the aim was to conduct an observational study, 
investigating possible associations between clinical and angiographic variables and 
outcomes such as death and LV function. I planned to use data from the RCT, HEAT-PPCI, to 
perform secondary observational studies. This type of work has the potential for 
confounding. In this chapter, I present an example of the potential for misleading results 
when considering the effects access site choice and default operator type on the outcomes 
of PPCI.  
 
 Background 
Major bleeding after PCI is associated with increased mortality and major adverse 
cardiovascular events.138 The choice of access site may influence the rate of complications 
and adverse events following primary PCI. Since the introduction of PPCI as the preferred 
treatment for reperfusion in the acute management of STEMI, there has been a shift in 
operator preference for radial over femoral access.3,139,140 However recent trials comparing 
the two access sites in PPCI have shown conflicting results regarding the incidence of MACE 
and major bleeding.141-144  
Previous trials comparing access sites do not consider the default preference of radial or 
femoral for each operator. Therefore, randomisation of the access site alone does not 
control for the varying experience of individual operators. The primary aim of this study 
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was to examine associations between default radial and default femoral operator type, 
irrespective of final access site chosen.  
Despite the increase in radial access (RA) use, femoral access (FA) is still used in certain 
circumstances by all operators. It is, therefore, important to establish the safety of the FA 
when used by both femoral and radial operators. A secondary aim of this study was to 
analyse all FA cases to establish differences between default radial and default femoral 
operators.  
 
 Methods 
The HEAT-PPCI trial recruited from the Liverpool Heart and Chest Hospital. For individual 
operators (defined as participants in the PPCI service, for the duration of the trial) the 
annual median PCI case volume was 218 cases (range: 158-283), based on data for the 
financial year 2013-14.  
When patients were recruited into the HEAT-PPCI trial, they were treated by the operator 
who was assigned to PPCI activity by a rota system. Over time, this creates a near-random 
allocation of patient-types and risk profiles between operators. Operators in the study had 
established practice patterns for vascular access that allowed their categorisation as 
“default femoral” or “default radial” based on the access site used as their natural first 
preference, accounting for over 90% of all historic and trial-specific activity. The route of 
arterial access was determined by operator preference and recorded in the trial 
documentation. This allowed analysis of clinical outcomes by final arterial access site, 
defined as the route used for completion of the procedure, and by default operator type. 
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The primary efficacy and safety outcomes in HEAT-PPCI were 28-day MACE and major 
bleeds, as defined in Chapter 2. In this analysis, I examined the effect of access site and 
default operator type on 28-day MACE or major bleed, as well as LV function measured on 
echocardiogram and a single measurement of CKMB release during the index MI.   
 
 Statistical analysis 
Data are presented as (n/ d = p%) for categorical variables and as means (standard 
deviations) or medians (interquartile ranges) for continuous variables after testing for 
normality. Comparisons between groups were made using chi-square test for categorical 
variables and unpaired t-test or Mann-Whitney U-test for continuous variables. A p value of 
< 0.05 (2 sided) was considered statistically significant. SPSS version 22 (SPSS Inc., Chicago, 
IL, USA) was used for analyses.  
 
 Results 
Between 7th February 2012 to 20th November 2013, 1829 patients were enrolled into the 
HEAT-PPCI trial. It was not possible to obtain consent in 17 cases. Brachial artery was 
chosen as the final access site in 2 patients. Angiography was not attempted in 6 
participants. Of the remaining 1804 cases, RA was used as the final access site in 
1472/1804 = 81.6% cases and FA was used in 332/1804 = 18.4% cases (Figure 5.1). In 
patients where FA access was used, the access site was closed using an internal vascular 
closure device in 215/332 = 64.8% of cases, manual pressure was used in 105/332 = 
31.6% of cases and 12/332 = 3.6% were not closed because the patient died during or 
shortly after the procedure. Table 5.1 details the baseline characteristics and 
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demographics of the participants categorised by final access site. There were significant 
differences between the two groups, with RA cases having a more favourable risk profile 
in term of younger age, higher systolic blood pressure, better renal function and a 
reduced incidence of previous MI/PCI/CABG. RA cases were also significantly less likely to 
have an intra-aortic balloon pump used during the procedure, to require venous access 
or receive glycoprotein IIb/IIIa inhibitors.   
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
  
  
  
1812 included in HEAT-PPCI analysis 
8 excluded: 
2 brachial access site used  
6 no angiogram was performed 
  
1804 have an angiogram performed via a radial or femoral access site 
332 final access site is femoral 1472 final access site is radial  
122 performed by 
default radial operators 
210 performed by default 
femoral operators 
Figure 5.1: Flow diagram outlining the number of participants where radial and femoral access sites 
were used 
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 Relationship between final access site and clinical outcomes 
Table 5.2 illustrates the clinical outcomes by final access site. The primary 
efficacy outcome of MACE occurred in a significantly higher number of FA cases 
 Radial Access Femoral Access   
  (n=1472)   (n=332)  p value  
Baseline Characteristics 
   
Age (years) 62.4+/-12.9 66.0+/-13.7 <0.001 
Body weight (Kg) 80.5+/-17.9 77.7+/-18.4 0.016 
SBP on admission (mmHg) 137.4+/-27.4 130.1+/-30.3 <0.001 
eGFR (ml/kg/min) 76.0+/-16.0 69.8+/-20.1 <0.001 
Haemoglobin (g/dl) 13.6+/-1.6 13.2+/-1.8 <0.001 
Diabetes 195/1472 (13.2%) 53/332 (16%) 0.84 
Previous MI 154/1472 (10.5%) 59/332 (17.8%) <0.001 
Previous CABG 16/1472 (1.1%) 26/332 (7.8%) <0.001 
Previous PCI 98/1472 (6.7%) 31/332 (9.3%) <0.001 
GPI Use 
Venous access Use 
IABP Use  
201/1471 (13.7%) 
32/1472 (2.2%) 
37/1373 (2.7%)  
61/332 (18.4%) 
33/331 (10.0%) 
22/305 (7.2%)  
0.03 
<0.001 
0.001  
Table 5.1: Baseline characteristics and demographics for radial and femoral 
access sites 
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vs. RA cases (36/332 = 10.8% vs. 91/1472 = 6.2% p = 0.003). The 28-day 
mortality was higher in the FA cases (27/332 = 8.1% vs. 55/1472 = 3.7% 
p=0.001). The number of major bleeding events was also significantly higher in 
the FA cases (22/332 = 6.6% vs. 38/1472 = 2.6% p=0.001). The proportion of 
patients with subsequent severe impairment of LV function was similar in both 
groups (131/1355 = 10.0% vs. 31/278 = 9.7% p=0.85). The median CKMB level in 
each group was similar (92 vs 94 p=0.42).  
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  Radial Access Femoral Access   
  (n=1472)  (n=332)  p value  
MACE 91/1472 (6.2%) 36/332 (10.8%) 0.003 
Mortality 55/1472 (3.7%) 27/332 (8.1%) 0.001 
Major Bleed 
Access site related 
38/1472 (2.6%) 
5/1472 (0.3%) 
22/332 (6.6%) 
7/332 (2.1%) 
0.001 
<0.001 
Minor Bleed 
Access site related 
118/1472 (8%) 
59/1472 (4.0%) 
62/332 (18.7%) 
55/332 (16.6%) 
<0.001 
<0.001 
Any Bleed 
Severe LV function (EF ≤35%) 
CKMB  
153/1472 (10.4%) 
131/1355 (10.0%) 
92 (33 to 182)  
81/332 (24.4%) 
31/278 (9.7%) 
94 (36 to 201)  
<0.001 
0.85 
0.42  
Table 5.2: 28-day clinical outcomes by final access site 
 
 Relationship between operator default access site and clinical outcomes 
Individual default radial operators performed a similar number of procedures to 
default femoral operators but, as there were only two femoral operators, in 
total more radial than femoral procedures were performed, (1575/1804 = 
87.3% vs. 229/1804 = 12.7%) (Figure 5.2). The baseline characteristics are 
detailed in Table 5.3. In procedures performed by femoral operators, there was 
a significantly higher incidence of previous CABG as well as a higher risk of 
requiring venous access or receiving GPIs.
 
 
  
 
 
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
1812 included in HEAT-PPCI analysis 
8 excluded: 
2 brachial access site  
6 no angiogram was performed 
  
1804 have an angiogram performed via a radial or femoral access site 
332 performed by default femoral operator 1575 performed by default radial operator  
Figure 5.2: Flow diagram outlining the number of cases where access was gained by default femoral and 
default radial operators 
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Default Radial 
Operators  
Default Femoral 
Operators    
  (n=1575)  (n=229)  p value  
Baseline Characteristics    
Age (years) 63.0+/-13.1 63.2+/-13.3 0.86 
Body weight (Kg) 79.9+/-17.9 80.8+/-18.3 0.48 
SBP on admission (mmHg) 136.0+/-28.1 136.1+/-28.0 0.92 
eGFR (ml/kg/min) 75.0+/-16.9 73.8+/-17.4 0.32 
Haemoglobin (g/dl) 13.5+/-1.6 13.6+/-1.5 0.59 
Diabetes 213/1575 (13.5%) 35/229 (15.3%) 0.75 
Previous MI 183/1575 (11.6%) 30/229 (13.1%) 0.66 
Previous CABG 30/1575 (1.9%) 12/229 (5.2%) 0.006 
Previous PCI 116/1575 (7.4%) 13/229 (5.7%) 0.48 
GPI Use 
Venous access Use 
IABP Use  
219/1574 (13.9%) 
61/1575 (3.9%) 
53/1469 (3.6%)  
43/229 (18.8%) 
16/228 (7.0%) 
6/219 (2.7%)  
0.05 
0.003 
0.47  
Table 5.3: Baseline characteristics and demographics for default radial and default 
femoral operators 
 
Table 5.4 illustrates the clinical outcomes by operators’ default choice of access site. 
There was no significant difference in rates of MACE between procedures performed by 
default radial vs. default femoral operators (111/1575 = 7% vs. 16/229 = 7% p=0.97). The 
rate of occurrence of any bleeding event was higher if the procedure was performed by a 
femoral operator (48/229 = 21% vs 186/1575 = 11.8%), however, the rate of major 
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bleeding events was not significantly different between the two groups (49/1575 = 3.1% 
vs. 11/229 = 4.8% p=0.18). The proportion of patients in each group with subsequent 
severe impairment of LV function was not significantly different (148/1445 = 10.2% vs 
14/219 = 6.4% p=0.073). There was no significant difference in the median CKMB release 
(91 vs 96 p=0.44). 
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Default Radial 
Operators  
Default Femoral 
Operators    
  (n=1575)  (n=229)  p value  
Outcomes    
MACE 111/1575 (7%) 16/229 (7%) 0.97 
Mortality 73/1575 (4.6%) 9/229 (3.9%) 0.63 
Major Bleed 
Access site related 
49/1575 (3.1%) 
8/1575 (0.5%) 
11/229 (4.8%) 
4/229 (1.7%) 
0.18 
0.055 
Minor Bleed 
Access site related  
142/1575 (9%) 
82/1575 (5.2%) 
38/229 (16.6%) 
32/229 (14.0%) 
<0.001 
<0.001 
Any Bleed 186/1575 (11.8%) 48/229 (21%) <0.001 
Severe LV function (EF ≤35%) 
CKMB 
 
148/1445 (10.2%) 
91 (33 to 182) 
 
14/219 (6.4%) 
96 (35 to 212) 
 
0.073 
0.44 
 
Table 5.4: 28-day clinical outcomes by default radial and default femoral operators  
 
 Relationship between operator default access site and clinical outcomes in cases 
where FA was used  
A total of 332/1804 cases were performed via FA, with 210/332 = 63.3% performed by 
default femoral operators and 122/332 = 36.7% performed by default radial operators. 
Table 5.5 illustrates the baseline characteristics of FA cases performed by radial operators 
and FA cases performed by femoral operators. Cases where FA was performed by default 
radial operators had a significantly higher risk profile in terms of more advanced age, lower 
systolic blood pressure, reduced renal function and increased incidence of previous MI and 
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PCI. FA cases performed by radial operators were significantly more likely to require venous 
access or have an IABP used during the procedure.   
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Femoral Cases by 
Radial Operators  
Femoral Cases by 
Femoral Operators    
  (n=122)  (n=210)  p value  
Baseline Characteristics    
Age (years) 70.2+/- 13.8 63.7+/-13.0 <0.001 
Body weight (Kg) 71.9+/-18.2 80.7+/-17.8 <0.001 
SBP on admission (mmHg) 121.1+/-33.0 135.2+/-27.6 <0.001 
eGFR (ml/kg/min) 63.6+/-22.8 73.8+/-19.4 <0.001 
Haemoglobin (g/dl) 12.6+/-2.0 13.5+/-1.5 <0.001 
Diabetes 22/122 (18%) 31/210 (14.8%) 0.19 
Previous MI 32/122 (26.2%) 27/210 (12.9%) 0.002 
Previous CABG 14/122 (11.5%) 12/210 (5.7%) 0.06 
Previous PCI 19/122 (15.6%) 12/210 (5.7%) 0.003 
GPI Use 
Venous access Use 
IABP Use 
  
21/122 (17.2%) 
28/122(23.0%) 
17/114 (14.9%) 
  
40/210 (19%) 
15/209 (7.2%) 
5/191 (2.6%) 
  
0.68 
<0.001 
<0.001 
  
Table 5.5: Baseline characteristics of participants where FA is used, by default operator 
type  
 
Table 5.6 illustrates the clinical outcomes for the FA cases by default operator type. FA 
performed by default radial operators was associated with a significantly higher rate of 
MACE compared to FA performed by default femoral operators (22/122 = 18% vs. 14/210 = 
6.7% p=0.003). Mortality rates at 28 days were significantly higher in the FA performed by 
radial operators. Major bleeding events occurred with more frequency in the FA cases 
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performed by RA operators (11/122 = 9% vs. 11/210 = 5.2% p<0.001). Rates of subsequent 
severe impairment of LV function were significantly higher in the FA cases performed by RA 
operators (18/107 = 16.8% vs 13/202 = 6.4% p=0.004). There was no significant difference 
in CKMB release between the two groups (96 vs 90 p=0.774).  
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Femoral Access by 
Default Radial 
Operators  
Femoral Access by 
Default Femoral 
Operators    
  (n=122)  (n=210)  p value  
Outcomes    
MACE 22/122 (18%) 14/210 (6.7%) 0.003 
Mortality 20/122 (16.4%) 7/210 (3.3%) 0.001 
Major Bleed 
Access site related 
11/122 (9%) 
3/122 (2.5%) 
11/210 (5.2%) 
4/210 (1.9%) 
<0.001 
0.71 
Minor Bleed 
Access site related 
24/122 (19.7%) 
23/122 (18.9%) 
38/210 (18.1%) 
32/210 (15.2%) 
0.72 
0.45 
Any Bleed 
Severe LV function (EF ≤35%) 
CKMB 
  
33/122 (27%) 
18/107 (16.8%) 
96 (35 to 206) 
  
48/210 (22.9%) 
13/202 (6.4%) 
90 (37 to 184) 
  
0.39 
0.004 
0.774 
  
Table 5.6: 28-day clinical outcomes in cases where FA was used, by default radial and 
default femoral operators 
 
 Discussion 
The results of this study suggest that there is no difference in outcomes of MACE (111/1575 
= 7% vs 16/229 = 7% p=0.97), major bleeding (49/1575 = 3.1% vs. 11/229 = 4.8% p=0.18) or 
subsequent severe impairment of LV function (148/1445 = 10.2% vs 14/219 = 6.4% 
p=0.073) when comparing cases based on operator default preference.  
Recent randomised controlled trials (RCTs) comparing radial and femoral access in PPCI 
show conflicting results. Three large trials have shown that use of RA in PPCI is associated 
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with lower mortality and fewer bleeding complications.141,142,145 The largest and most recent 
trial, MATRIX (Minimising Adverse Haemorrhagic Events by Transradial Access Site and 
Systemic Implementation of angioX), randomised 8404 patients with acute coronary 
syndrome to radial or femoral access and reported a significant difference in all-cause 
mortality (1.6% vs 2.2%, RR 0.72, 95% CI 0.53-0.99; p=0.045) and major bleeding (1.6% vs 
2.3%; RR 0.67, 95% CI 0.49-0.92; p=0.013).This has reinforced a trend towards increased 
RA. RA is now recommended as the preferred access site by ESC guidelines on management 
of STEMI.3 Other trials have shown no difference in outcomes between RA and FA.143,144 
There are several possible reasons for these differing results. Firstly, recent advances in 
technology, such as use of vascular closure devices, have improved the safety of FA.146 
Secondly, RCTs often use different exclusion criteria, definitions of clinical outcomes and 
doses of antithrombotic medications which may affect the external validity of the results. 
Thirdly, randomising the access site does not consider the skill level of the operator. A 
recent observational trial of British Cardiovascular Intervention Society (BCIS) data showed 
total procedural volume and proportion of procedures undertaken radially by an operator 
was associated with lower mortality in patients undergoing PPCI via RA.147 Therefore, the 
experience and familiarity of the operator is likely to affect the outcomes of the patient. For 
an RCT to compare the access sites in a useful way, operators would have to be similar and 
competence in using both RA and FA. Few operators meet this requirement and most RCTs 
do not consider operator or centre experience. Both MATRIX and RIVAL found that 
improvements in outcomes in RA cases were only significant when considering centres with 
high radial volume.142,145  
Operators usually have a default access preference, with which they are more 
experienced.115 This study compared outcomes by default operator type, reflecting real-
world practice in a high-volume regional centre. Patients, therefore, benefitted from the 
clinical judgement exercised by the operator in their choice of access site. The results 
119 
 
showed no significant difference in clinical outcomes between radial and femoral 
operators, with comparable baseline characteristics in the two groups. Selection bias is 
likely to be minimal because patients were allocated to the operator at random, based on a 
rota system. The operator does not receive any clinical details of patients prior to their 
arrival at the PPCI centre and does not have any influence over patient referrals for PPCI, 
which are usually initiated by ambulance crews or physicians in local emergency 
departments. These results suggest that FA may not be associated with increased MACE 
when performed by experienced femoral operators. In trials where the access site is 
randomised, complications in FA cases could be overestimated because the operator may 
have to perform via an access site which they would not have chosen in normal clinical 
practice. As far as we know, this is the first study analysing outcomes by default operator 
type. 
There have been multiple observational trials examining potential differences in outcomes 
when comparing access sites in PCI.140,148,149 However, the circumstances and conduct of the 
HEAT-PPCI study afford a, possibly, unique opportunity to perform a comparison of the 
strategies of default femoral and radial access, free from much of the bias that normally 
confounds observational research. The data used in this study are from an RCT, with 
rigorous tracking of events and high-quality data collection. HEAT-PPCI used real-world, 
consecutive, unselected cases, making participant selection more reflective of routine 
practice.   
A simple observational analysis of our data would suggest that the performance of PPCI 
cases with RA is associated with reduced incidence of mortality, MACE and major bleeding. 
However, examination of the baseline characteristics of patients grouped by final access 
site shows a less favourable risk profile in patients who had FA. Default radial operators 
only attempt femoral access in specific circumstances, many of which are associated with 
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higher risk.  Such reasons include circulatory collapse resulting in an impalpable pulse; 
radial occlusion associated with previous procedures (a marker of chronic or advanced 
disease); a requirement to access bypass graft conduits and a need to access the groin for 
reasons of intra-aortic balloon pump insertion or placement of a temporary wire. 
Some studies have suggested that procedures performed through FA by radial operators 
have higher complication rates.150,151 This seems logical because increased experience with 
an access site leads to better outcomes.147 However, a recent observational study showed 
that a reduction in the number and proportion of femoral cases is not associated with a loss 
of femoral proficiency.152 This may be because although the radial operators are more 
experienced in RA in uncomplicated cases, in cases where the patient presents in 
cardiogenic shock or haemodynamically unstable, they perform PCI via FA and therefore 
maintain competency in the use of FA in complex cases. Our study shows that cases 
performed via FA had higher rates of MACE, major bleeding and severe LV function when 
performed by default RA operators, but the risk profile of these patients was less 
favourable. This suggests that the overall clinical condition of the patient may explain the 
increased incidence of MACE, major bleeding and poor LV function, rather than the access 
site used or access skills of the operator.  
 
 Limitations 
The post-PPCI measurement of LV function does not consider the LV function of patients 
prior to the acute event. Patients who have had a previous MI or other cardiac event may 
have decreased LV function at baseline that is not a result of the index event. Therefore, 
the post-PPCI LV function may be misleading because we cannot assess the change in LV 
function that results from the index MI. Data for LV function was missing in 172/1804 = 
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9.5% patients. This may be because when a patient died early following randomisation, 
there was no opportunity to measure LV function, resulting in missing LV function data for 
that patient. The result of this missing data may be to mask any true difference in LV 
function between the two groups because patients with poor LV function are more likely to 
die early, before echocardiography can be performed.  
The CK-MB measurement was not sampled at a consistent time interval from either 
symptom onset or hospital arrival and, therefore, it was not guaranteed that this 
measurement would capture the peak CK-MB release. The preferred method used in other 
trials is to take several measurements of CK-MB and select the peak CK-MB level as a 
surrogate marker of infarct size. Only one measurement of CK-MB was taken in HEAT-PPCI, 
limiting meaningful interpretation in this trial.   
The number of cases performed by the default femoral operators (and the number of 
associated adverse events) is low and hence it is difficult to characterise results in this 
group with precision. There was no routine use of radiographic guidance, micropuncture or 
ultrasound imaging for femoral access during the trial. It is likely use of a more fastidious 
technique would improve outcomes for patients who have procedures performed via FA. 
This is an analysis of observational data and therefore cannot be used to infer a causal 
relationship between access site and outcomes. There may be a risk of unmeasured 
confounding. HEAT-PPCI was a single centre study so the results are not necessarily 
generalisable to all patient groups or operator experiences.  
 
 Conclusion 
Default femoral operators achieved comparable outcomes compared to default radial 
operators. The less favourable outcomes observed in FA cases may result from its selective 
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use by radial operators in high risk cases. Further studies are required to establish the 
differences between RA and FA since the introduction of vascular closure devices and 
should compare the default operator type as this would better reflect real-world practice.      
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 Assessing the intra- and inter-observer agreement 
of angiographic grading systems 
 
 Introduction 
In Chapter 2, I described the methods of assessing four selected angiographic variables: 
TIMI flow, thrombus burden, myocardial blush grade (MBG) and corrected TIMI frame 
count (cTFC). In this chapter, I evaluate my ability to match my assessments of the variables 
on repeat testing and compare my assessments against the assessments of a single other 
observer. I then quantify the intra- and interobserver agreement. 
 
 Methods 
Using the random number generator function in Microsoft Excel, I identified a random 
sample of 100 participants with angiographic data in the HEAT-PPCI database.  (See 
Appendix 3 for the power calculations used to define the sample size). 
I analysed each angiogram (primary observer = SB) and assessed the variables at specific 
time points during the PPCI angiogram (Figure 6.1). On assessing each variable, I assessed 
the quality of the angiogram (as described in Chapter 2) and, from this, my ability to make 
an accurate quantitative judgement. When a variable could not be assessed with 
confidence and was marked as “estimated” or “unable to assess”, the datapoint was 
excluded from these analyses.   
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 Intraobserver agreement 
I repeated an assessment of the variables 2 weeks after performing the initial assessment 
(primary assessment = SB1, repeat assessment = SB2). The repeat assessments were made 
on the same 100 angiograms using the same angiographic runs, blinded to the results of the 
initial assessment. The paired values of each variable were then compared (SB1 vs. SB2).  
 Interobserver agreement 
The angiograms of the 100 participants were assessed a third time by a second observer 
(CP). CP undertook a period of training to ensure he was competent in assessing the 
variables as described in Chapter 2. CP reviewed the angiograms of the same 100 
participants and assessed each variable using the same angiographic runs used by SB.  The 
interobserver agreement was evaluated by comparing the paired assessments from each 
run made by the two observers (SB vs CP). 
Final angiographic 
run: 
 
2) Thrombus burden, 
cTFC, TIMI flow and 
MBG assessed 
 
Immediately prior 
to stent 
deployment: 
1b) cTFC, TIMI flow 
and MBG assessed 
Patient enters lab 
 
Stent deployed 
 
Procedure close 
Blood flow is 
restored in the 
culprit:  
1a) Thrombus 
burden assessed 
Figure 6.1: The time points when the grading systems were assessed: 1a) and 1b) pre-stent and 
2) post-stent 
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 Because the “true” value of each variable was not known, I could not say whether 
measurements made by SB were more accurate on initial or repeat assessments, or 
whether assessments made by SB was more accurate than those made by CP. I, therefore, 
compared the differences between all three sets of paired values (SB1 vs SB2, SB1 vs CP, 
and SB2 vs CP).  
 
 Statistical analysis  
Chapter 7 describes the development of the Liverpool MI risk model. This model was 
developed from the ordinal angiographic variables once they had been dichotomised into 
“normal” and “abnormal” assessments (Table 6.1). I also dichotomised the continuous 
variable cTFC according to an agreed cut-off for normal (<27).99 The dichotomised variables 
were relevant to the Liverpool MI risk model, therefore, I assessed agreement based on the 
dichotomised variables instead of using the full range of grades. CTFC was also assessed as 
a continuous variable. 
 
 
  TIMI TB MBG cTFC 
Normal 3 0 3 <27 
Abnormal 0,1,2 1,2,3,4,5 0,1,2 ≥27 
 
Table 6.1: The values of each angiographic variable considered “normal” and “abnormal” 
 
Dichotomous variables were assessed using percentage agreement, Cohen’s kappa (𝑘). 
Continuous variables were assessed using intraclass correlation coefficient (ICC) and Bland-
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Altman (BA) plots. Further explanation of the statistical analyses used in this chapter are 
detailed in Appendix 3.   
 
 Results 
All 100 participants included in the study had an angiogram performed. Of these, 97/100 = 
97% had a stent implanted during the PPCI procedure and therefore had two time-points 
assessed by each observer for TIMI flow, MBG and cTFC. All 100 angiograms had two 
assessments for thrombus burden because the initial assessment was performed regardless 
of whether a stent was inserted. 
 
TIMI flow grade was assessed with confidence in 187/195 = 95.9% angiographic runs; 
thrombus burden 195/200 = 97.5%; cTFC 119/195 = 61.0%; MBG: 148/195 = 75.9%. Figure 
6.2 describes the reasons for estimated or absent assessments for each grading system.  
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47 assessments estimated/absent: 
41: short run 
1: inadequate flow 
1: poor panning 
1: device left in the culprit which interfered with 
flow assessment 
1: poor image resolution 
2: view obscured by mechanical CPR 
76 assessments estimated/absent: 
3: short run 
49: poor panning 
10: poor image resolution 
2: inadequate views 
7: inadequate flow 
1: device left in the culprit which interfered with 
flow assessment 
2: view obscured by mechanical CPR 
2: contrast from previous run interfered with flow 
assessment 
187 assessments made with confidence 
8 estimated/absent: 
2: device left in artery  
4: inadequate flow 
2: view obscured by mechanical CPR 
195 assessments made with confidence 
5 assessments estimated/absent: 
1: inadequate views  
1: inadequate flow 
1: poor image resolution 
2: view obscured by mechanical CPR 
 
119 assessments made with confidence 
148 assessments made with confidence 
195 TIMI flow grade 
assessments 
195 MBG assessments 
195 cTFC assessments 
200 thrombus burden 
assessments 
Figure 6.2: The quality of assessment of TIMI flow, TFC, thrombus burden and MBG. 
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 Intraobserver agreement 
 TIMI flow 
Table 6.2 and Figure 6.3 illustrate the agreement between assessments of TIMI flow made 
by SB1 and SB2. The observed agreement (Po) was 92.5%, with a 𝑘 statistic of 0.79 (95% CI 
0.68 to 0.89), indicating good agreement.  
 
TIMI flow (n=187) 
 SB2 Po Pe 𝒌 (95% CI) 
    TIMI 3 TIMI 0 to 2 92.5% 64.4% 0.79 (0.68 to 0.89) 
SB1 
TIMI 3 137 2     
TIMI 0 to 2 12 36     
              
Table 6.2: A crosstabulation table demonstrating the intraobserver agreement for TIMI 
flow (categorised as normal or abnormal), and associated 𝒌 statistic 
 
 
 
Figure 6.3: A histogram demonstrating the differences in assessments of TIMI flow made 
by SB1 and SB2 
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 Myocardial blush grade 
Table 6.3 and Figure 6.4 illustrate the agreement between assessments of MBG made by 
SB1 and SB2. Po was 81.1%, with a kappa statistic of 0.40 (95% CI 0.22 to 0.58), indicating 
fair agreement.  
 
MBG (n=148) 
   SB2 Po Pe 𝑘 (95% CI) 
    MBG 3 MBG 0 to 2 81.1% 68.5% 0.40 (0.22 to 0.58) 
SB1 
MBG 3 105 12     
MBG 0 to 2 16 15     
              
Table 6.3: A crosstabulation table demonstrating the intraobserver agreement for MBG 
(categorised as normal or abnormal), and associated 𝒌 statistic 
 
 
 
Figure 6.4: A histogram demonstrating the differences in assessments of MBG made by 
SB1 vs SB2  
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 Thrombus burden 
Table 6.4 and Figure 6.5 illustrate the agreement between assessments of thrombus 
burden made by SB1 and SB2. Po was 97.9%, with a 𝑘 statistic of 0.96 (95% CI 0.91 to 0.99), 
indicating excellent agreement.  
 
Thrombus burden (n=195) 
 SB2 Po Pe 𝒌 (95% CI) 
    TB 0 TB 1-4 97.9% 50.0% 0.96 (0.91 to 0.99) 
SB1 
TB 0 93 2     
TB 1-4 2 98     
              
Table 6.4: A crosstabulation table demonstrating the intraobserver agreement for 
thrombus burden (categorised as normal or abnormal), and associated 𝒌 statistic  
 
 
 
Figure 6.5: A histogram demonstrating the differences in assessments of thrombus 
burden made by SB1 vs SB2 
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 cTFC: as a dichotomous variable 
Table 6.5 and Figure 6.6 illustrate the agreement between assessments of cTFC made by 
SB1 and SB2, once dichotomised into normal (cTFC <27) and abnormal (cTFC ≤ 27). Po was 
95.8%, with a 𝑘 statistic of 0.89 (95% CI 0.80 to 0.98), indicating excellent agreement.  
 
cTFC (n=119) 
  SB2 Po Pe 𝒌 (95% CI) 
    cTFC <27 cTFC ≥ 27 95.8% 60.3% 0.89 (0.80 to 0.98) 
SB1 
cTFC <27 84 1     
cTFC ≥ 27 4 30     
            
Table 6.5: A crosstabulation table demonstrating the intraobserver agreement for cTFC 
(categorised as normal or abnormal), and associated 𝒌 statistic  
 
 
 
Figure 6.6: A histogram demonstrating the differences in assessments of dichotomised 
cTFC made by SB1 vs SB2 
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 cTFC: as a continuous variable 
The intraobserver agreement of cTFC as a continuous variable was assessed using ICC. 
Comparison of assessments made by SB1 and SB2 gave an ICC of 0.95 (95% CI 0.93 to 0.97) 
indicating excellent agreement (Table 6.6).  
 
 Intra-class correlation coefficient (95% CI) 
SB1 vs SB2 0.95 (0.93 to 0.97) 
Table 6.6: The ICC for intraobserver agreement between assessments of cTFC   
 
Figure 6.7 shows the Bland-Altman plot for the differences in assessments made by SB1 and 
SB2. The Bland-Altman analysis shows the limits of agreement are -7.06 to 8.98.  
In our power calculation, I defined a priori that the paired measurements of cTFC 
performed by at different times or by different observers should be within +/- 8 of one 
another, for 95% of the paired measurements. For a cTFC of 20, this gives a SD of 4 and a 
mean difference of 0 (+-0.75). The mean difference when comparing SB1 vs SB2 was 0.95 
(95 % CI -0.22 to 2.24) and the SD was 4.09. This demonstrates that the agreement is within 
the limits we considered acceptable for use in clinical practice.   
The mean difference was close to zero, with a 95% CI that crossed the line of equality. This 
indicates a low possibility of bias between the repeated measurements. There are a similar 
number of values above and below the line of equality, suggesting a constant, random 
variability in errors of cTFC measurement i.e. differences appear to be independent of the 
absolute value of cTFC. There are several outliers that fall outside of the limits of 
agreement although these appear to be random errors, lying both above and below the line 
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of equality. There is no obvious trend showing a higher frequency of outliers for very high 
or very low values of cTFC. 
 
 
 
Figure 6.7: A Bland-Altman plot of cTFC measurements performed by SB1 and SB2
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 Interobserver agreement 
 TIMI flow 
Table 6.7 and Figure 6.8 illustrate the agreement between assessments of TIMI flow made 
by SB1 and CP. Po was 86.1%, with a 𝑘 statistic of 0.61 (95% CI 0.48 to 0.75), indicating good 
agreement.  
 
TIMI flow (n=187) 
 CP Po Pe 𝒌 (95% CI) 
    TIMI 3 TIMI 0 to 2 86.1% 63.9% 0.61 (0.48 to 0.75) 
SB1 
TIMI 3 130 9     
TIMI 0 to 2 17 31     
              
  CP Po Pe 𝒌 (95% CI) 
   TIMI 3 TIMI 0 to 2 88.2% 66.9%  0.64 (0.51 to 0.78) 
SB2 
TIMI 3 137 12    
TIMI 0 to 2 10 28    
       
Table 6.7: A crosstabulation table demonstrating the interobserver agreement for TIMI 
flow (categorised as normal or abnormal), and associated 𝒌 statistic 
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Figure 6.8: A histogram showing the differences in assessments of TIMI flow made by SB1 
and CP 
 
Table 6.7 and Figure 6.9 illustrate the agreement between assessments of TIMI flow made 
by SB2 and CP. Po was 88.2%, with a 𝑘 statistic of 0.64 (95% CI 0.51 to 0.78), indicating good 
agreement.  
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Figure 6.9: A histogram showing the differences in assessments of TIMI flow made by SB2 
and CP 
 MBG 
Table 6.8 and Figure 6.10 illustrate the agreement between assessments of MBG made by 
SB1 and CP. Po was 79.1%, with a 𝑘 statistic of 0.39 (95% CI 0.21 to 0.57), indicating fair 
agreement.  
 
MBG (n=148) 
   CP Po Pe 𝒌 (95% CI) 
    MBG 3 MBG 0 to 2 79.1% 65.7% 0.39 (0.21 to 0.57) 
SB1 
MBG 3 100 17     
MBG 0 to 2 14 17     
              
  CP    
   MBG 3 MBG 0 to 2 Po Pe 𝒌 (95% CI) 
SB2 
MBG 3 104 17 81.8% 67.2% 0.44 (0.27 to 0.62) 
MBG 0 to 2 10 17    
       
Table 6.8: A crosstabulation table demonstrating the interobserver agreement for MBG 
(categorised as normal or abnormal), and associated 𝒌 statistic 
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Figure 6.10: A histogram showing the differences in assessments of MBG made by SB1 
and CP 
Table 6.8 and Figure 6.11 illustrate the agreement between assessments of MBG made by 
SB2 and CP. Po was 81.8%, with a 𝑘 statistic of 0.44 (95% CI 0.27 to 0.62), indicating 
moderate agreement.  
 
 
Figure 6.11: A histogram showing the differences in assessments of MBG made by SB2 
and CP 
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 Thrombus burden 
Table 6.9 and Figure 6.12 illustrate the agreement between assessments of thrombus 
burden made by SB1 and CP. Po was 97.4%, with a 𝑘 statistic of 0.95 (95% CI 0.90 to 0.99), 
indicating excellent agreement.  
 
Thrombus burden (n=195) 
 CP Po Pe 𝒌 (95% CI) 
    TB 0 TB 1-4 97.4% 50.1% 0.95 (0.90 to 0.99) 
SB1 
TB 0 92 3     
TB 1-4 2 98     
       
  CP    
   TB 0 TB 1-4 Po Pe 𝒌 (95% CI) 
SB2 
TB 0 91 4 96.4% 50.0% 0.93 (0.88 to 0.98) 
TB 1-4 3 97    
       
 
Table 6.9: A crosstabulation table demonstrating the interobserver agreement for 
thrombus burden (categorised as normal or abnormal), and associated 𝒌 statistic 
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Figure 6.12: A histogram showing the differences in assessments of thrombus burden 
made by SB1 and CP 
 
Table 6.9 and Figure 6.13 illustrate the agreement between assessments of thrombus 
burden made by SB2 and CP. Po was 96.4%, with a 𝑘 statistic of 0.93 (95% CI 0.88 to 0.98) 
indicating excellent agreement.  
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Figure 6.13: A histogram showing the differences in assessments of thrombus burden 
made by SB2 and CP 
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 cTFC as a dichotomous variable 
Table 6.10 and Figure 6.14 illustrate the agreement between assessments of cTFC made by 
SB1 and CP. Po was 89.9%, with a 𝑘 statistic of 0.76 (95% CI 0.63 to 0.89), indicating good 
agreement.  
 
cTFC (n=119) 
  CP Po Pe 𝒌 (95% CI) 
    cTFC <27 cTFC ≥ 27 89.9% 57.7% 0.76 (0.63 to 0.89) 
SB1 
cTFC <27 77 8     
cTFC ≥ 27 4 30     
            
  CP    
  cTFC <27 cTFC ≥ 27 Po Pe 𝒌 (95% CI) 
SB2 
cTFC <27 79 9 90.8% 58.7% 0.78 (0.65 to 0.90) 
cTFC ≥ 27 2 29    
       
 
Table 6.10: A crosstabulation table demonstrating the interobserver agreement for cTFC 
(categorised as normal or abnormal), and associated K statistic 
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Figure 6.14: A histogram showing the differences in assessments of cTFC made by SB1 and 
CP 
Table 6.10 and Figure 6.15 illustrate the agreement between assessments of cTFC made by 
SB2 and CP. Po was 90.8%, with a 𝑘 statistic of 0.78 (95% CI 0.65 to 0.90) indicating good 
agreement.  
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Figure 6.15: A histogram showing the differences in assessments of cTFC made by SB2 and 
CP 
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 cTFC as a continuous variable 
The interobserver agreement of cTFC as a continuous variable was assessed using ICC. 
Comparison of assessments made by SB1 vs CP gave an ICC of 0.81 (95% CI 0.73 to 0.86). 
SB2 vs CP gave an ICC of 0.80 (95% CI 0.70 to 0.86), indicating good agreement (Table 6.11).  
 
 Intra-class correlation coefficient (95% CI) 
SB1 vs CP 0.81 (0.73 to 0.86) 
SB2 vs CP 0.80 (0.70 to 0.86) 
Table 6.11: The ICC for interobserver agreement between assessments of cTFC  
 
Figure 6.16 shows the Bland-Altman plot for the differences in assessments made by SB1 
and CP. The Bland-Altman analysis shows the limits of agreement are -22.86 to 17.45.  
The mean difference when comparing assessments made by SB1 vs CP was -2.61. The      
95% CI was -4.58 to -0.92 and the SD was 10.24. This demonstrates that the agreement is 
outside of the limits I considered acceptable for use in clinical practice.   
The mean difference was -2.61, with a 95% CI that did not cross the line of equality. This 
indicates the presence of bias, with CP measuring cTFC values an average of 2.61 higher 
than measurements made by SB1.   
When values of cTFC are less than 40, the variability in errors appears to be random, with 
values of SB1-CP appearing both above and below the line of equality. However, when the 
cTFC is above 40, the majority of differences are negative (appear below the line of 
equality). This indicates that as the value of cTFC increases, CP is consistently measuring 
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higher values of cTFC than SB1. Two outliers, lying outside of the limits of agreement, occur 
when CP records values that are significantly higher than those recorded by SB1.    
 
 
 
Figure 6.16: A Bland-Altman plot of cTFC measurements performed by SB1 and CP.
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Figure 6.17 shows the Bland-Altman plot for the differences in assessments made by SB2 
and CP, showing a similar pattern of differences to the BA plot in Figure 6.16 (SB1 vs CP).  
The Bland-Altman analysis shows the limits of agreement are -23.10 to 15.95.  
The mean difference when comparing SB2 vs CP was -3.51 (95 % CI -1.97 to -5.47) and the 
SD was 9.96. Similar to SB1 vs CP, this demonstrates that the agreement is outside of the 
limits considered acceptable for use in clinical practice.   
The mean difference was -3.51, with a 95% CI that does not cross the line of equality, 
indicating the presence of significant bias, with CP measuring values an average of 3.51 
higher than measurements made by SB2. When the mean of the paired measurements is 
between 10 and 40, the differences appear above and below the line of equality. However, 
as the mean cTFC increases, the differences increase and are negative values. This suggests 
that as the mean cTFC increases, CP consistently measures higher values of than SB2.
 
 
 
Figure 6.17: A Bland-Altman plot of measurements performed by SB2 and CP.
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 Discussion 
 Main findings 
TIMI flow showed good intra- and interobserver agreement (intra: 𝑘 =0.79; inter: 𝑘=0.61 
and 𝑘=0.64), with a better agreement in the intra- than interobserver analysis. MBG 
showed fair agreement, with similar 𝑘 values for both intra- and interobserver analyses 
(intra: 𝑘=0.40; inter: 𝑘=0.39 and 𝑘=0.44). Thrombus burden showed excellent agreement in 
both analyses (intra: 𝑘=0.96; inter: 𝑘=0.95 and 𝑘=0.93). Dichotomised cTFC showed good 
agreement, with better agreement in the intraobserver analysis (intra: 𝑘=0.89, inter 𝑘=0.76 
and 𝑘=0.78). 
  
Intraobserver agreement of cTFC as a continuous variable showed excellent agreement 
when evaluated using ICC and BA analysis (ICC: 0.95; limits of agreement: -7.06 to 8.98; 
mean difference: 0.95; 95 % CI -0.22 to 2.24) Interobserver analysis showed good 
agreement when evaluated using ICC (0.81 and 0.80) but did not show clinically acceptable 
limits of agreement in the BA analyses (-22.86 to 17.45 and -23.10 to 15.95). There was also 
evidence of bias between observers in the interobserver analyses (mean difference: -3.51; 
95 % CI -1.97 to -5.47 and -2.61; 95 % CI -4.58 to -0.92).  
 
 What is known from other studies? 
Several studies have assessed reproducibility and agreement of TIMI flow, thrombus 
burden, MBG and cTFC, showing good agreement for all 4 angiographic grading systems.  
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 TIMI flow 
Although the original authors of the TIMI flow grade did not assess reproducibility between 
observers, this has been done in several subsequent studies.26,153 Gibson et al. used Cohen’s 
𝑘 to assess agreement in TIMI flow measurements between the study centre and core lab, 
reporting 89% interobserver agreement and a 𝑘 statistic of 0.59.99  
 Myocardial blush grade 
Van‘t Hof et al. published the original method for assessing myocardial blush.104 In their 
paper they report estimations of inter- and intraobserver agreement as percentage 
agreement (intra: 90%, inter: 97%). Several other studies describe the intra- and 
interobserver agreement in MBG using percentage agreement alone, with values ranging 
from 85% to 95% total agreement.107,110,154 Assessing the percentage agreement alone risks 
an overestimation because chance agreement is not considered. For example, if we 
consider that there are 2 grades used to assess the dichotomous variables (normal and 
abnormal), there is a 1 in 2 chance of selected a single observer selected a grade by chance. 
The probability that a pair of assessments taken by 2 different observers will agree is 0.50 x 
0.50 = 0.25. If there is equal prevalence of each grade within the data, the assessments will 
agree in 25% of cases simply due to chance. Therefore, reporting 𝑘 statistics alongside 
percentage agreement is preferred to reporting percentage agreement alone. Some more 
recent studies used Cohen’s 𝑘 to quantify agreement between MBG measurements, 
reporting 𝑘 values between 0.82 to 0.92.93,155,156  
 cTFC 
Cohen’s 𝑘 was used by Gibson et al. to assess repeatability between injections of contrast 
performed minutes apart in the measurement of cTFC. 99 No assessment was made of 
reliability between different observers. Other studies comparing cTFC measurements have 
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also used the 𝑘 statistic, reporting 𝑘 values between 0.84 and 0.85, as well as reporting the 
mean difference +- standard deviation of paired measurements of cTFC.102,103,157  
 Thrombus burden 
The original publication describing thrombus burden also does not report levels of 
agreement between observers.94 Several subsequent trials have assessed agreement of 
thrombus burden using Cohen’s 𝑘 but none have used the original TIMI thrombus grading 
system that I have used in this thesis.95,96,158  
 What does this study add? 
The 𝑘 values for intra- and inter-observer agreement for MBG are disappointing when 
compared to 𝑘 values of the other variables. By examining the distribution of the grades of 
MBG in the comparison of SB1 and SB2 (Table 6.3) I can see that the decision made by 
observers to choose normal or abnormal MBG results in a similar number of assessments 
where the grades agree (SB1 = SB2: 15) and disagree in both directions (SB1<SB2: 17; 
SB1>SB2: 12). This is likely because the “true” value of MBG is on the border of normal and 
abnormal, creating errors when one observer decides the blush is normal whereas the 
other observer decides it is abnormal. The assessments disagree even though both 
observers thought the blush was on the border of normal and abnormal. This demonstrates 
how quantisation - splitting up into ordinal categories - creates artefact and noise on the 
category boundaries. If MBG could be assessed using a continuous scale this would avoid 
categorising and creating arbitrary boundaries that have little clinical meaning. A 
continuous measure of MBG would likely improve both the intra- and interobserver 
agreement as well as the predictive ability of the variable.  
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As shown in the methods section, the prevalence of each grade within the dataset will 
affect the 𝑘 statistic, with high prevalence resulting in a lower 𝑘 value. Therefore, when 
interpreting a 𝑘 statistic we must consider the frequency that each grade occurs. Individual 
grades within each grading system are likely to occur with differing frequencies depending 
on the variable, which will influence the 𝑘 statistics. This makes comparisons of 𝑘 statistics 
in between the variables more challenging. To mitigate this limitation, I included 
assessments from multiple time points throughout the angiogram. Assessments of coronary 
flow, myocardial perfusion and thrombus burden are likely to change before and after 
intervention. Therefore, by including assessments of each variable at these two time points, 
the underlying disease state is likely to be more varied, increasing the heterogeneity of the 
data. To the best of our knowledge, this is the only study that examines the agreement of 
the grading systems at more than one time-point on the angiogram. 
 ICC 
Using ICC demonstrated excellent reliability in intra- and interobserver measurements of 
cTFC. ICC is a good measure of reliability when assessing continuous data because it reflects 
both the degree of correlation and the agreement between measurements.159 A limitation 
of ICC is that it is affected by both sample size and sample heterogeneity. Therefore, a small 
sample with a lack of variability among subjects would result in a lower ICC.  
 BA plots 
Several studies use mean difference and 95% confidence intervals to assess agreement for 
cTFC.93,102,103 BA analysis has the advantage of displaying the mean difference at different 
magnitudes of the measured cTFC. Calculating the limits of agreement gives a visual 
impression of the variability of 95% of the mean differences.160   
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The BA analysis performed to evaluate interobserver agreement (SB1/CP, SB2/CP) showed 
less than clinically acceptable agreement. For SB1 vs CP, the limits of agreement were             
-17.45 to 22.68. This is a significantly larger limit than the stated acceptable limits of +/- 8. 
This variability indicates that the measurements made by the two observers are 
significantly different and not interchangeable. This disagreement between observers is 
unlikely to be due to the underlying method of measuring cTFC because the intraobserver 
analysis shows acceptable agreement on repeat measurements. It is possible that further 
training for operators who plan measure cTFC during PPCI may improve the interobserver 
agreement. 
The interobserver agreement will have been affected by presence of outliers within the 
data. The distribution of mean differences in all three distributions of cTFC (SB1/SB2, 
SB1/CP, SB2/CP) is non-normal, likely in part because of complete agreement (mean 
difference = 0) making up a high percentage of differences (SB1/SB2: 60/119 = 51%). BA 
plots can be used for non-normal distributions as they are still likely to have around 95% of 
observations within 2 standard deviations of the mean.161 However, several outliers in the 
data will have contributed to the non-normal distribution and may be responsible for wide 
limits of agreement, skewing the data and resulting in a mean difference moving away from 
0.   
For example, when comparing SB1/CP there are 3/119 paired measurements that give 
mean differences >40 frames, with 116/119 paired measurements giving a mean difference 
<23 frames. Once the 3 anomalous results were removed from the data, the mean 
difference (95% CI) becomes -1.28 (-2.29 to -0.22) with a SD of 5.7 and the limits of 
agreement decrease (-12.46 to 9.89), indicating that when anomalies are removed, the 
overall agreement is improved.  
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These outliers are likely to result from the variability between observers in selection of the 
coronary branch used for the final frame calculation. PPCI angiograms tend to be limited in 
quality when compared to angiograms performed during elective procedures. This is 
because the aim of the procedure is to reduce infarct size by delivering timely 
revascularisation, therefore, the quality of the angiogram obtained may be compromised in 
favour of delivering speedy treatment. Reduced angiogram quality makes it more 
challenging to identify the distal branch that should be used for assessing the final frame in 
the cTFC measurement. Therefore, when it is unclear which branch should be used, or 
there is more than one suitable branch identified, different observers may select different 
branches. This results in large differences in paired measurements of cTFC which, in turn, 
produces a wide standard deviation and limits of agreement on BA analysis. This occurs 
despite a high percentage total agreement because the anomalies skew the data. When 
assessing cTFC in future studies, observers should make a note of angiograms where two 
possible branches could be used for the final frame calculation and employ a third observer 
to assess cTFC in that run.  
 
A limitation of BA plots is the assumption that the mean of the two values is the “true” 
value. The error of each observer from the true value is therefore assumed to be the same. 
One observer may be closer to the true value than the other and the BA plot may give an 
inaccurate view of the error of each observer. The method of BA analysis defines the limits 
of agreement but does not determine whether this limit is clinically acceptable, therefore 
acceptable limits of agreement should be set prior to data analysis.  
 Limitations of the study design 
Sample size was a limitation in this study. For dichotomous variables, I decided a kappa 
coefficient of the sample population could differ up to 20% from the "true" value of kappa 
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in the population. If a more accurate value for kappa was required, the sample size would 
have to be increased.  
Only two observers were used in this analysis, limiting interpretation of the agreement to 
these two observers. If I wanted to generalise the results to a wider population of 
observers, more observers would need to be trained and included in the study.  
A proportion of assessments for each angiographic grading system were excluded due to 
poor angiographic quality leading to estimated values for the variable. These exclusions will 
have limited the sample size. Using angiograms that were obtained specifically for the 
purpose of assessing the selected grading systems would have increased the quality of the 
angiograms, increased sample size and likely improved agreement between observers.  
 
 Conclusion 
The TIMI flow grade, thrombus burden and dichotomised cTFC show good intra- and 
interobserver variability. MBG showed less agreement than other variables, although this 
should not result in the exclusion of this variable from predictive models because the 
percentage agreement was good and kappa statistics have limitations. cTFC as a continuous 
variable did not show adequate interobserver agreement, with evidence of systematic bias 
between observers. There is potential for this to improve if observers undergo further 
training in assessing cTFC.  
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 Evaluating the association between clinical and 
angiographic factors, and mortality at 28-days or poor LV 
function: the development of the Liverpool MI Risk Model 
 
 Introduction 
Several scores have been developed to help risk-stratify patients with STEMI, but few can 
be calculated during the acute event. Development of a risk model that could be applied 
during PPCI may aid operators’ decisions regarding adjunctive reperfusion therapies or 
additional post-procedure monitoring. This could improve patient outcomes and be cost 
effective for hospitals. Current ESC guidelines on management of STEMI recommend all 
patients be admitted to CCU or ITU for a period of monitoring following revascularisation.3 
However, a recent registry study showed that only 16% of STEMI patients develop a 
complication that requires admission to the ITU.162 Risk stratifying patients during the acute 
event could help operators decide which patients are most likely to benefit from admission 
to ITU, and decide the optimal length of stay in critical care areas.  
The aim of this study was to evaluate whether clinical and angiographic variables, recorded 
during the acute event, could predict a composite outcome of 28-day mortality or 
subsequent severe impairment of LV function. Any associations could then be used to 
create a practical tool linking the selected variables with the clinical outcome for use by 
operators during PPCI.   
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 Methods 
 Source of data 
This study was a prospective design, conducted on data collected during the HEAT-PPCI trial 
at the Liverpool Heart and Chest Hospital. Specific information was collected by structured 
review of existing angiograms. Clinical data on participants were obtained from the existing 
HEAT-PPCI database.  
 Participants 
Patients recruited into the HEAT-PPCI trial were eligible for the study if they fulfilled the 
following inclusion criteria:  
 Inclusion criteria 
• Angiography performed during the HEAT-PPCI trial.  
• Angiographic evidence of MI decided by the operator.  
• PCI attempted, defined as the use of a guidewire, balloon catheter, 
thrombus aspiration catheter or stent 
 Exclusion criteria 
• Patients with coronary artery bypass grafts  
• Patients identified on angiography as having more than one culprit lesion 
• Patients who experienced a recurrent MI within 28 days following the acute 
event 
• Patients who experienced in-lab MACE or require emergency surgery prior 
to PCI completion 
• Patients where the culprit vessel was the RV branch 
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 Clinical outcomes 
Clinical outcomes collected in HEAT-PPCI included all-cause mortality at 12 months, MACE 
at 28 days, LV function prior to discharge and CK-MB release. The primary outcome used in 
this study was a composite of subsequent severe impairment of LV function (defined as an 
ejection fraction ≤ 35%) or all-cause mortality at 28 days following randomisation. 
LV function was included in the composite outcome because it is an important prognostic 
marker, with a decreased ejection fraction (EF) predicting mortality after STEMI.25,163-165 LV 
function also predicts infarct size following MI and is one of the diagnostic criteria for heart 
failure.25,166 When accompanied by symptoms of heart failure, patients with poor LV EF 
report severe impairment of quality of life, although several trials show that LV EF alone is 
not an independent predictor.167-171  
LV function was measured in 95.1% participants. LV function was measured using 
transthoracic echocardiography and recorded as the following categories of ejection 
fraction (%):   
▪ Normal: ≥55 
▪ Mild impairment: 45-54 
▪ Moderate impairment: 36-44 
▪ Severe impairment: ≤35 
All-cause mortality was recorded for HEAT-PPCI participants up to 28 days. In Chapter 4, I 
extended follow-up and explored the cardiovascular and non-cardiovascular deaths in the 
HEAT-PPCI trial up to 12 months. I noted that the hazard was highest immediately following 
the acute event, and most cardiovascular deaths occurred during the first 28 days. Hence, I 
selected 28-day mortality as the outcome measure in this study. The use of death 
certificates gave an indication as to the cause of death in patients who survived to 28 days 
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but had died by 12 months, however, it had limitations as a method of determining cause 
of death. I, therefore, chose to use all-cause mortality at 28 days as the outcome.  
Major adverse cardiovascular events (MACE) were recorded at 28-days following the index 
procedure. These included all-cause mortality, stroke, recurrent MI and unplanned 
revascularisation. Stroke, recurrent MI and unplanned revascularisation are unlikely to be 
associated with infarct size during the acute event and were therefore not included as 
outcome measures.  
An increased CK-MB value reflects a greater size of infarct in patients following AMI.21 CK-
MB was measured in 94.8% patients with confirmed MI on angiography but, as discussed in 
Chapter 5, was not sampled at a consistent time interval and was unlikely to consistently 
capture the peak CK-MB release. The available data on CK-MB was unlikely to be a reliable 
surrogate marker for infarct size and was not used as an outcome in this study.  
 Selection of predictors  
Table 7.1 illustrates the clinical and angiographic variables that were considered potential 
predictors for inclusion in the study.  
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Clinical variables: Angiographic variables: 
Age TIMI flow 
Gender 
Culprit vessel  
cTFC 
Thrombus burden 
MBG 
Table 7.1: Variables considered for use in the study 
 
 Clinical variables 
Data regarding the clinical variables (age, gender, culprit vessel) were taken from the HEAT-
PPCI database. 
 Angiographic variables 
The angiographic variables included in this study were TIMI flow, thrombus burden, cTFC 
and MBG, all as dichotomous variables. The PPCI angiogram of each eligible participant was 
analysed and the angiographic variables assessed in the final angiographic run at the end of 
the PPCI procedure (Figure 7.1). The methods of assessing the angiographic grading 
systems that were used in this study are described in Chapter 2. 
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 First device inserted 
 
 
 
Figure 2.1: Definitions of 
the first frame used for 
TIMI frame counting First 
device inserted 
 
Final angiographic image 
taken 
TIMI flow, cTFC, Thrombus 
burden and MBG measured 
Patient enters 
cath lab 
 
Stent 
deployed 
Procedure close 
 
 
 
 
 
 
 
 
 
Figure 7.1: A timeline of the index procedure in HEAT-PPCI demonstrating the time-point 
for assessment of angiographic variables. 
 
When recording the data on the angiographic variables, I was blinded to associated clinical 
characteristics and clinical outcomes for a given participant. It was not possible to blind 
results of other angiographic variables as I frequently used the same angiographic runs to 
assess more than one variable.  
For each angiographic variable assessed, I made a judgement on the quality of the 
assessment and recorded this in the database.   
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 Sample size 
The sample size in HEAT-PPCI was powered to uncover differences between antithrombotic 
medications in PPCI which is not relevant to this study. Therefore, I needed to check that 
the sample size in HEAT-PPCI would be large enough for the purposes of this study.  
HEAT-PPCI included 1812 patients in their analysis, 1803/1812 = 99.5% had an angiogram 
performed for suspected STEMI.   
An accepted “rule-of-thumb” when developing a risk model is to use the event per variable 
(EPV) ratio to determine the sample size.172 The EPV is the number of events in the data 
divided by the number of regression coefficients in the risk model. One study suggests that 
an EPV of 10 or more is needed to avoid overfitting the risk model. Therefore, a dataset 
should contain complete data on at least 10 times the number of patients who experience 
an event as the number of predictors in the model. I estimated at least 1000 complete 
datasets would be available from HEAT-PPCI and patient records. HEAT-PPCI reported a 
rate of all-cause mortality or subsequent severe impairment of LV function in 215/1812 = 
11.8% patients. Therefore, our outcome event will occur in approximately 120 patients, 
giving good statistical power for up to 12 predictors.  
 
 Statistical Analysis 
Categorical data was compared using the chi-square test. Continuous variables are 
presented as median and interquartile ranges and were compared using the Mann-Witney-
U test. For all analyses a two-sided p < 0.05 was considered statistically significant. I 
identified 7 potential predictors (3 clinical and 4 angiographic) for inclusion in the study, 
however, it did not seem practical for operators to have to calculate 7 variables during an 
emergency procedure. The inclusion of too many variables can lead to a complex model 
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which is overfitted to the specific features of the sample, rather than reflecting the general 
population.172 Therefore, I aimed to reduce the tool to include only the minimum number 
of predictors that would still provide an accurate estimate of the outcome. Selected clinical 
and angiographic variables were examined by univariate logistic regression analysis for their 
relation to the outcome. TIMI flow, thrombus burden, culprit location, cTFC and MBG were 
dichotomized and treated as binary variables. Values for angiographic variables were only 
included in the analysis if they had been assessed “with confidence”. Significant univariate 
predictors of the outcome, using an accepted arbitrary cut-off of p=0.25, were selected for 
the final multivariate logistic regression analysis used to derive the risk prediction model.173  
 
 Results 
1812 patients entered the lab in the HEAT-PPCI trial. Of these, 1479 had confirmed MI on 
angiography, with 1410 receiving a completed PCI procedure with no other exclusion 
criteria (Figure 7.2). A total of 1371/1410 = 97.2% patients had complete information on 
the composite outcome of death at 28 days or subsequent severe impairment of LV 
function.  
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1410 assessed in the study 
 
1803 angiography is performed 
225 have no angiographic evidence of MI 
1812 enter the lab 
9 enter lab but angiography is not performed 
1578 confirmed MI on angiography  
86 PCI not performed 
1 early death before the wire advanced 
2 too unwell for PCI 
45 Surgical disease 
38 PCI not attempted for other reasons 
 
1492 PCI was attempted  
31 have incomplete PCI 
9 die after PCI started 
3 require immediate cardiac surgery 
19 have in-lab MACE 
1461 PCI completed 
51 excluded because 
15 have previous CABG 
1 has more than 1 culprit vessel 
1 RV branch culprit 
4 no angiogram available 
30 have a recurrent MI within 28 days 
 
Figure 7.2: Flow diagram for the inclusion of participants in the study 
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 Age 
The median age of all patients was 63 (53 to 73) (Table 7.2). The median age was 
significantly different between those patients who experienced the composite outcome 
and those who did not (71 vs 62, p <0.001) (Table 7.2).  
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 Gender 
Male patients accounted for 1025/1410 = 72.7% of participants (Table 7.2). Comparing the 
proportion of men vs women who experienced the composite outcome did not show a 
significant difference between the two groups (103/1001 = 10.3% vs 43/370 = 11.4%; 
p=0.57) (Table 7.2).  
 
  
 
All patients 
n=1410 
Alive at 28 days and 
  LV EF > 35% 
Died at 28 days or  
LV EF ≤ 35% p value 
Age  63 (54 to 73) 62 (54 to 73) 71 (60 to 80) <0.001  
         
Gender        
Male 1025/1410 (72.7%) 898/1001 (89.7%) 103/1001 (10.3%) 0.57 
Female 385/1410 (27.3%) 328/370 (88.6%) 43/370 (11.4%)   
     
Culprit location     
LAD 531/1410 (37.7%) 415/521 (79.7%) 106/521 (20.3%) <0.001 
LMS 13/1410 (0.9%) 9/13 (69.2%) 4/13 (30.8%)   
RCA 632/1410 (44.8) 581/607 (95.7%) 26/607 (4.3%)   
Cx 206/1410 (14.6%) 196/202 (97.0%) 6/202 (3.0%)   
Dx 28/1410 (2.0%) 25/28 (89.3%) 3/28 (10.7%)   
Table 7.2: Clinical variables categorised according to the occurrence of the outcome 
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 Culprit vessel 
The culprit vessel was most frequently the RCA (632/1410 = 44.8%) and the LAD (531/1410 
= 37.7%) (Table 7.2). The LMS made up only 13/1410 = 0.9%, Cx 206/1410 = 14.6% and Dx 
28/1410 = 2.0%. Table 7.2 demonstrates significant differences in the culprit vessel when 
comparing patients who experienced the composite outcome compared to those who did 
not (LAD culprit: 106/521 = 20.3% vs 415/521 = 79.7%; p=<0.001). To increase the 
predictive power of culprit location, I dichotomised this variable into the LAD or LMS vs. any 
other culprit vessel prior to performing further analyses. 
 TIMI flow 
An assessment of TIMI flow was made in 1410/1410 = 100% patients, with 1395/1410 = 
98.9% made with confidence (Figure 7.3). TIMI flow grade 0 accounted for 17/1395 = 1.2% 
of confident assessments; Grade 1: 12/1395 = 0.9%; Grade 2: 184/1395 = 13.2%; Grade 3: 
1182/1395 = 84.7% (Table 7.3). Comparing TIMI flow grades in patients who experienced an 
outcome showed a significant difference (p=0.002) (Table 7.4).
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1410 assessments 
of thrombus burden 
Grading of TIMI flow, cTFC, Thrombus burden and MBG was attempted 
54 unable to assess cTFC 
33 distal vessel occluded 
13 inadequate views/flow   
   6 poor panning 
   2 poor image resolution 
 
4 unable to assess MBG  
1 poor panning 
1 inadequate view 
   2 short run 
1410 PPCI angiograms reviewed 
1410 assessments 
of TIMI flow  
1356 assessments 
of cTFC 
1406 assessments of 
MBG 
1395 confident assessments 
  15 estimated: 
  1 short run 
  1 poor panning 
  2 poor image resolution 
  10 inadequate flow 
  1 mechanical CPR 
 
1395 confident assessments 
  15 estimated: 
  3 short run 
  4 poor panning 
  5 poor image resolution 
  2 inadequate flow 
  1 mechanical CPR  
 
901 confident assessments 
455 estimated: 
6 short run 
373 poor panning 
40 poor image resolution 
25 inadequate views 
10 inadequate flow 
1 mechanical CPR  
 
1289 confident assessments 
117 estimated: 
69 short run 
15 poor panning 
17 poor image resolution 
11 inadequate views 
4 inadequate flow 
 1 mechanical CPR  
 
Figure 7.3: A flow diagram showing the quality of assessments made using the 4 angiographic grading systems 
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Assessments made with confidence 
TIMI flow 
 
0 17/1395 (1.2%) 
1 12/1395 (0.9%) 
2 184/1395 (13.2%) 
3 1182/1395 (84.7%) 
  
 
0 1318/1395 (94.5%) 
1 17/1395 (1.2%) 
2 2/1395 (0.1%) 
3 13/1395 (0.9%) 
4 27/1395 (1.9%) 
5 18/1395 (1.3%) 
  
MBG 
 
0 20/1289 (1.6%) 
1 34/1289 (2.6%) 
2 135/1289 (10.5%) 
3 1100/1289 (85.3%) 
  
cTFC 
 
All 20 (14 to 30) 
≤27 620/934 (66.4%) 
>27 314/934 (33.6%) 
Table 7.3: Distribution of assessments made with confidence for angiographic variables  
 
 
 
  
 
Alive at 28 days and  
Died at 28 days or  
LV EF ≤ 35% p value 
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LV EF > 35% 
TIMI flow    
 
0 11/16 (68.8%) 5/16 (31.3%) 0.002 
1 7/10 (70.0%) 3/10 (30.0%) 
 
2 155/181 (85.6%) 26/181 (14.4%) 
 
3 1043/1150 (90.7%) 107/1150 (9.3%) 
 
    
Thrombus burden 
  
0 1159/1287 (90.1%) 128/1287 (9.9%) 0.015 
1 13/16 (81.3%) 3/16 (18.8%) 
 
2 2/2 (100%) 0/1 (0%) 
 
3 10/12 (83.3%) 2/12 (16.7%) 
 
4 20/26 (76.9%) 6/26 (23.1%) 
 
5 11/16 (68.8%) 5/16 (31.3%) 
 
    
MBG 
  
0 13/19 (68.4%) 6/19 (31.6%) <0.001 
1 23/34 (67.6%) 11/34 (32.4%) 
 
2 107/130 (82.3%) 23/130 (17.7%) 
 
3 980/1075 (91.2%) 95/1075 (8.8%) 
 
    
cTFC 
  
All 20 (14 to 30) 20.5 (14 to 28) 0.92  
≤27 567/602 (94.2%) 35/602 (5.8%) 
 
>27 274/301 (91.0%) 27/301 (8.9%)   
Table 7.4: Angiographic variables of included participants categorised according to the 
occurrence of the outcome 
 
 
 Thrombus burden 
An assessment of Thrombus burden was made in 1410/1410 = 100% patients, with 
1395/1410 = 98.9% made with confidence (Figure 7.3). Thrombus burden grade 0 made up 
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1318/1395 = 94.5% of confident assessments; Grade 1: 17/1395 = 1.2%; Grade 2: 2/1395 = 
0.1%; Grade 3: 13/1395 = 0.9%; Grade 4: 27/1395 = 1.9%; Grade 5: 18/1395 = 1.3% (Table 
7.3). Comparing thrombus burden grades in patients who experienced an outcome showed 
a significant difference in the distribution of the grades (p=0.015) (Table 7.4). 
 Myocardial blush grade 
An assessment of MBG was made in 1406/1410 = 99.7% patients, with 1395/1410 = 98.9% 
made with confidence (Figure 7.3). MBG 0 accounted for 20/1289 = 1.6% of confident 
assessments; MBG 1: 34/1289 = 2.6%; MBG 2: 135/1289 = 10.5%; MBG 3: 1100/1289 = 
85.3% (Table 7.3). Comparing MBG in patients who experienced an outcome showed a 
significant difference in the distribution of the grades (p=<0.001) (Table 7.4). 
 cTFC 
An assessment of cTFC was made in 1356/1410 = 96.1%, with 901/1356 = 66.4% made with 
confidence (Figure 7.3). The median cTFC for all assessments was 20 (13 to 29) and the 
median for cTFC made with confidence was 20 (14 to 30) (Table 7.3). cTFC could not be 
assessed in vessels where there was distal obstruction present (TIMI flow 0), regardless of 
angiogram quality. Therefore, I dichotomised the cTFC variable into assessments less than 
or equal to 27 (normal flow) and assessments greater or equal to 27 (abnormal flow). In the 
group of patients with abnormal cTFC, I included those where the cTFC could not be 
assessed due to distal obstruction. 1356/1410 = 96.1% cTFC assessments were completed 
with 934/1410 = 66.2% made with confidence (Table 7.3). Comparing cases based on the 
composite outcome showed no significant difference between the groups (35/602 = 5.8% 
vs 27/301 = 8.9%; p=0.06) (Table 7.4). 
Table 7.4 demonstrates small numbers in the lower grades for all angiographic grading 
systems. To increase the power of the predictive model and to ensure easy calculation of 
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the resulting risk prediction score, ordinal variables were dichotomised prior to performing 
the univariate analysis (see Table 6.1 in Chapter 6). Dichotomising continuous variables is 
not recommended in logistic regression, therefore, age and cTFC remained as continuous 
variables.174-176 
 Selection of variables for the multivariate analysis 
Table 7.5 shows the results of the logistic regression analysis performed for each variable to 
assess the univariate association with the composite outcome. Increasing age, LAD or LMS 
culprit location, abnormal TIMI flow, abnormal thrombus burden and abnormal MBG all 
demonstrated a significant association with the occurrence of the composite outcome, with 
age, culprit location and MBG identified as the strongest predictors. Variables that were 
statistically significant predictors, defined using the arbitrary cut-off of p=0.25, were then 
included in the multivariate analysis.173    
 
 
 
 
 
 
 
Odds ratio 95% CI p value 
Age 1.04 1.02 to 1.05 <0.001 
Male gender 0.896 0.612 to 1.31 0.571 
LMS/LAD culprit 5.945 3.992 to 8.852 <0.001 
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Abnormal TIMI flow (<3) 1.916 1.261 to 2.910 0.002 
Abnormal Thrombus burden (>0) 2.587 1.442 to 4.643 0.001 
Abnormal MBG (<3) 2.886 1.917 to 4.343 <0.001 
cTFC 1.005 0.989 to 1.022 0.530 
 
Table 7.5: Results from the univariate analysis  
 
 Results of the multivariate analysis 
The multivariate analysis was performed by Dr Antonio Eleuteri, University of Liverpool, and 
the author. The variables included in this analysis were culprit vessel location (CV), TIMI 
flow (TF), thrombus burden (TB), MBG (all dichotomised as previously described) and Age 
(as a continuous variable). A total of 1271 patients had complete data on the predictors 
included in this analysis. Of these, 30/1271 = 2.4% had data missing for the composite 
outcome.  
 
 The model 
A logistic regression model was fitted to the data to estimate the probability of the 
outcome event (outcome=1) conditional on the vectors of factors X. The model expressing 
the log-odds of the event as a function of the factors is shown in equation (7.1): 
𝑙𝑜𝑔 (
𝑃𝑟{Outcome=1|𝑋}
1−𝑃𝑟{Outcome=1|𝑋}
) = 𝛽0 + 𝛽1Age + 𝛽2CV + 𝛽3TF + 𝛽4TB + 𝛽5MBG            (7.1) 
We assume the regression model is linear in the parameters 𝛽, however we do not make 
any linearity assumption about Age (the other predictors are binary, so non-linearity is not 
relevant). We estimated Spearman’s 𝜌2 statistic177 to assess the strength of the marginal 
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relationship between the outcome and age; this informs us about the complexity of the 
(possibly non-monotonic) relationship.  The 𝜌2 statistic is 0.03 (p value <0.0001). Since it is 
small, Age will enter linearly in the model. 
The total Wald statistic for the model is 105.8 (5 d.f., p<0.0001). In Table 7.6, the Wald 
statistics for each factor, and the attendant odds ratio with 95% confidence limits are 
shown. 
 
Factor Odds ratio (95% CI) χ2 (p value) 
Age 2.07 (1.55 to 2.78) 23.82 (<0.0001) 
Culprit location 6.16 (4.00 to 9.47) 68.42 (<0.0001) 
TIMI Flow 1.21 (0.70 to 2.09) 0.48 (0.49) 
Thrombus burden 1.57 (0.74 to 3.32) 1.37 (0.24) 
MBG 2.32 (1.39 to 3.88) 10.39 (0.0013) 
Table 7.6: Logistic regression model statistics 
 
Internal validation was performed using bootstrapping (1000 repetitions) and the 
discrimination and calibration performance of the model were assessed.177 In Figure 7.4 are 
reported the apparent, ideal and bias-corrected calibration graphs. The model tends to 
overestimate the probability of the event when it’s larger than 0.4. The maximum absolute 
error in predicted probability is estimated to be 0.02. The estimated shrinkage factor is 0.96 
(this is the likelihood the model will reliably predict new observations). 
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Figure 7.4: Calibration performance. The rug plot at the top of the graph shows the 
observed data. (Outcome = 1 denotes the occurrence of the outcome) 
 
The model’s discrimination (AUC) is 0.79 (0.75 to 0.83), with an upward estimated bias of 
0.014. In Figure 7.5 the ROC curve is shown. 
 
Predicted Probability (Outcome=1) 
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Figure 7.5: ROC curve with 95% bootstrapped confidence interval (1000 repetitions) 
 
 Approximating the full model 
Step-down variable selection via Akaike Information Criterion (AIC)177 was also performed 
with bootstrap resampling. 54% of the models selected Age, Culprit Location and MBG as 
relevant factors (in agreement with the statistics in Table 7.7). 36% of the models also 
considered Thrombus Burden as relevant. 8% of the models considered all the factors 
relevant, and 2% of the models only Age and Culprit Location. 
A parsimonious model is of interest for clinical practice, so approximations can be 
developed that can predict the outcomes of the full model with high accuracy.177 The 
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simplification is done using a fast backward step-down against the full model predicted 
values. Table 7.7 shows the factors, the cumulative AIC and cumulative R2. The simpler 
model with highest accuracy is the one that includes all factors excluding Thrombus Burden 
and TIMI flow, with R2=0.987. Note that adding Thrombus Burden only marginally improves 
the accuracy, to R2=0.997.  
 
Deleted factor AIC R2  
Culprit location 1499.2 0 
Age 514.12 0.654 
MBG 165.49 0.886 
Thrombus burden 15.44 0.987 
TIMI flow 2.38 0.997 
Table 7.7: Step-down model selection 
 
The variance matrix of the coefficients of the reduced model differs from the variance 
matrix of the original model, and it accounts for the selection procedure so that the 
statistics are “honest”.177 The ratios of the variances of the reduced model to the variances 
of a reduced model fitted against the actual outcomes, range from 1.0030 to 1.0096, so the 
variability of the coefficients does not increase appreciably. 
The total Wald statistic for the reduced model is 103.9 (3 d.f., p<0.0001). The Wald 
statistics for the factors are shown in Table 7.8. 
 
Factor χ2 (p value) 
Age 25.69 (<0.0001) 
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Culprit location 68.14 (<0.0001) 
MBG 18.77 (<0.0001) 
Table 7.8: Reduced model statistics 
 
The statistics are similar to those reported in Table 7.7 for the full model. This would not be 
the case had deleted variables been very collinear with retained variables. 
The equation for the simplified model is as follows: 
 
𝑙𝑜𝑔 (
𝑃𝑟{Outcome=1|𝑋}
1−𝑃𝑟{Outcome=1|𝑋}
) = −5.96 + 0.0395 ⋅ Age + 1.81 ⋅ CV + 1.01 ⋅ MBG   (7.2) 
 
A logistic regression model, termed the Liverpool MI Risk Model, was developed to predict 
the outcome (outcome=1) conditional on observed patient Age, Culprit location and MBG. 
The model exhibits good discrimination (AUC 0.79 95% CI: 0.75 to 0.83) and calibration 
(maximum absolute error 0.02, shrinkage 0.96) properties.  
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Using equation (7.2), we can predict the outcome for any values of the predictors using the 
Liverpool MI Risk Model. We created a risk prediction chart that could be used to look-up 
predictions of the outcome for categories of age (Figure 7.6). This form is more practical for 
use during PPCI compared to entering the values of each predictor into a computer or 
calculator.  
 
 LAD or LMS culprit Other culprit 
 
      
 Myocardial Blush Grade Myocardial Blush Grade 
Age Abnormal (<3) Normal (3) Abnormal (<3) Normal (3) 
<20 8.4 3.2 1.5 0.5 
21-30 12.4 4.9 2.3 0.8 
31-40 17.4 7.1 3.3 1.2 
41-45 20.3 8.5 4.0 1.5 
46-50 23.8 10.2 4.9 1.8 
51-55 27.5 12.2 5.9 2.2 
56-60 31.6 14.4 7.0 2.7 
61-65 36.1 17.0 8.5 3.3 
66-70 40.7 20.0 10.1 3.9 
71-75 45.6 23.4 12.1 4.8 
76-80 50.5 27.1 14.3 5.7 
81-85 55.4 31.2 16.9 6.9 
86-90 60.2 35.5 19.9 8.2 
91-95 64.9 40.2 23.2 9.9 
96-100 69.2 45.0 26.9 11.8 
% risk of death at 28-days or LV EF ≤ 35% 
Figure 7.6: Risk prediction chart for the occurrence of 28-day death or subsequent severe 
impairment of LV function following PPCI 
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 Discussion 
 Main findings of the study 
The main findings of this study showed that the composite outcome of 28-day mortality or 
subsequent severe impairment of LV function can be accurately predicted by a combination 
of age, abnormal MBG and LAD/LMS culprit lesions. Using these results, we developed the 
Liverpool MI Risk Model.   
 What is known? 
There is a large amount of research into the associations between clinical and angiographic 
variables and outcomes following STEMI.178 Here, I discuss studies that have created 
practical tools and scoring systems aimed for use in clinical practice to identify high-risk 
patients undergoing PPCI. 
 Risk scores that use clinical factors only 
There have been several studies that use clinical characteristics alone to develop scores to 
predict outcomes following STEMI.  Clinical variables have been developed into risk scores 
in thrombolysis trials where PPCI was not routine therapy, therefore, angiographic data 
were not available.179 PPCI is now the preferred treatment for reperfusion in STEMI and the 
majority of patients in recent trials will have angiographic data available for inclusion in a 
risk score. 
The GRACE score is used to predict risk of in-hospital and 6-month mortality.11 This score 
includes age, heart rate, blood pressure, serum creatinine, Killip class, cardiac arrest on 
admission, ST-segment deviation on ECG and elevated cardiac enzymes. This shows 
excellent discrimination (c statistic for STEMI patients: 0.82 derivation, 0.83 validation). 
However, this score cannot always be used by operators during PPCI because it includes 
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results from bloods tests which may not be available in time for review during the acute 
event. 
The PAMI risk score was developed from the data of 3252 patients who underwent PPCI for 
STEMI.179 The score included age, Killip class, heart rate, diabetes and anterior myocardial 
infarction, and was predictive of 6-month mortality (c-statistic 0.78). No external validation 
of the score was performed. The aim of the score was to enable risk assessment of patients 
prior to reperfusion therapy, therefore, angiographic variables were not included.  
Andrews et al. developed a risk score that predicts 30-day mortality in patients undergoing 
PPCI for STEMI.180 This required only 4 variables: age, call-to-balloon time, cardiogenic 
shock and heart failure. This model showed excellent discrimination (c statistic: 0.87 
derivation, 0.86 validation). Like PAMI, this study aimed to develop a score that could risk 
stratify patients prior to any reperfusion therapy and, therefore, angiographic variables 
were excluded.  
 Risk scores that use angiographic factors 
The CADILLAC score incorporated post-procedural TIMI flow as well as clinical variables.181 
This study showed good discrimination and accurately predicts 30-day and 1-year mortality 
based on age, Killip class, ejection fraction based on left ventriculography during PPCI, TIMI 
flow post-procedure, anaemia, renal insufficiency and the presence of triple vessel disease 
(c-statistics for 30-day mortality: 0.83 derivation 0.81 validation; 1-year mortality: 0.79 
derivation, 0.78 validation). However, this score is complex, and it is unlikely operators will 
be able to easily calculate it during the acute event. It also requires results from blood tests 
that may not be available. Performing left ventriculography adds cost to the procedure as 
well as risk to the patient from increased contrast and radiation exposure. It is not routinely 
performed by operators during PPCI.  
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De Luca et al. derived a score aimed at identifying low-risk patients for early discharge, 
predicting 30-day mortality.182 This included age, anterior infarction, Killip class, ischaemic 
time, post-procedural TIMI flow grade and the presence of multivessel disease. This score 
could identify 73.4% of low-risk patients (score ≤3) with good discrimination (c statistic 
0.907).  
The angiographic perfusion score developed by Gibson et al. includes TIMI flow grade and 
TIMI myocardial perfusion grade measured before and after PCI.183 This gives a single score 
that indicates successful reperfusion. This score was associated with 30-day mortality and 
infarct size measured on SPECT, but no predictive model was developed. Although this 
score is simple and can easily be calculated by the operator during PPCI, inclusion of simple 
clinical factors would likely improve discrimination.   
A small study (n=253) by Haager et al. showed that the addition of abnormal MBG and 
persistent ST-elevation post-intervention (STE) increased the predictive power of clinical 
characteristics when predicting 30-day mortality following STEMI.93 A combination of STE 
and MBG demonstrated good discrimination (c statistic 0.71). Like our results, this study 
demonstrated that cTFC was not an independent predictor of mortality. This study did not 
develop a risk score from the results or externally validate the model.  
 Risk scores that use additional invasive measurements 
The ATI score was developed with an aim to predict the risk of microvascular impairment 
using factors that could be assessed at the time of coronary reopening.71 The score aimed 
to predict the IMR cut-off of >40 (indicating microvascular obstruction). The score included 
age, pre-stenting IMR and thrombus burden. These factors accurately predicted the final 
dichotomised IMR value (c statistic: 0.87 derivation, 0.81 validation). However, this score 
gives no information regarding subsequent mortality or infarct size. The inclusion of pre-
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stenting IMR limits the practical use of the ATI score as operators would have to perform 
the additional invasive test for all STEMI patients. This would add cost and time to the 
procedure as well as additional risk to the patient from further instrumentation to the 
coronaries.  
 What our study adds 
 Inclusion criteria 
HEAT-PPCI represents unselected, real-world population, with minimal exclusion criteria. 
The risk score is, therefore, generalisable to a wide demographic of PPCI patients. This 
differs from other risk scores, such as the CADILLAC score, where patients with cardiogenic 
shock, or any comorbidities that were judged to affect their prognosis (likely to die within a 
year) were excluded.181 
 Choice of clinical factors  
Although there are multiple clinical characteristics that are associated with increased 
infarct size and mortality, the included variables must be available, or at least estimable, in 
the catheter lab during PPCI. For example, estimating the age of an unconscious or very 
unwell patient may be possible whereas eliciting their past medical history and risk factors 
is likely to be more challenging in an emergency setting. Therefore, some clinical factors, 
such as diabetes and ischaemic time, were excluded from the study because unwell 
patients may not be able to relay the required information to hospital staff. 
ECG changes were not included as a variable because often only a 3-lead ECG is available 
prior to PPCI. A 3-lead ECG would not allow proper evaluation of degrees of ST-elevation or 
ST-elevation resolution.  
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 Choice of angiographic factors 
All angiographic variables included in our analysis could be measured from information 
already obtained from the PPCI angiogram. No additional tests, equipment or time was 
required to calculate the variables. The risk model could, therefore, be implemented 
immediately by any operator performing PPCI, and provide valuable information without 
adding time, expense or risk.  
 Using a univariate analysis 
We performed a univariate analysis to select variables for inclusion in the multivariate 
analysis. Performing a univariate analysis is widely used for developing risk models and has 
the advantage of utilising all available data for each variable. Multivariate analyses require 
complete datasets for every variable if a participant is to be included, which reduces the 
sample size.  However, performing univariate analyses prior to multivariate analysis has 
been criticised because it may wrongly reject potentially important variables when the 
relationship between the outcome and a risk factor is confounded.175,176  
 
 Limitations 
Use of LV function as a clinical outcome has limitations. LV function prior to the acute event 
is not known, therefore, some patients may have poor LV function as a result of a previous 
cardiac event. In these cases, the LV function will not give reliable information regarding an 
estimation of the infarct size resulting from the acute event. 
Killip class has been included in several similar risk scores and is a good predictor of poor LV 
function and mortality, and easily assessed in patients with suspected STEMI. I could not 
include Killip class in our analysis because this was not recorded in the HEAT-PPCI trial. 
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The HEAT-PPCI angiograms were reviewed in retrospect, therefore, the images were not 
obtained with consideration of the measurement of the angiographic variables. This may 
account for the high proportion of estimated assessments in the study, resulting in a 
smaller number of complete datasets for use in the analysis.  
 
 Conclusions 
The simple addition of MBG in the assessment of the PPCI angiogram gives valuable 
information to the operator regarding risk of adverse outcome. The Liverpool MI risk model 
developed from the HEAT-PPCI database is simple and practical. It can be calculated in-lab 
during PPCI and accurately predicts the composite outcome of 28-day mortality or 
subsequent severe impairment of LV function (EF ≤ 35%). This model could aid operators in 
risk-stratifying patients and identifying those who could be considered for shorter stays in 
critical care areas or early discharge.  
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 External validation of the Liverpool MI Risk Model 
 
 Introduction 
Chapter 7 describes the development of the Liverpool MI risk model. This model was 
derived using data from the HEAT-PPCI trial and includes the predictors of age, culprit 
location and MBG measured at the end of the procedure. It produces a percentage risk of 
death at 28-days or poor LV function following PPCI. HEAT-PPCI was a single-centre trial 
and, therefore, there are limits on the generalisability of the risk model to other hospitals 
or patient groups.  
Risk prediction scores should be validated internally and externally.184 We have performed 
internal validation of the Liverpool MI risk model using bootstrapping described in Chapter 
7. However, external validation involves assessing the model in a new but similar cohort of 
patients. It is the strongest test of a risk model, although rarely done.185 External validation 
assesses the generalisability of a model to ensure it performs well in other groups and can 
then be used in clinical practice.185 It can be performed in a different geographical area and 
over different time periods.176 A good model should retain clinical utility proven by good 
statistical performance in the new dataset.  
In this study, we aimed to externally validate the Liverpool MI risk model using an 
independent cohort of PPCI patients from another UK centre.  
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 Methods 
 Study design 
The Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction (BHF 
MR-MI) was a single-centre, prospective, cohort study.186 BHF MR-MI recruited 324 patients 
with STEMI at the Golden Jubilee National Hospital, Glasgow. The study recorded clinical 
and angiographic variables including age, culprit location and TMPG. In the Liverpool MI 
Risk Model, we collected data on MBG. The main difference between the two grading 
systems is that the TMPG measures the clearance of contrast from the myocardium 
whereas the MBG measures the maximum density of contrast.104,111 We chose to use the 
MBG because this can be calculated on shorter cineruns without the need to continue the 
run until all contrast has cleared from the myocardium.  
By assuming the TMPG is equivalent to the MBG (see Table 8.1), we were able to include 
the TMPG assessments taken in the BHF MR-MI study for use in the validation of the 
Liverpool MI Risk Model. 
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 Myocardial blush grades 
(MBG) 
TIMI myocardial perfusion 
grades (TMPG) 
Grade 0 No myocardial blush No myocardial blush  
Grade 1 Minimal myocardial blush 
 
 
Minimal blush and very slow 
clearing (e.g. present at 
beginning of next cine) 
Grade 2 Myocardial blush exists to a 
lesser extent and with less 
clearance than would be 
expected in a non-infarct 
related artery 
Good blush with slow 
clearing of myocardial 
contrast (present at end of 
cine but gone at beginning of 
next) 
Grade 3 Normal myocardial blush 
 
 
Good blush and normal 
clearing (ie. gone by end of 
cine) 
Table 8.1: Grade equivalents for myocardial blush grades and TIMI myocardial perfusion 
grades 
 
The BHF MR-MI study recorded LV function on CMR following the acute event and all-cause 
mortality up to a minimum follow-up of 3 years. This data set contained all the variables 
and outcomes required for application of the Liverpool MI Risk Model. It was, therefore, 
possible to use this data set for external validation of the model.   
 Participants 
324 patients with a diagnosis of acute STEMI were enrolled in the trial between 11th May 
2011 and 22nd November 2012.  
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 Inclusion criteria 
• a diagnosis of acute STEMI.  
 Exclusion criteria 
• Major systemic illness (e.g. cancer limiting survival < 6 months) 
• Metallic implant or metallic foreign body (contraindications to CMR) 
• Pregnancy  
 Clinical outcomes 
The BHF MR-MI measured several clinical outcomes. The primary outcome was myocardial 
salvage measured on CMR at baseline and 6 months after index hospitalisation. Secondary 
outcomes included CMR measurements of myocardial salvage index, final infarct size, 
myocardial haemorrhage, microvascular obstruction, area-at-risk and left ventricular 
ejection fraction. Other outcome measures included recurrent myocardial infarction within 
6 months, MACE defined as cardiac death, non-fatal MI or hospitalisation for heart failure 
over 12 months, and all-cause death or hospitalisation for heart failure.  
We used the composite outcome of 28-day death or poor LV function (defined as EF ≤35%) 
measured on CMR for use in the validation of the Liverpool MI Risk Model.  
 Statistical analysis 
The statistical analysis was performed by Dr Antonio Eleuteri, University of Liverpool in 
collaboration with the author. To validate the model, we followed a model-based 
framework for calibration.187 Specific details of the statistical analysis are included in 
Appendix 4.  
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 Results 
The external validation data set is comprised of 305/324 = 94.1% complete observations; 19 
observations were excluded from the analysis because of missing data. The number of 
outcome events is 12/305 = 3.7%. In the Liverpool data, 131/1241 = 11% outcome events 
were observed. A two-sided test to compare the proportions of events in the two 
populations rejects the null hypothesis of equality; the 95% confidence interval on the 
difference between proportions is 3.9% to 9.7% with a p-value of 0.0002. There is therefore 
evidence of a higher risk of outcome events in the Liverpool population.  
Table 8.2 illustrates the clinical and procedural characteristics of the Liverpool derivation 
cohort compared with the Glasgow validation cohort. There are significant differences 
between the two groups, with the Glasgow cohort having a more favourable risk profile in 
terms of renal function (a lower proportion of patients with eGFR <60), reduced incidence 
of hypertension, hyperlipidaemia and less likely to be smokers. The Glasgow cohort were 
significantly more likely to have normal TIMI flow at the end of the procedure, despite 
having a higher risk of abnormal MBG.  
The renal function between the two cohorts was compared by examining the proportion of 
patients with an eGFR <60 because in the BHF MR-MI trial, the cut-off for quantifying eGFR 
was ≥60 (in Liverpool the cut-off was >90). Therefore, I considered a normal eGFR as ≥60 in 
both cohorts for the purpose of this analysis.  
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Liverpool 
derivation cohort 
(n=1410) 
Glasgow 
validation cohort 
(n=324) p value 
 
Age 63.5 (12.8) 59.3 (11.5) <0.001 
Male gender 1025/1410 = 72.8% 237/324 = 73.1% 0.869 
Hypertension 572/1409 = 40.6% 105/324 = 32.4% 0.006 
Hyperlipidaemia 522/1402 = 37.2% 94/324 = 29.0% 0.005 
Diabetes 180/1404 = 12.8% 34/324 = 10.5% 0.252 
Smoker 985/1391 = 70.8% 196/324 = 60.5% <0.001 
Previous MI 136/1410 = 9.6% 25/324 = 7.7% 0.281 
Previous PCI 92/1410 = 6.5% 18/324 = 5.6% 0.519 
Systolic BP 134 (118 to 153) 134 (118 to 150) 0.956 
Heart rate 
eGFR <60 
75 (62 to 88) 
180/1116 = 16.1% 
77 (65 to 89) 
26/324 = 8.0% 
0.133 
<0.001 
    
 
MBG TMPG 
 
3 1160/1406 = 82.5% 65/309 = 21.0% <0.001 
2 
1 
0 
176/1406 = 12.5% 
49/1406 = 3.5% 
21/1406 = 1.5% 
157/309 = 50.8% 
17/309 = 5.5% 
70/309 = 22.6% 
 
    
Final TIMI flow 
   
0 21/1410 = 1.5% 0/324 = 0% <0.001 
1 15/1410 = 1.1% 3/324 = 0.9% 
 
2 192/1410 = 13.6% 20/324 = 6.2% 
 
3 
 
1194/1410 = 84.7% 
 
301/324 = 92.9% 
 
 
  
Table 8.2: Characteristics of the Liverpool and Glasgow cohorts. 
 
 
 
 
193 
 
 Validation of the risk model 
We applied equation (7.2) derived in Chapter 7 for the Liverpool MI Risk Model to create a 
risk score (𝑠) for each participant in the Glasgow cohort. We then plotted a ROC curve to 
establish the discrimination of the model for Glasgow participants (Figure 8.1). This showed 
good discrimination with an AUC of 0.837 (95% CI 0.723 to 0.951).  
 
 
Figure 8.1: ROC curve for the Liverpool MI Risk Model when applied to the Glasgow 
cohort 
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We fitted the three logistic regression models. These showed that the Liverpool MI Risk 
Model consistently overestimates the risk of an outcome in the Glasgow cohort. The results 
of this analysis are detailed in Appendix 4.   
The Liverpool MI Risk Model was recalibrated to accurately predict outcome events in the 
Glasgow cohort using the following equation: 
                                                      𝑟 = 1.433𝑠 − 1.06                                                              (8.1) 
𝑟 is the recalibrated risk score and 𝑠 is the risk score derived from the Liverpool MI Risk 
Model. Table 8.3 shows a risk prediction chart developed from the model after calibration. 
This can be used in clinical practice when assessing patients similar to those in the Glasgow 
cohort.  
     
 LAD or LMS culprit Other culprit 
 
      
 Myocardial Blush Grade Myocardial Blush Grade 
Age Abnormal (<3) Normal (3) Abnormal (<3) Normal (3) 
<20 1.1 0.3 0.08 0.02 
21-30 2.1 0.5 0.2 0.04 
31-40 3.6 0.9 0.3 0.1 
41-45 4.7 1.1 0.4 0.1 
46-50 6.1 1.5 0.5 0.1 
51-55 8.0 2.0 0.6 0.2 
56-60 10.3 2.6 0.9 0.2 
61-65 13.3 3.5 1.1 0.3 
66-70 16.8 4.5 1.5 0.4 
71-75 21.2 5.9 2.0 0.5 
76-80 26.3 7.7 2.6 0.6 
81-85 32.1 10.0 3.4 0.8 
86-90 38.6 12.9 4.5 1.1 
91-95 45.5 16.4 5.9 1.4 
96-100 52.5 20.6 7.6 1.9 
Table 8.3: Risk prediction chart for the occurrence of 28-day death or subsequent severe 
LV function recalibrated for use in Glasgow patients 
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 Discussion 
The Liverpool MI Risk Model shows good discrimination when tested on the Glasgow cohort 
(c statistic 0.873; 95% CI 0.723 to 0.951). However, the Liverpool MI Risk Model predicts an 
overall higher risk on the Glasgow data, as reflected in the simple comparison of the 
percentage of outcome events in the two populations. The model can be recalibrated to 
provide accurate predictions on the Glasgow population. The need for recalibration 
highlights the existence of unknown variables that affect the risk that are not included in 
the model. 
Some risk models may over- or underestimate the number of outcome events on validation 
because the design or methods used are deficient, for example, if the model is overfitted or 
an important predictor has not been included.185 Poor performance in external validation 
can also result if the validation cohort show significant differences in the patient 
characteristics, measurement methods of variables or treatments delivered. The Liverpool 
MI Risk Model overestimates the occurrence of outcome events when tested on the 
Glasgow validation dataset.  
One reason for this may be differences in the measurement methods of MBG. The 
proportion of assessments of normal MBG following PPCI in each cohort is significantly 
different (Liverpool: 1160/1406 = 82.5% vs Glasgow: 65/309 = 21.0%; p<0.001). These 
results suggest that reperfusion was better in the Liverpool cohort which could be 
accounted for simply due to differences in procedure success and operator skills. If this 
were true, we would expect improved outcomes for the Liverpool patients. However, the 
Liverpool patients were at higher risk of adverse events compared to the Glasgow patients. 
Therefore, the differences in the distributions of MBG grades in the two cohorts is more 
likely to be due to differences in the measurement method of myocardial blush grade.  
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The BHF MR-MI research group collected data on the TIMI myocardial perfusion grade 
(TMPG) rather than the MBG.70,186 Table 8.1 shows how the MBG grades used in the 
Liverpool cohort were mapped to the TMPG grades used in the Glasgow cohort.  However, 
this is an approximation and differences in the different methods of measuring blush 
grades may affect the performance of the model on validation.  
If the measurement methods of blush in the two studies differed significantly, we can 
estimate which method was more accurate by comparing the distributions of MBG in other 
studies in a PPCI setting. Table 8.4 shows the proportion of normal and abnormal MBG 
grades assessed post-PPCI in 8 studies. We can see that there is significant variation 
between the studies, with an increased proportion of normal MBG in the more recently 
published studies. This may be due to improved treatment and the development of 
streamlined PPCI services over the past decade. Because of the wide variation in the 
proportions of normal MBG, it is difficult to determine whether the Glasgow or Liverpool 
cohorts more closely reflect the results from other studies. These studies use MBG rather 
than TMPG to measure blush.  
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  MBG grades 0/1/2 MBG grade 3 
Mahmoud et al., 2019188 27/100 (27.0%) 73/100 (73.0%) 
Badjaoui et al., 2019189 59/160 (36.8%) 101/160 (63.1%) 
Groot et al., 2017190 113/376 (30.1%) 263/376 (69.9%) 
Di Vito et al., 2016191  53/128 (41.4%) 75/128 (58.5%) 
Kampinga et al., 2010108 1305/2118 (61.6%) 813/2118 (38.3%) 
Kaya et al., 2007110 59/103 (57.3%) 44/103 (42.7%) 
Haager et al., 200393 174/253 (68.8%) 79/253 (31.2%) 
Stone et al., 2002154 125/173 (72.2%) 48/173 (27.7%) 
Table 8.4: This table compares the distribution of MBG grades across several studies of 
PPCI 
For the Liverpool MI Risk Model, I dichotomised MBG into normal (grade 3) and abnormal 
(grades 0,1,2). However, it may be that errors are occurring when operators are asked to 
distinguish between grade 2 and grade 3. Therefore, it is reasonable to think that 
dichotomising the grades as grades 0 and 1 vs grades 2 and 3 may be more useful when 
comparing the Liverpool and Glasgow cohorts. Table shows that the difference in the 
proportion of participants with “normal” MBG decreases when we dichotomise the grades 
as 0/1 and 2/3 (see Table 8.5).  
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Dichotomisation of 
MBG 
Liverpool 
derivation cohort 
Glasgow 
validation cohort  p value 
Original model 
   
Grade 3 1160/1406 = 82.5% 65/309 = 21.0% <0.001 
Grades 0/1/2 
 
New model 
Grades 2/3 
Grades 0/1 
246/1406 = 17.5% 
 
 
1336/1406 = 95.0% 
70/1406 = 5.0% 
244/309 = 79.0% 
 
 
222/309 = 71.8% 
87/309 = 28.2% <0.001 
Table 8.5: The distribution of grades when MBG is dichotomised for the original model 
(grade 3 vs grades 0/1/2) and in the new model (grades 2/3 vs grades 0/1) 
 
We can test whether this has an impact on the outcome by creating a risk model using the 
same three variables as in the Liverpool MI Risk Model but dichotomising MBG as normal 
(grades 2/3) and abnormal (grades 0/1). If the Glasgow cohort validates well on this new 
risk model, this would indicate that errors in distinguishing between grade 3 and the other 
grades of MBG could be the reason for overestimation of outcome events when applying 
the Liverpool MI Risk Model to the Glasgow cohort. Table 8.6 shows the logistic regression 
analysis when changing the cut-offs for dichotomising the MBG.  
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  B SEB Wald df p value Exp(B) 95% CI for Exp (B) 
Age 0.04 0.008 26.680 1.00 <0.001 1.041 1.025 to 1.057 
Culprit Location 1.797 0.218 68.088 1.00 <0.001 6.033 3.937 to 9.245 
MBG 1.259 0.363 12.029 1.00 0.001 3.522 1.729 to 7.123 
Constant -5.880 0.570 106.515 1.00 <0.001 0.003   
Table 8.6: Result of the logistic regression analysis predicting an adverse event when 
MBG is dichotomised into grades 0/1 vs 2/3 
 
The discrimination of the new model is similar to the original model (AUC 0.78; 95% CI 0.74 
to 0.82). Table 8.7 shows that the new model predicts the total number of events in the 
Liverpool cohort to a good approximation (mean percentage predicted events is 11.9% vs 
observed events is 10%.)  When applied to the Glasgow cohort, the mean percentage 
predicted events is 11.9% but the observed events is 3.7%. This shows that changing the 
dichotomised cut-offs for MBG does not improve the ability of the Liverpool Risk Model to 
predict outcome events in the Glasgow cohort.  
 
  
Liverpool 
cohort 
Glasgow 
cohort 
Predicted events (%) 
 
11.9 11.8 
Observed events (%) 
 
10.3 3.8 
Table 8.7: Predicted vs observed total events using the new model when MBG is 
dichotomised by grades 0/1 vs 2/3 
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Even if the categorisation of MBG had accounted for some of the differences between the 
cohorts, it does not explain why the total number of events in the Liverpool is significantly 
higher than in Glasgow (131/1241 = 11% vs 12/305 =3.7%; p value 0.0002). One possible 
explanation is the use of different eligibility criteria for patient recruitment. In the BHF MR-
MI study, patients who were deemed to have a major systemic disease or poor prognosis 
(likely to die within 6 months) were not eligible to participate in the study. In contrast, 
HEAT-PPCI included all adults who had not previously been recruited into the study and did 
not exclude patients with a poor prognosis. This may explain the more favourable risk 
profile and lower risk of outcome events seen in the Glasgow cohort.  
In addition, HEAT-PPCI employed a strategy of delayed consent to allow recruitment of 
patients who were too unwell to consent to participation in the study. BHF MR-MI did not 
employ this strategy and it is likely that patients who were unable to consent prior to PPCI 
due to severe illness or incapacity were excluded from the study. This would result in 
exclusion of patients who are more likely to have a less favourable risk profile and a higher 
risk of experiencing an outcome event.  
The primary outcome in BHF MR-MI was myocardial salvage measured on CMR 6 months 
after the acute event. The study, therefore, aimed to recruit patients who were likely to 
survive for at least 6 months following PPCI to allow data collection for the primary 
outcome. However, excluding patients with major systemic illness or a poor prognosis 
decreases the generalisability of the study. We can demonstrate this by examining the 
national statistics for mortality and comparing them to the risks predicted for patients in 
the Glasgow cohort. Table 8.4 shows that the predicted risk of an outcome event in 
Glasgow patients who are 85 years old could be as low as 0.8% if patients have a normal 
MBG and an RCA/Cx/Dx culprit (compared to 6.9% in the Liverpool cohort). Between 2015 
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and 2017, the Office of National Statistics reported the number of registered UK deaths in 
people aged 80-84 was 5.9%.192 The Glasgow cohort is, therefore, unlikely to be 
generalisable because the risk of an outcome event (which includes death at 28 days) is 
lower than that seen in the general population.  
We explored the differences in patient recruitment for each study by examining the total 
number of PPCI procedures performed by each centre and comparing this to the number of 
participants recruited into each study. The Golden Jubilee Hospital in Glasgow performed 
650 PPCI procedures in 2016 (650/12 = 54 per month).13 The BHF MR-MI study recruited 
324 participants over 16 months. We do not have access to the screening log for BHF MR-
MI so we do not know the proportion of patients who had a PPCI and were excluded due to 
major illness or poor prognosis. Therefore 324/(54 x 16) = 324/864 =37.5% of the likely PPCI 
procedures performed over 16 months were recruited into the study. In comparison, HEAT-
PPCI reported near 100% recruitment of all eligible patient. The study population 
represented 97% of all patients who were managed with angiography in the context of 
suspected STEMI. The high proportion of patients recruited into the HEAT-PPCI is likely to 
result from a combination of broad eligibility criteria, using a strategy of delayed consent 
and setting out with an aim to collect data on different primary outcomes that did not 
require patients to survive at least 6 months following PPCI.  
Glasgow patients had a more favourable risk profile in terms of better renal function, 
reduced incidence of hypertension, hyperlipidaemia and less likely to be smokers (Table 
8.2). The difference in risk profiles of the two cohorts may have contributed to the 
observed difference in the percentage of outcomes events.  
  
Following validation, the Liverpool MI Risk Model should be tested using an impact study, 
where we assess the effect of the model on physician behaviour, patient outcome and cost 
effectiveness of care when compared to usual care without the model.176   
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 Limitations 
The Glasgow cohort consisted of 324 participants. This is a reasonable sample size if the 
percentage of outcomes events was approximately 10%, matching that in the Liverpool 
cohort (and national registries). As discussed in chapter 7, The recommended rule of thumb 
for a model is 10 events per variable (EPV). There were three variables included in the 
Liverpool MI Risk Model so to accurately validate the model required at least 30 events in 
the Glasgow dataset. However, the event rate in the Glasgow cohort was 3.7%, with 12 
events in total. A further cohort with at least 30 events should be used to validate the 
model.  
The BHF MR-MI study was not designed to be used as a validation cohort for the Liverpool 
MI Risk Model. This is an important limitation of our study. Therefore, we must expect the 
observed differences in baseline demographics and risk of outcome events because the aim 
of BHF MR-MI was to collect 6-month CMR data, and not to report the outcome of 28-day 
death or subsequent severe LV function. A study was designed to report the composite 
outcome used in the Liverpool MI Risk Model would likely perform better if used for 
external validation of the model.  
 
 Conclusions 
This study shows that age, MBG and culprit location create a similar gradient of risk in an 
external cohort of STEMI patients. When tested on the Glasgow cohort, the Liverpool MI 
Risk Model shows good discrimination (c statistic 0.873). The model overestimates the risk 
of an outcome event in the Glasgow cohort; however, the model can make accurate 
predictions after simple recalibration. Differences between the two studies that provided 
the derivation and validation cohorts may account for the need to recalibrate the model 
after initial testing. These differences include eligibility criteria, strategies to obtain 
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consent, primary outcome measures and measurement methods of myocardial blush. A 
study of unselected STEMI patients, using the standardised method of measuring MBG, 
should be used to validate the model. Further studies should then assess the impact of 
using the model in clinical practice. 
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 The BHF MR-MI database: CMR insights into 
infarct size in STEMI 
 
 Introduction 
The Liverpool MI Risk Model uses age, culprit location and myocardial blush grade to 
predict the risk of death or subsequent severe impairment of LV function. LV function was 
measured on echocardiography in the HEAT-PPCI trial and on CMR in the BHF MR-MI study. 
LV function may reflect larger infarct size, with a lower LV ejection fraction indicating a 
larger infarct. CMR allows direct visualisation and measurement of the area of infarcted 
myocardium. It is considered the gold standard in quantifying infarct size, although not 
routinely performed in all STEMI patients.193 In this chapter, I used data from the BHF MR-
MI to conduct an exploratory study, examining possible associations between three 
variables (age, culprit location and TIMI myocardial perfusion grade) and the outcome of 
infarct size measured on CMR in STEMI survivors.  
 
 Quantifying infarct size using CMR  
Infarct size is quantified on CMR by late gadolinium enhancement.194 In normal 
cardiomyocytes, the contrast agent, gadolinium chelate, cannot cross cell membranes. 
Following myocardial necrosis, the cell membranes rupture allowing the contrast into the 
cells. Therefore, the infarct size can be determined by the percentage volume of the total 
LV mass where gadolinium is present and visible on CMR.193 The myocardial tissue at risk, 
frequently termed “area-at-risk” is the myocardial territory supplied by the culprit artery 
and includes the myocardium that is reversibly damaged as well as the myocardium that is 
infarcted. “myocardial salvage” can be calculated by subtracting the infarct size from the 
area-at-risk. The “myocardial salvage index” refers to the ratio of myocardial salvage to the 
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area-at-risk.193 The myocardial salvage index is, therefore, useful in quantifying the success 
of revascularisation therapy because it records the volume of myocardium salvaged from 
infarction as a proportion of the potential volume that might have infarcted had 
revascularisation not been performed or if there was no blood supply from collateral or 
adjacent vessels.   
In Chapter 1, I introduced the concept of microvascular obstruction (CMVO), which can be 
measured on CMR. CMVO is identified on CMR as a dark hypo-intense core within areas of 
hyper-enhancement on early or late gadolinium enhancement (termed early or late CMVO 
respectively).193 The presence of CMVO is associated with decreased LV function and 
increased mortality.36,38,39  
 
 Methods 
The BHF MR-MI study was a single-centre prospective cohort study described in detail in 
Chapter 8.186 The study recruited STEMI patients who had a CMR performed at baseline and 
6 months following the acute event.  
 Clinical outcomes  
The BHF MR-MI study measured several clinical outcomes. The primary outcome was 
myocardial salvage measured on CMR at baseline and 6 months after index hospitalisation. 
Secondary outcomes included CMR measurements of myocardial salvage index, final infarct 
size, myocardial haemorrhage, microvascular obstruction, area-at-risk and LV ejection 
fraction. Other outcome measures included recurrent myocardial infarction within 6 
months, MACE (defined as cardiac death, non-fatal MI or hospitalisation for heart failure 
over 12 months), and all-cause mortality.  
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For this study the primary outcome was: 
• Percentage late gadolinium enhancement (%LGE): The myocardial mass of 
late gadolinium (grams) was quantified with computer-assisted planimetry. 
The territory of infarction was delineated with the use of a signal intensity 
threshold of >5 SD above a remote reference region and expressed as a 
percentage of total LV mass % (LGE).70 
Secondary outcomes included: 
• Myocardial salvage index (MSI) 
• Any microvascular obstruction (CMVO) 
 Statistical analysis 
Data are presented as (n/d = p%) for categorical variables and as means (standard 
deviations) or medians (interquartile ranges) for continuous variables after testing for 
normality. Comparisons between groups were made using a chi-squared test for categorical 
variables and unpaired t-test or Mann-Whitney U-test for continuous variables. A p value of 
< 0.05 (2 sided) was considered statistically significant. Multivariate analyses were 
performed to evaluate the degree of variation in a dependent variable (LGE, MSI and 
CMVO) that could be explained by the independent variables (age, culprit location and 
TMPG). Standard multiple regression was performed if the dependent variable was 
continuous, and binomial logistic regression if the variable was dichotomous. SPSS version 
24 (SPSS Inc., Chicago, IL, USA) was used for analyses.  
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 Results 
In the BHF MR-MI study, 324/324 = 100% of patients had a CMR performed 2-3 days 
following the acute event and 299/324 = 92.2% had a follow-up CMR performed at 6 
months.  
 % LV on late gadolinium enhancement 
Of the included patients, 322/324 = 99.4% had values for LGE. Any association between Age 
and LGE was evaluated by visual inspection of a scatter plot of the two variables (Figure 
9.1). This showed no clear correlation, confirmed by calculating the Pearson’s R correlation 
coefficient for age vs LGE, which was 0, indicating no correlation between the two 
variables.   
 
Figure 9.1: A scatterplot demonstrating the lack of correlation between age and LGE 
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The difference in median LGE was compared for the dichotomised culprit location. This 
showed a statistically significant difference in the median LGE in LAD/LMS culprits 
compared to other culprit locations (Table 9.1). The difference in median LGE was 
compared for normal and abnormal TMPG. This showed there was a difference, although it 
did not reach conventional levels of statistical significance.  
 
  LGE (%) p value 
Culprit location 
  
LAD/LMS 26.4 (12.9 to 36.3) <0.001 
Other 12.4 (4.4 to 21.9) 
 
   
TMPG 
  
Normal 13.3 (4.8 to 25.2) 0.162 
Abnormal 17.7 (7.2 to 28.2) 
 
Table 9.1: The median (IQR) LGE % according to culprit lesion and TMPG 
 
A multiple regression analysis was run to evaluate the degree of variation in LGE due to the 
culprit location and TMPG. Age was excluded because there was no correlation between 
age and LGE, and, therefore, age failed the assumption of linearity required for multiple 
regression. The model was significantly better than the mean model (the mean of all values 
of LGE)  (p=<0.001) and the R squared for the overall model was 17.3%, with an adjusted R 
square of 16.7%.195 Therefore, the addition of culprit location and TMPG explained 16.7% of 
the variability in LGE measurements compared to the mean model. The coefficients for the 
model are demonstrated in Table 9.2, with both variables adding significantly to the model 
to predict LGE (culprit location: p<0.001, TMPG: p=0.039). 
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Variable B SEB Beta p value 95% CI for B 
Intercept 10.978 1.648  <0.001 7.74 to 14.22 
Culprit location 11.366 1.452 0.41 <0.001 8.51 to 14.22 
TMPG 3.56 1.713 0.109 0.039 0.19 to 6.93 
B = unstandardised regression coefficient; SEB = Standard error of the coefficient; Beta = standardised 
coefficient 
Table 9.2: Results of the multiple regression analysis for predicting LGE from culprit 
location and TMPG 
 
 Myocardial salvage index 
295/324 = 91.0% patients had values for myocardial salvage index (MSI). Figure 9.2 
demonstrates no correlation between age and MSI. Pearson’s R correlation coefficient for 
age vs MSI was 0.031, confirming a lack of correlation.  
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Figure 9.2: A scatterplot of age vs MSI 
 
The difference in median MSI was compared for the dichotomised culprit location and 
normal/abnormal TMPG (Table 9.3). This showed a difference in the median MSI in 
LAD/LMS vs other culprit lesions which was not statistically significant (57.5 vs 64.8 
p=0.167). The difference in median LGE was compared for normal and abnormal TMPG, 
showing a statistically significant difference (68.1 vs 60.4 p=0.009).   
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  MSI p value 
Culprit location 
  
LAD/LMS 57.5 (42.4 to 81.1) 0.167 
Other 64.8 (46.6 to 86.3) 
 
   
TMPG 
  
Normal 68.1 (51.2 to 93.3) 0.009 
Abnormal 60.4 (42.3 to 81.1)   
Table 9.3: The median (IQR) MSI according to culprit lesion and TMPG 
  
A multiple regression analysis was performed to evaluate the degree of variability in MSI 
measurements due to culprit location and TMPG. Age was excluded because there was no 
relationship between age and MSI. The multiple regression model statistically significantly 
predicted MSI (R squared = 3.1 %; adjusted R squared = 2.4%; p=0.013). Therefore, the 
addition of culprit location and TMPG explained 2.4% of the variability in MSI 
measurements.  The coefficients for the model are demonstrated in Table 9.4, with TMPG 
adding significantly to the model, although culprit location did not (TMPG: p=0.007, culprit 
location: p=0.137). 
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Variable B SEB Beta p value 95% CI for B 
Intercept 71.758 3.435 
 
<0.001 64.99 to 78.52 
Culprit location -4.515 3.026 -0.089 0.137 -10.47 to 1.44 
TMPG -9.689 3.557 -0.162 0.007 -16.69 to -2.69 
B = unstandardised regression coefficient; SEB = Standard error of the coefficient; Beta = standardised 
coefficient 
Table 9.4: The results of the multiple regression analysis to predict MSI from culprit 
location and TMPG 
 Coronary microvascular obstruction (CMVO) 
Of the patients recruited into the study, 324/324 = 100% had an assessment of CMVO on 
CMR. When comparing age, culprit location and TMPG by presence or absence of CMVO, 
there was no significant differences between the two groups (Table 9.5).  
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Presence of CMVO 
 
 
Yes No p value 
Age 59 (11.7) 59 (11.2) 0.589 
    
Culprit location 
   
LAD/LMS 75/118 (63.6%) 43/118 (36.4%) 0.118 
Other 112/205 (54.6%) 93/205 (45.4%) 
 
    
TMPG 
   
Normal 32/65 (49.2%) 33/65 (50.8%) 0.11 
Abnormal 147/244 (60.2%) 97/244 (39.8%) 
 
Table 9.5: Comparing age, culprit location and TMPG by presence of CMVO 
 
 
In a multiple logistic regression analysis, age, culprit location and TMPG were not significant 
predictors of CMVO (p=0.157). The full model is demonstrated in Table 9.6. 
 
  B SEB Wald df p value Exp(B) 95% CI for Exp (B) 
Age -0.01 0.01 0.46 1.00 0.499 0.99 0.97 to 1.01 
Culprit Location 0.36 0.25 2.15 1.00 0.143 1.43 0.89 to 2.32 
TMPG 0.50 0.28 3.06 1.00 0.080 1.65 0.94 to 2.88 
Constant 0.21 0.65 0.10 1.00 0.752 1.23   
Table 9.6: Result of the logistic regression analysis predicting CMVO using age, culprit 
location and TMPG 
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 Discussion 
 Main findings 
This study showed that both culprit location and TMPG are predictors of LGE. In multiple 
regression analysis, these predictors account for 16.7% of the variability in measurements 
of LGE (adjusted R squared = 16.7%; p=<0.001). Culprit location and TMPG are associated 
with MSI, accounting for 2.4% of the variability (Adjusted R squared = 2.4%, p=0.013). Age 
has no clear association with LGE or MSI. (R = 0.0 and 0.013). Age, culprit location and 
TMPG did not predict presence of CMVO on binomial logistic regression analysis (full model 
p=0.157; age p=0.499; culprit location p=0.143; TMPG p=0.080).  
 Exploration of %LGE 
Age does not have a clear association with LGE, suggesting that increased age is not related 
to an increased infarct size. In multiple regression analysis, the culprit location and TMPG 
explain 16.7% of the variability seen in LGE compared to the mean model. This suggests 
that a LAD/LMS culprit location is associated with an increased infarct size. Coronary 
arteries supply different sized areas of myocardium. LAD or LMS occlusion is likely to result 
in a larger infarct than any occlusion in any other artery because the LAD usually supplies a 
larger area of myocardium, therefore a larger area-at-risk. This is supported by a previous 
study of patients with STEMI treated with thrombolysis, that showed larger infarcts on CMR 
with anterior location of the infarct.196  
For the purposes of this discussion, we assume that MBG and TMPG are equivalent, as 
defined in Chapter 8, Table 8.1. Abnormal TMPG is predictive of increased LGE. TMPG 
quantifies the contrast clearance from the myocardium, indicating the degree of blood flow 
reaching the microvasculature. A larger infarct will result in a lower blush grade/abnormal 
blush grade. This has been shown in a previous study: the INFUSE-AMI study compared 
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infarct size measured on CMR with MBG in a trial of STEMI patients managed with 
thrombolysis.109 This study showed that a higher % infarcted LV mass was associated with 
MBG of 0 or 1 (19.5% vs 16.7%; p=0.002).  
These results support the choice of variables used in the Liverpool MI Risk Model, as both 
culprit lesion and TMPG are predictive of infarct size measured on CMR. The addition of age 
is likely to add important information simply because increasing age results in an increased 
risk of death, although the results suggests that the effect of age is independent of 
reperfusion impact. 
 MSI  
MSI is a measure of the success of revascularisation, reporting the ratio of salvaged 
myocardium and area-at-risk. Culprit location and TMPG explain 2.4% of the variability seen 
in MSI measurements whereas age had no clear association with MSI. Anatomical location 
of the occlusion cannot be altered by reperfusion therapy and therefore is a constant 
predictor of infarct size and less likely to predict MSI.  
TMPG may be related to MSI because successful PPCI is more likely to result in good blood 
flow in the microvasculature of the myocardium, visible as increased contrast density and 
improved clearance in the culprit territory i.e. normal blush. However, blush grades do not 
consider the salvaged myocardium or area-at-risk so is more likely to have an association 
with infarct size.  
Several risk scores have been developed and validated that use anatomical information 
from the angiogram to predict potential infarct size or area-at-risk.197,198 One study showed 
that initial TIMI flow grade, presence of >1 collateral vessel and time-to-reperfusion were 
independent predictors of MSI.199 Therefore, the addition of these predictors to a model 
using MBG and culprit location may increase the ability of the model to predict MSI.  
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 CMVO 
Age, TMPG and culprit location were not predictive of presence of CMVO. A study showed 
that a risk score comprising of Killip class, diabetes status, age, ST-elevation on ECG, and 
delayed presentation of STEMI (>3hrs) could be used to predict the presence of CMVO (c-
statistic 0.904).200 The study also showed that a proximal anterior LAD culprit was also 
predictive of MVO but did not improve discrimination when added to the model. Although, 
this analysis did not find the combination of age, culprit vessel and MBG was predictive of 
CMVO, however this does not exclude the possibility that these variables are predictive 
when combined in a model with other variables. This is a common phenomenon, known as 
Simpson’s paradox, whereby the associations between variables may change with the 
addition of other variables.201  
 
 Limitations 
The limitations of the BHF MR-MI study are discussed in full in Chapter 8. This was an 
analysis of observational data and therefore cannot be used to infer a causal relationship 
between variables as there may be a risk of unmeasured confounding. The assumptions 
that TMPG and MBG are equivalent and equal has limitations, as discussed previously in 
Chapter 8. 
 
 Conclusion 
Culprit location and TMPG are associated with infarct size quantified as % LGE of the LV 
mass on CMR. This supports the inclusion of culprit location and MBG in the Liverpool MI 
Risk Model where they likely contribute to the predictive power of the model because of 
associations with subsequent LV function, a surrogate for infarct size. Age was not 
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associated with LGE and likely adds predictive power to the Liverpool model because of the 
association with increased risk of death. 
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Final word 
The aim of this thesis was to explore possible methods of improving outcomes for STEMI 
patients. STEMI is associated with significant mortality and morbidity even if timely 
treatment with primary PCI is performed. The 12-month mortality follow-up in the HEAT-
PPCI trial showed a mortality rate of 8.9%. This result reflects the rates of national registries 
and highlights the potential to improve mortality rates in STEMI.   
 
Current assessment of the PPCI angiogram includes a statement of the final TIMI flow grade 
and a description of the luminal geometry of the treated culprit. However, there are several 
well-validated angiographic grading systems that can be assessed on the PPCI angiogram. 
These include thrombus burden, myocardial blush grade and corrected TIMI frame count. 
The development of a systematic approach to angiogram interpretation, including 
assessment of these additional variables, is likely to add information regarding the success 
of PPCI and possibly identify more patients with poor myocardial reperfusion. To 
recommend the use of the variables in clinical practice I attempted to establish the 
reliability of the variables on repeat assessment. The TIMI flow grade, thrombus burden 
and dichotomised cTFC showed good intra- and interobserver variability, with MBG 
showing moderate agreement. 
 
Several risk scores have been developed to help risk-stratify patients with STEMI, but few 
can be calculated during the acute event. If patients who are more likely to experience an 
adverse event following STEMI could be identified during PPCI they may benefit from timely 
administration of adjunctive therapies or longer surveillance in critical care. The Liverpool 
MI Risk Model combined an assessment of the MBG with age and culprit vessel location to 
accurately predict 28-day death or subsequent severe impairment of LV function (ejection 
fraction ≤35%).  
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All risk models should be validated on an external cohort of patients. I used data from the 
BHF MR-MI study to validate the Liverpool MI Risk Model. The discrimination of the model 
on validation was similar to the derivation cohort (c statistic: 0.837; 95% CI 0.723 to 0.951), 
however, the model overestimated the number of adverse events in the validation cohort. 
This is likely due to differences in the method of measuring myocardial blush used by each 
study as well as significant differences in eligibility criteria, strategies to obtain consent, and 
primary outcome measures. A study of unselected STEMI patients should be used to 
validate the Liverpool MI Risk Model. Following validation, an impact study should be 
performed to assess the effect of using the Liverpool MI Risk Model on patient outcomes. 
  
MBG is a well-known grading system for assessing contrast density in the myocardium and 
reflects the degree of microvascular reperfusion achieved. However, in the UK, it is not 
routine practice to assess MBG. The results from the Liverpool MI Risk Model show that the 
simple addition of MBG to the assessment of a PPCI angiogram could help operators risk 
stratify patients adding minimal extra time to the procedure. In clinical practice, the 
Liverpool MI Risk Model could be used during PPCI to help operators identify low-risk 
patients. These patients could then be directed to lower intensity clinical areas, facilitating 
earlier discharge and improving resource utilisation. 
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 Appendix 1: Database creation 
 Aim 
The original HEAT-PPCI database was created in Microsoft Access. I used the same software 
to develop the database and associated data collection form which allowed the data 
collection form to be more easily populated by the existing data from HEAT-PPCI database.  
Access provides for full Structured Query Language (SQL) database functionality in a 
product that is practical to learn as a junior researcher. I was able to develop a secure 
application that was efficient to use yet also involved computer code for date entry checks 
and automated calculation. 
 Flat versus relational database 
Relational databases have advantages over flat databases because they can record multiple 
episodes/vessels/admissions/events per patient. Using a relational database would allow 
entry of data into several distinct tables. Therefore, one patient could have several 
episodes which were linked to their unique clinical record form (CRF) number (see Figure 
10.1). However, I was using a database where the number of events was already known 
from the previous data collection during the HEAT-PPCI trial. I, therefore, used a flat design 
because I was not adding extra episodes per patient, but was adding additional procedural 
information to pre-existing episodes. Theoretically, if a patient had more than one 
admission for STEMI during the trial, they could have more than one episode entered the 
database. This did not apply to the HEAT-PPCI trial, as patients who presented with a STEMI 
and had already been enrolled in the trial were excluded and, therefore, I did not have to 
examine multiple episodes during data collection. 
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Figure 10.1: Example of one-to-many relationships within the database 
 The data collection form 
Figure 10.2 shows the data collection form. This includes the fields populated by existing 
data from the HEAT-PPCI database as well as data filled during this analysis of the HEAT-
PPCI angiograms. The angiographic grading systems were assessed from several cineruns 
selected from each angiogram and the grades recorded in the form. This form then 
automatically populated a database table. The fields used for data collection are listed in 
Figure 10.3.   
 
 
 
Figure 10.2: The form designed in Microsoft Access to collect data on each angiographic grading system 
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Figure 10.3: Database documenter showing the fields used to collect data 
 
 Using data from the HEAT-PPCI trial database 
Selected data from the HEAT-PPCI trial were linked to the form and populated the relevant 
fields. These fields were used to identify the correct angiogram within the viewing software 
as well as the culprit segment and type of coronary intervention performed. The culprit 
segment and the segments where intervention was performed were defined using a 
numbering system detailed in Figure 10.4. 
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Figure 10.4: Labelling of coronary segments in the HEAT-PPCI trial 
 Collecting data from the angiograms 
Data was collected from the angiograms that described the overall procedure, such as the 
treated coronary segments, collateral grade and angiographic quality. I also collected data 
on the selected angiographic grading systems. These were assessed prior to stent insertion 
(if one or more stents were implanted during the procedure) and in the final angiographic 
cinerun, once all intervention was complete. Throughout the thesis I refer to these time-
points as “pre-stent” and “post-stent”. The thrombus burden prior to stent insertion was 
calculated at an earlier time point (referred to as “pre-stent”). In addition to the value for 
each angiographic system, the cinerun as numbered in Xcelera, was also recorded. If the 
angiogram was acquired in a biplane lab, the plane (lateral or frontal) was recorded.  This 
allowed easy re-review of the cinerun used for data collection to check data quality.  
 Drop-down menus 
The possible inputs for a given field were limited using drop-down menus to create 
structured data entry. Each option was labelled with a number code. By allowing selection 
of a data input option by simply typing the number code into the field, I aimed to increase 
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the speed of data entry, reduce errors and erroneous free text. This also allowed for easier 
searching within the database during data analysis.  
To create a drop-down menu, I created a separate table, termed ZRef, and created a link in 
the “lookup” function (Figure 10.5). 
 
  
An example of a drop-down menu is illustrated in Figure 5.3. On selecting the arrow at the 
side of the data field, the pre-set options could be displayed, each with a number code. The 
button displayed at the top right-hand side of the form saying “TIMI Flow Grades” could be 
selected and displayed the full list of pre-set options in a pop-up window (Figure 5.4).   
 
 
 
I populated the ZRef look-up table “ZrefTIMI_Flow” with the options listed in Figure 10.6. 
These options were then the only data that could be entered into that field. The drop-down 
menu can be seen in the data collection form in Figure 10.7.  
 
Figure 10.5: The process of creating a drop-down menu for data entry 
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Figure 10.6: An example of a Zref table used to create drop-down menus for data entry
 
 
 
Figure 10.7: An example of a drop-down menu with pre-set options for data-entry
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Buttons and associated pop-up windows were also available for thrombus burden 
grades, myocardial blush grades and Rentrop collateral grades. These could be used 
as quick reminders of the definitions of each grading system (Figure 10.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.8: Example of the TIMI flow grade button (outlined in red) programmed to display a pop-up window of the TIMI flow grading 
system for quick reference during data collection 
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If I judged that the angiographic grade could not be confidently assessed, a data field was 
filled describing the degree of uncertainty in the assessment and the reason for selecting 
this option (Figure 10.9). Common reasons included poor angiographic image resolution, 
poor angiographic panning, and cineruns that were too short to allow confident assessment 
of a grading system. An assessment of confidence was made each time a value was 
recorded for each system, at each time point. 
 
 
 
Figure 10.9: The drop-down options for recording the level of confidence in the assessment of a variable and the reason the input has been either 
estimated or not assessed
233 
 
 Programming automated values to fill the database 
Several fields were programmed to automatically fill when data was manually entered into 
other related fields in the database. This was to increase the speed and accuracy of data 
collection. Visual Basic for Applications (VBA) was used to programme the automated 
calculation.  
According to the original published method of calculating cTFC, assessment of the left 
anterior descending (LAD) artery differs from the circumflex (Cx) or right coronary artery 
(RCA) due to the longer mean length of the LAD.99 To ensure the frames counted were 
corrected for longer LAD length, the database was programmed to automatically divide the 
frames counted by 1.7 if the culprit vessel was the LAD.   
The frame rate of the cinerun (frames per second) was recorded and entered into the 
corresponding field in the database. The database was programmed to automatically 
correct the frames counted according to the frame rate, using 30 frames per second as the 
standard, as per the published method.  
When initially testing the methods on the HEAT-PPCI angiograms, a high proportion of the 
angiographic runs did not display the full length of the culprit vessel. This made assessment 
of the cTFC more challenging. I, therefore, estimated the true length of the culprit vessel by 
calculating the cTFC in the visible section as a fraction of the estimated true vessel length. 
The cTFC calculated from the visible section was then multiplied by the visible section as a 
fraction of the estimated total length of the vessel. This allowed an estimate of the true 
cTFC to be made. This process was recorded in the “Parameter assessed?” field as “2. 
Estimated – poor panning”. When both the estimated vessel fraction and the cTFC from the 
visible section were recorded in the form, the cTFC was automatically calculated and 
recorded in the corresponding field.  
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The field labelled “cTFC corrected for vessel fraction” contained the frame count, once it 
had been corrected for frame rate, LAD length (if the LAD was the culprit) and vessel 
fraction (if the full length of the culprit vessel was not visualised on the angiogram). I have 
termed this value the “estimated cTFC”. Recording the estimated cTFC in the database gave 
the option to use these values in addition to the cTFC, assessed with confidence, increasing 
the amount of data I could use in the final analysis.  
The time taken to complete one data form was recorded in the database. A timer was 
programmed into the form using VBA and is illustrated in Figure 10.10. 
 
 
Figure 10.10: Buttons programmed to measure the time it takes to fill the form (outlined 
in red) 
 
Figure 10.2 shows a button in the bottom left-hand corner of the data form labelled “if the 
branch off the culprit is stentable (>2.5mm) and has a final TIMI flow <3, click here to enter 
details”. On pressing this button, a further form appears as illustrated in Figure 10.11. This 
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form is then filled with the details of the stentable branch. The fields used for data 
collection using the “stentable branch” form are listed in full in Figure 10.12.  
 
 
Figure 10.11: Figure illustrating the pop-up form for identifying and assessing any 
subsidiary branch of the culprit vessel that has poor flow at the end of the procedure 
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Figure 10.12: Database documenter displaying the fields used in the “stentable branch” 
data collection form 
 
 Queries 
I used the query function in Microsoft Access to access data results. Simple select queries 
were used to retrieve data from one table. Complex select queries allowed linking if data 
between tables and were used to answer questions that involved data from more than one 
table.  
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 Simple queries 
Using simple select queries, I could count the number of events from a single table. For 
example, to count the number of patients who had TIMI 3 flow at the end of PPCI I created 
a 2-column query and used the count function to identify the proportion of each TIMI flow 
grade (Figure 10.13).  
 
 
Figure 10.13: A 2-column query used to identify the counts of each TIMI flow grade  
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 Complex queries 
Queries that required data from more than one table were more complex. The unique CRF 
number assigned to each study participant allowed me to link tables within the database 
and display data from several tables within one query. I could then examine the 
associations between the outcome data collected in the HEAT-PPCI trial data table 
(tbl_HEAT_MainDataAndSummaryOutcomes) and the angiographic variables recorded into 
the study data collection form (BLAKE_tbl_DataMainAngio). For example, I wanted to 
retrieve data on the mortality rate at 28 days in patients with abnormal MBG. I linked the 
two required tables (Figure 10.14) and created a 2-column query with the final MBG grade 
and death. Using the “criteria” function in the Final_Angio_MBG field I could then specify 
only patients with MBG <3.  
 
 
Figure 10.14: Complex query showing occurrence of death and MBG grade <3 
 
Once retrieved from simple and complex queries, I exported the data to IBM SPSS Version 
24 for statistical analysis.  
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 Appendix 2: Copyright agreement for reproduction of cTFC figures 
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 Appendix 3: Assessing intra- and inter-observer agreement: statistical 
analysis  
 Dichotomous variables 
To determine the agreement between two assessments of a dichotomous variable, I 
calculated the percentage agreement or the proportion of cases where the assessments 
agree. This gives a measure called the overall proportion of agreement.202 However, this 
measure does not take into account the chance agreement, defined as the proportion of 
agreement you would expect from the two assessments based on chance alone. We, 
therefore, used Kappa (𝑘) statistics to assess agreement for all dichotomous variables. 
 Cohen’s Kappa (𝒌) 
Cohen’s 𝑘 was developed to measure agreement between observers whilst considering any 
agreement due to chance.203  Cohen’s 𝑘 is represented by the following equation:204 
 
𝑘 =
𝑃𝑜 − 𝑃𝑒
1 − 𝑃𝑒
 
 
(10.1) 
 
𝑃𝑜 is the observed agreement and 𝑃𝑒 is the agreement expected to occur by chance. 𝑘 is 
therefore dependent on the prevalence of disease in the population. If disease prevalence 
is high, 𝑃𝑒 increases and the 𝑘 statistic decreases.  
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A value for 𝑘 can range from -1 to +1. A negative value for 𝑘 indicates that the agreement is 
less than that expected due to chance. A value of 0 indicates that the observed agreement 
was no better than that due to chance. A value increasing above 0 represents agreement 
that is better than that expected to occur by chance. The classification of 𝑘 values is shown 
in Table 10.1. 
Value of 𝑘 Strength of agreement 
<0.20 Poor 
0.21-0.40 Fair 
0.41-0.60 Moderate 
0.61-0.80 Good 
0.81-1.00 Excellent 
Table 10.1: Classification of 𝒌 values 
 
 Continuous variables 
For continuous variables, intra-class correlation coefficient (ICC) estimates and their 95% 
confidence intervals were calculated based on a single-rater, absolute-agreement, 2-way 
random effects model for interobserver reliability (SB1 vs CP or SB2 vs CP) and a single-
rater, absolute agreement, 2-way mixed effects model for intraobserver reliability (SB1 vs 
SB2). Bland-Altman plots were used to display agreement between observers.   
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 Intra-class correlation coefficient 
The intra-class correlation co-efficient (ICC) was designed to assess the degree of 
correlation and agreement between measurements. ICC assesses reliability, defined as a 
ratio of true variance over true variance plus error variance. There are many types of ICC 
and selecting the correct type is essential for an accurate assessment of reliability.159 There 
are several decisions that must be made to allow selection of the correct type of ICC for the 
specific analysis. For the interobserver analysis I used a two-way random effects model. 
This model assumes the observers used in the study are randomly selected from a wider 
population of similar observers, allowing generalisation of the results to any observers who 
possess similar characteristics to the observers used in the study. For example, I assumed 
that other observers will be trained to the same standard of assessing cTFC as SB and CP. A 
one-way random effects model would be used if every assessment of cTFC was assessed by 
a different set of observers randomly selected from a general population of observers. A 
two-way mixed-effect model should be used if the same observers are used and these are 
the only observers of interest i.e. the results do not need to be generalised to a larger 
population of observers. When assessing intraobserver reliability (SB1 vs SB2), the two-way 
mixed effects model is appropriate because I cannot assume that the results from only one 
observer can be generalised to a population. The calculation is the same as for the two-way 
random effects model so the statistics do not change.159 
 
Another variation between ICC types depends on the application of the measure. For 
example, in clinical practice the cTFC is likely to be assessed by one operator in the cath lab, 
therefore, I use a “single measure” ICC. If the cTFC was assessed by taking the mean of 
several measures of cTFC from several operators, I would use an “average measures” ICC.  
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I then had to decide if I used absolute agreement or consistency in our assessment of ICC.  
Consistency is the degree to which the grade assessed by one observer can be equated to 
other observer’s grade plus a systematic error. Absolute agreement concerns the extent to 
which one assessment equals the other.  
 
For this analysis I used the absolute agreement of two-way random effects model and 
assumed the following model: 
𝑥𝑖𝑗𝑘 = 𝜇 + 𝑟𝑖 + 𝑠𝑗 + 𝜀𝑖𝑗𝑘       (10.2) 
In this model, 𝑥𝑖𝑗𝑘  is the k
th measurement on the jth subject by the ith observer; 𝜇 is the 
overall population mean of the measurements; 𝑠𝑗 is the difference from 𝜇 of the j
th 
subject’s so-called true score (i.e. the mean over repeated measurements on the jth 
subject); 𝑟𝑖 is the difference from 𝜇 of the i
th observer’s measurement; and 𝜀𝑖𝑗𝑘  is the 
random error in the kth measurement on the jth subject by the ith observer. 
We assumed that 𝑟𝑖 and 𝑠𝑗 vary normally with zero mean and variances respectively 𝜎𝑟
2 and 
𝜎𝑠
2. The error terms are assumed to be independently and normally distributed with zero 
mean and variance 𝜎𝜀
2.205 
The ICC can be expressed as the variance ratio: 
𝜌inter =
𝜎𝑠
2
𝜎𝑠
2+𝜎𝑟
2+𝜎𝜀
2.     (10.3) 
An ICC approaching 1.0 indicates excellent reliability, whereas an ICC of less than 0.5 
indicates poor reliability.206 
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 Bland-Altman plots 
Bland-Altman (BA) plots examine the potential for bias between the mean differences of 
paired measurements and were used to demonstrate the magnitude of the difference 
between observers over the range of cTFC measurements.  BA plots quantify the 
“agreement interval” within which 95% of the observed differences fall:  
 Limits of agreement = mean difference +- 1.96 x standard deviation (10.4) 
For this analysis, the difference between the two paired values of cTFC and the mean of the 
two values were plotted against one another.161 The limits of agreement considered 
acceptable were decided a priori and are explained in the power calculation in section 
6.3.3.2. Bias was defined as the consistent tendency for the cTFC measured at one time 
point to exceed the measurement made at the second time point or by the second 
observer.161 This was evaluated by both a visual assessment of the BA plot and calculating 
the mean difference plus 95% CI. If measurement error was truly random then the mean of 
all the differences in the sample should be close to 0, with a 95% CI that crosses the line of 
equality (the line all points would lie on if the two assessments always gave exactly the 
same measurement).161   
 Defining the sample size 
 Dichotomous variables 
Because I was estimating the interobserver reliability coefficient (Cohen’s 𝒌) of a 
population from a sample, I aimed to ensure the coefficient did not differ by more than 
20% (an arbitrary value frequently chosen by researchers) from the “true” coefficient of the 
population. Therefore, it was important to use a sample size that would give an estimate 
that differs no more than 20% from the “true” value. Gwet et al. proposed a solution to this 
for use when estimating kappa-like agreement coefficients.207   
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For all kappa-like coefficients, the required number of subjects (n) depends on the relative 
error (r) and the difference between the observed agreement (𝑃𝑜) and the chance-
agreement (𝑃𝑒) as follows: 
𝑛 =
𝑛∗
1+𝑛∗/𝑁
  where  𝑛 ∗=
1
𝑟2(𝑃𝑜−𝑃𝑒)2
                        (10.5) 
 𝑁 is the number of subjects in the entire population. If a sample size is obtained using 
equation (10.5), the difference between the calculated coefficient and its “true” value will 
not exceed r (the probability will be less than 0.05). This equation shows that if the relative 
error is to be decreased, the sample size must be increased. The smaller the difference 
between Po and Pe, the larger the required sample size. Table 10.2 shows the magnitude 
required for 𝑛 for different values of relative error and agreement probability differences. If 
we assume that the chance agreement probability is 0, this will give us a minimum sample 
size requirement. Therefore if we conservatively assumed that the observers are likely to 
agree at least 50% of the time with a relative error of 20%, our sample size should be 
100.207  
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𝑃𝑜 − 𝑃𝑒  Relative error 
20% 30% 40% 
0.1 2500 1111 625 
0.2 625 278 156 
0.3 278 123 69 
0.4 156 69 39 
0.5 100 44 25 
0.6 69 31 17 
0.7 51 23 13 
0.8 39 17 10 
0.9 31 14 8 
1.0 25 11 6 
Table 10.2: The number of subjects required by relative error and probability difference 
from Gwent et al. 
 Continuous variables 
To decide a sample size for the study, I chose an acceptable level of variability for the cTFC 
as an observed difference +/- 8 frames or less of the absolute value of the arithmetic mean 
of the two individual observations, for 95% of the paired comparisons. The acceptable 
difference between measurements was a clinical judgement based on preliminary 
measurements of cTFC made while testing the methods. The sample size required for a 
precise estimation of agreement between measurements of the cTFC was determined by 
assuming a mean difference between observers of 0 and a standard deviation of 4. If the SD 
was 4 and 100 subjects were included, for a typical cTFC of 20, the mean difference is 0 
(95% CI: 0.78 to -0.78). I assumed that 100 patients would each have an average of 2 cTFC 
assessments, with 60% made with confidence, yielding 120 measurements.  
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 Appendix 4: External validation of the Liverpool MI Risk Model: 
Statistical Analysis 
The following statistical analysis was performed for the validation of the Liverpool MI Risk 
Model: 
Let 𝑠 be the linear predictor for each subject using the original model coefficients: 
𝑠 = 𝛽0 + 𝛽𝐴𝑔𝑒𝐴𝑔𝑒 + 𝛽𝐶𝑉𝐶𝑉 + 𝛽𝑀𝐵𝐺𝑀𝐵𝐺 
We then fit the following set of logistic regression models: 
𝐸[𝑦] = 𝑓(𝛾0 + 𝑠)     (10.6) 
𝐸[𝑦] = 𝑓(𝛾0 + 𝛾1𝑠)     (10.7) 
𝐸[𝑦] = 𝑓(𝛾1group1 + 𝛾2group2 + ⋯ + 𝛾𝑘group𝑘 + 𝑠)   (10.8) 
where E [ ] is the expectation operator (expected value), y is the binary outcome (event/no 
event) and f () is the logistic function.  
The parameter 𝛾0 from model (10.6) is the calibration-in-the-large (a comparison of the 
mean of all predicted risks with the mean observed risk). The group variables in model 
(10.8) are used to categorize 𝑝 into deciles of predicted risk, to assess the relevance of risk 
groups. The parameter 𝛾1 from model (10.7) is the calibration slope and appears as a 
coefficient of the predictor 𝑝. The usefulness of these parameters stems from their 
interpretability as Standardised Incidence Ratios (SIR), calculated as the ratio of observed 
number of outcome events to the expected number of outcome events. 
In models (10.6) and (10.8), the linear predictor 𝑠 acts as an offset, without an attached 
parameter i.e. they are obtained from parameters that do not appear as coefficients of the 
predictor 𝑠. In models (10.6) and (10.7), 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡( 𝛾0) estimates the ratio of observed 
events in the validation data set to the number predicted by the model, either globally 
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(model 10.6: calibration-in-the-large) or by risk groups (model 10.8). A value of 
𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡( 𝛾0) close to 1 indicates that the model is a good predictor of events in the 
validation population.  
From model (10.7), 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡( 𝛾1) describes the impact of a unit increase of predictor 𝑠 in 
terms of increased risk i.e. how many more events we can expect in the original population 
vs. the validation population per unit increase of predictor 𝑠. A value of 𝑒𝑥𝑝𝑜𝑛𝑒𝑛𝑡( 𝛾1) 
close to 0 indicates that the model performs well in the validation population.  
The validation process is described by all three models; however, we use model (10.7) to 
recalibrate the model to make it useful in a new population.  
In model (10.8) we used two groups (since the number of events in the validation data set is 
small.) The two groups are defined by the median (2.3) of the predicted risk score in the 
Glasgow data. 
The following table shows the SIRs estimated from the three models, with 95% robust 
confidence intervals.177  
 
Model (10.6) 0.22 (0.12, 0.39) 
Model (10.7) 4.2 (1.9, 9.1) 
Model (10.8), group 1 (score ≤ 2.3) 0.11 (0.016, 0.81) 
Model (10.8), group 2 (score > 2.3) 0.24 (0.13, 0.44) 
Table 10.3: SIRs with 95% confidence intervals 
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The SIRs for models (10.6) and (10.8) are significantly less than 1, with 95% CI that do not 
include 1 (Table 10.7). This indicates that the Liverpool MI Risk Model tends to predict more 
events than observed in the Glasgow data, both globally (model 10.6) and when divided 
into risk groups (model 10.8). The SIR for model (10.7) is 4.2 (95% CI 1.9 to 9.1) suggesting 
that for each unit increase in the risk predictor 𝑝, we can expect the SIR to increase by a 
factor of at least 1.9 and up to 9.1, with 95% confidence. These results confirm the previous 
observation that the Liverpool population exhibits a higher proportion of adverse events 
with respect to the Glasgow population. 
In Table 10.4 we show the actual observed and expected number of events in the two risk 
groups defined in model (10.8). Using model (10.7) we recalibrated the predictions of the 
Liverpool model, and calculated the recalibrated expected number of events. The 
recalibrated model accurately predicts the observed number of events. See also Figures 
10.15 and 10.16 for a graphical representation. 
 
 Observed Expected Recalibrated expected 
Group 1 (score ≤ 2.3) 1 8.9 0.95 
Group 2 (score > 2.3) 11 46 11 
Table 10.4: Observed and expected event counts 
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Figure 10.15: Observed vs. Expected number of events in Groups 1 and 2, with 95% 
confidence intervals. The black line is the identity line (where x=y). 
 
 
Figure 10.16: Observed vs. Recalibrated expected number of events. The black line is the 
identity line. 
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